SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
September 30, 1994
Date of Report (Date of earliest event reported)
ST. JUDE MEDICAL, INC.
(Exact name of registrant as specified in charter)
Minnesota 0-8672 41-1276891
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
One Lillehei Plaza, St. Paul, MN 55117
(Address of principal executive offices)(Zip Code)
(612) 483-2000
Registrant's telephone number including area code
Not applicable
(Former name or former address, if changed since last report)
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS
Effective September 30, 1994, St. Jude Medical, Inc. acquired substantially
all of the assets (the "Acquisition") of the worldwide cardiac rhythm management
business of Siemens AG, pursuant to two asset purchase agreements: (i) the Asset
Purchase Agreement dated as of June 26, 1994 among St. Jude Medical, Inc. (the
"Company"), SJM Acquisition Corp., Siemens-Pacesetter, Inc. and Siemens Medical
Systems, Inc. ("SMS") and (ii) the [Non-U.S.] Asset Purchase Agreement dated as
of June 26, 1994 among the Company, St. Jude Medical International, Inc. and
Siemens-Elema AB (collectively, the "Purchase Agreements").
The Acquisition consisted of the tangible and intangible assets,
properties, rights and goodwill of Siemens-Pacesetter, Inc. and the Cardiac
Systems Division of Siemens-Elema AB used in their Cardiac Stimulation Device
business, excluding cash and certain other assets. The principal production
facilities acquired are located in Sylmar, California and Solna, Sweden, with
sales and support resources in over 70 countries. The Company presently intends
to continue to utilize the assets acquired for the research, development,
manufacturing, marketing and sale of cardiac rhythm management products
(including technology related to bradycardia, tachycardia, atrial fibrillation
and electrophysiology) in a manner similar to that used by the sellers prior to
the Acquisition.
In consideration for the Acquisition, the Company paid $524.3 million, of
which $13 million was placed into an escrow account pending final adjustments
based on the net book value of the net assets transferred to the Company. The
Company funded the Acquisition through a combination of $274.3 million of its
general funds and $250 million bank debt provided by an eleven-member bank group
lead by Bank of America National Trust and Savings Association. The terms of the
Acquisition were the result of arms-length negotiation between the parties, and
the Acquisition will be accounted for as a purchase.
Except for certain matters provided for in the Purchase Agreements and
other agreements designed to provide an orderly transition, it is expected that
the Company and Siemens will cease to have any material contractual or other
material relationship with each other following the final purchase price
adjustment. The Purchase Agreements provide that, subject to limitations, SMS
and Siemens-Elema AB will indemnify the Company for certain losses resulting
from the breach of any of their representations and warranties and losses
resulting from excluded liabilities, and the Company will indemnify SMS and
Siemens-Elema AB for certain losses resulting from assumed liabilities. The
Purchase agreements also provide for the cooperation and access to facilities
and personnel of the parties to assist in matters continuing past closing, such
as the payment of taxes and resolution of outstanding claims and litigation.
Other agreements provide for the use of the Siemens name on products, literature
and tooling for a transitional period, as well as for the provision of
transitional services by Siemens in several foreign countries for a limited
period of time.
ITEM 7. FINANCIAL STATEMENTS, PROFORMA FINANCIAL INFORMATION
AND EXHIBITS
(a) Financial Statements of Business Acquired:
At this time, it is impractical to provide the financial
statements of the acquired business. Pursuant to
paragraph(a)(4) of Item 7 of Form 8- K, such financial
statements will be filed with the Commission no later than 60
days after the due date of this report on Form 8-K (December
16, 1994).
(b) Proforma Financial Information:
At this time, it is impractical to provide the required
proforma financial information of the acquired business.
Pursuant to paragraph (b)(2) of Item 7 of Form 8-K, such
proforma financial information will be filed with the
Commission no later than 60 days after the due date of this
report on Form 8K (December 16, 1994).
(c) Exhibits:
2.1 Asset Purchase Agreement dated June 26, 1994.
2.2 Non-U.S. Asset Purchase Agreement dated June 26, 1994.
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ST. JUDE MEDICAL, INC.
Date By _________________________________
Stephen L. Wilson
Vice President - Finance
and Chief Financial Officer
EXHIBIT INDEX
EXHIBIT
NO. DESCRIPTION
2.1 Asset Purchase Agreement among St. Jude Medical, Inc.,
SJM Acquisition Corp., Siemens-Pacesetter, Inc. and
Siemens Medical Systems, Inc. dated as of June 26, 1994.
Pursuant to Item 601(b)(2) of Regulation S-K, the registrant
has omitted the following schedules and exhibits and agrees
to furnish supplementally a copy of any such omitted schedule
or exhibit to the Commission upon request:
Schedule 2.2.2 - Adjustments to Closing Balance Sheet
Schedule 2.2.2.1- Intercompany Eliminations
Schedule 4.1.3 - Subsidiaries
Schedule 4.1.5 - Officers and Directors of
Siemens-Pacesetter, Inc.
Schedule 4.1.6 - Consents
Schedule 4.1.7 - Defaults
Schedule 4.2 - Deal Balance Sheet
Schedule 4.3 - Certain Developments
Schedule 4.4 - Title to Personal Property and Assets
Schedule 4.5 - Trademarks, Patents, Patent Applications
and Copyrights
Schedule 4.6 - Commitments
Schedule 4.7 - Litigation
Schedule 4.8 - Permits
Schedule 4.9 - Governmental Consents, Filings, etc.
Schedule 4.10 - Employee Benefit Plans
Schedule 4.11 - Employees
Schedule 4.12 - Environmental Conditions
Schedule 4.18 - Insurance
Schedule 4.19 - Real Property
Schedule 5.2 - Consents
Schedule 6.2.2 - Agreements Outside the Ordinary Course
Schedule 6.10 - Certain Assets
Schedule 7.3 - Retention Agreements
Exhibit 3.2.1 - Form of Shareholder Officers' Certificates
Exhibit 3.2.2 - Form of Opinions of Counsel for
Shareholder and the Company
Exhibit 3.2.4 - Form of Assignment and Assumption Agreement
Exhibit 3.2.8A - Form of Bill of Sale and Assignment
Exhibit 3.2.8B - Form of Deed
Exhibit 3.2.10 - Form of Canadian Transitional
Services Agreement
Exhibit 3.3.2 - Form of SJM Officer's Certificate
Exhibit 3.3.3 - Form of Opinion of Counsel for SJM
Exhibit 3.3.7 - Form of Assumption Agreement
2.2 [Non-U.S.] Asset Purchase Agreement among St. Jude
Medical, Inc., St. Jude Medical Interanational, Inc. and
Siemens-Elema AB dated as of June 26, 1994
Pursuant to Item 601(b)(2) of Regulation S-K, the registrant has
omitted the following schedules and exhibits and agrees to
furnish supplementally a copy of any such omitted schedule or
exhibit to the Commission upon request:
Schedule 1.1(a) - Shareholder Affiliates
Schedule 1.1(a)(i) - Furniture, Fixtures, Equipment, Machinery and
Other Tangible Personal Property
Schedule 1.1(a)(ii) - Vehicles
Schedule 1.1(a)(iii) - Inventories
Schedule 1.1(a)(iv) - Accounts Receivable
Schedule 1.1(a)(viii) - Contracts, Licenses, etc.
Schedule 1.1(a)(ix) - Intellectual Property
Schedule 1.1(a)(xiii) - Advances, Deposits, Prepaid Invoices and
Other Prepaid Expenses
Schedule 1.1(a)(xv) - Interests in Real Property Leases
Schedule 2.2.2 - Adjustments
Schedule 2.2.2.1 - Intercompany Eliminations
Schedule 4.1.4 - Consents
Schedule 4.1.5 - Defaults
Schedule 4.2 - Financial Statements
Schedule 4.3 - Certain Developments
Schedule 4.4 - Personal Property
Schedule 4.5 - Patents, Trademarks, Service Marks,
Trade Names, Copyrights; Registrations;
Applications for Registration
Schedule 4.6 - Commitments
Schedule 4.7 - Litigation
Schedule 4.8 - Permits; Consents
Schedule 4.9 - Governmental Consents
Schedule 4.10 - Employee Benefit Plans
Schedule 4.11 - Employees
Schedule 4.13 - Governmental Notices
Schedule 4.14 - Real Property
Schedule 4.17 - Affiliated Transactions
Schedule 4.18 - Insurance
Schedule 5.2 - Consents
Schedule 6.2 - Conduct of Business; Agreements, etc.
Schedule 7.1.2 - Assumed Employee Benefit Plans
Schedule 8.5 - Certain Consents
Exhibit 1.4.1 - Form of Siemens Transitional Services Agreement
Exhibit 3.2.2 - Form of Assignment and Assumption Agreement
ASSET PURCHASE AGREEMENT
THIS ASSET PURCHASE AGREEMENT is entered into as of June 26,
1994, among Siemens-Pacesetter, Inc., a Delaware corporation (the "Company"),
St. Jude Medical, Inc., a Minnesota corporation ("SJM"), SJM Acquisition Corp.,
a Delaware corporation and a wholly owned subsidiary of SJM ("Acquisition
Subsidiary") and Siemens Medical Systems, Inc., a Delaware corporation
("Shareholder").
WHEREAS, the Company and the Subsidiaries are engaged in the
Business (each as defined herein);
WHEREAS, Shareholder is the sole shareholder of the Company;
and
WHEREAS, the Boards of Directors of SJM, Acquisition Subsidiary
and the Company have each determined that it is in their best interests and the
best interests of their respective shareholders that the Sellers sell, assign,
transfer, convey and deliver to SJM or its Affiliates all of the Assets, and
that SJM or its Affiliates purchase and acquire the same, subject to the
assumption by SJM or its Affiliates of the Assumed Liabilities (each such term
being used as defined herein), all upon the terms and subject to the conditions
set forth in this Agreement;
The parties hereto agree as follows:
ARTICLE 1
TRANSFER OF ASSETS
1.1 Assets to Be Sold. (a) On the terms and subject to the
conditions of this Agreement, the Company and the Subsidiaries shall, and
Shareholder shall cause Siemens Electric Limited, a company organized under the
laws of Canada (the "Shareholder Affiliate" and, together with the Company and
the Subsidiaries, the "Sellers"), on the Closing Date, to sell, assign,
transfer, convey and deliver to SJM, or to such Affiliate or Affiliates of SJM,
as SJM may designate in writing to Shareholder (collectively, "SJM Affiliates"),
and SJM shall purchase or shall cause one of the SJM Affiliates to purchase from
the Sellers on the Closing Date, all of the right, title and interest of the
Sellers in the assets, properties, rights and goodwill of every kind and
description and wherever located, whether tangible or intangible, real, personal
or mixed, owned by the Sellers which are used or held for use in the Business or
Prior Business, other than the Excluded Assets (the assets to be purchased by
SJM or the SJM Affiliates pursuant to this Section 1.1 being referred to as the
"Assets"), including, without limitation, the following:
(i) all furniture, fixtures, equipment, machinery
and other tangible personal property, used or held for use by a Seller
and used in the Business or otherwise owned or held by a Seller on the
Closing Date for use in the Business;
(ii) all vehicles used in the Business on the
Closing Date;
(iii) all inventories sold as part of the Business
and all merchandise, supplies or other personal property used in the
Business;
(iv) all third-party accounts and notes receivable
of the Sellers arising from the conduct of the Business or Prior
Business before the Closing Date;
(v) all books of account, general, financial and
personnel records, invoices, shipping records, supplier lists, device
history records, manufacturing records, traceability records,
regulatory documents, records, reports and correspondence, laboratory
notes, research records, correspondence and other documents, records,
data files and service manuals and any rights thereto (and copies of
tax records) used in, or relating to, the Business on the Closing Date;
(vi) all claims, causes of action, choses in action,
rights of recovery and rights of set-off of any kind (including rights
to insurance proceeds and rights under and pursuant to all warranties,
representations and guarantees made by suppliers of products, materials
or equipment, or components thereof), pertaining to, arising out of,
and enuring to the benefit, of any Seller and relating to the Business;
(vii) all sales and promotional literature, customer
lists and other sales-related materials owned, used, associated with or
employed by and used in the Business on the Closing Date;
(viii) all rights of each Seller under all contracts,
licenses, sublicenses, agreements, leases, commitments, and sales and
purchase orders, and under all bids and offers (to the extent such
offers are transferable) relating to the Business on the Closing Date;
(ix) all patents, trademarks, service marks, trade
names, copyrights, registrations and applications for registration with
respect to any of the foregoing, trade secrets, know-how and other
intellectual property owned by any Seller and used in the Business on
the Closing Date;
(x) all goodwill of the Sellers with respect to the
Business on the Closing Date;
(xi) all permits, licenses, agreements, waivers and
authorizations held or used by any Seller in connection with the
Business, to the extent transferable;
(xii) all product approvals, clearances,
registrations, permits, consents, waivers, certificates, listings and
exemptions submitted to or granted by a regulatory authority, foreign
or domestic, for the purpose of allowing the manufacture, sale or
distribution of a product of the Business, and all other permits,
orders, certificates, authorizations or approvals of any supranational,
national, federal, state, provincial or local, domestic or foreign,
governmental authority or regulatory agency held by a Seller in respect
of the Business;
(xiii) all advances, deposits, loans, prepaid
interest and other prepaid expenses of all kinds of the Business,
including but not limited to prepaid expenses;
(xiv) computer software and firmware used in the
Business, including, without limitation, software used in connection
with production, inventory tracking and work in process testing;
(xv) any and all interests in real property leases
(including leases for warehouse space) used or held for use in the
Business by each Seller and described in Schedule 4.19 attached hereto,
including, without limitation, the benefit of any prepaid rent,
security deposits and options to renew or purchase in connection
therewith;
(xvi) all real property owned by each Seller and
SI-Pace, Inc., a California corporation ("SI-Pace") and used in respect
of the Business, which is described in Schedule 4.19 attached hereto,
together with (a) all privileges, rights, easements and appurtenances
belonging to such real property, (b) all development rights, air
rights, mineral rights, water, water rights and water stock relating to
such real property, (c) all rights of Sellers and SI-Pace in and to any
streets, alleys, passages, other easements and other rights-of-way or
appurtenances included in, adjacent to or used in connection with such
real property, before or after the vacation thereof, (d) all buildings,
systems, facilities, fixtures, structures, fences, parking areas,
machinery, equipment, apparatuses and appliances used in connection
with the operation, maintenance, use or occupancy of the real property,
such as heating and air conditioning systems and facilities used to
provide any utility services, refrigeration, ventilation, garbage
disposal, recreation or other services on the real property, and (e)
all tangible personal property owned by Sellers and used in connection
with the operation, maintenance, use or occupancy of the real property
and located on the real property;
(xvii) all right, title and interest of the Sellers
in and to any stock, options, warrants, debentures or other securities
of Angeion, Inc.;
(xviii) all insurance contracts (other than worker's
compensation contracts) and other assets under the direction or control
of the Sellers maintained for the purpose of funding the liabilities
assumed by SJM or any SJM Affiliate that are assumed by SJM or any
designated SJM Affiliate pursuant to Section 7.1 or 7.3;
(xix) all patents, trademarks, service marks, trade
names, copyrights, registrations and applications for registration with
respect to any of the foregoing, trade secrets, know-how and other
intellectual property owned by any Seller and related to the Prior
Business;
(xx) copies of all device history records,
traceability records, manufacturing records, regulatory documents,
records, reports and correspondence, laboratory notebooks and research
records relating to the Prior Business;
(xxi) all product approvals, clearances,
registrations, permits, consents, waivers, certificates, listings and
exemptions submitted to or granted by a regulatory authority, foreign
or domestic, for the purpose of allowing the manufacture, sale or
distribution of a product of the Prior Business; and
(xxii) (A) all rights of the Sellers to any
insurance proceeds, or claims therefor, covering all damages to the
Business as a result of the January 17, 1994 earthquake (other than
proceeds for reimbursement of expenses paid prior to the Closing Date)
and (B) the reservation of any rights under any applicable insurance
policies relating to that earthquake.
(b) Notwithstanding any provision of Section 2.1(a) to the
contrary, the Assets shall exclude the following assets owned by one or more of
the Sellers (the "Excluded Assets"):
(i) all cash, cash equivalents and bank accounts
owned by each Seller at the Closing Date other than cash representing
insurance proceeds transferred to SJM pursuant to Section 1.1(a)(xxii);
(ii) all assets and properties of the Shareholder
Affiliate (other than copies of the portion of any customer list used
in the Business), whether tangible or intangible, that are not
predominantly used in the conduct of the Business;
(iii) the shares of capital stock of each Subsidiary
and the corporate books and records of each Subsidiary;
(iv) all rights of each Seller under this Agreement;
and
(v) any forward foreign exchange contract.
1.2 Assumption and Exclusion of Liabilities. (a) On the terms
and subject to the conditions of this Agreement, on the Closing Date, SJM shall,
or shall cause the appropriate SJM Affiliate to, assume and shall pay, perform
and discharge when due all Liabilities of each Seller arising out of the conduct
of the Business or relating to the Assets, whether accrued or arising before or
after the Closing, including, without limitation, (x) all third-party accounts
payable, Liabilities arising in connection with any contracts, licenses,
sublicenses, agreements, leases, commitments, and sales and purchase orders
included in the Assets and all Liabilities relating to employees, employee
benefits assumed by SJM or the appropriate SJM Affiliate pursuant to Sections
7.1 and 7.3, except for the Excluded Liabilities, and (y) all Post-Closing
Products Liability Losses and all Post-Closing Litigation Losses (the "Assumed
Liabilities").
(b) The Sellers shall retain, and shall be responsible for
paying, performing and discharging when due, and neither SJM nor the SJM
Affiliates shall assume or have any responsibility for, the following
Liabilities of the Sellers (the "Excluded Liabilities"):
(i) all Liabilities (as defined in Section 13.1)
relating to or arising out of the Excluded Assets;
(ii) Liabilities for contracts or Permits not
assigned because a consent or approval referred to in Section 6.1
cannot be obtained, except to the extent that a Seller or any of its
Affiliates provides SJM or an SJM Affiliate the rights and benefits of
any such contract or Permit;
(iii) Liabilities relating to employees, employee
benefits and Taxes retained by the Sellers under Sections 7.1, 7.2 and
7.3;
(iv) Liabilities to third parties for borrowed
monies;
(v) Liabilities for intercompany Tax-sharing
arrangements referred to in Schedule 4.6(viii) and indebtedness
referred to in Section 6.3;
(vi) Pre-Closing Products Liability Losses;
(vii) Pre-Closing Litigation Losses;
(viii) Liabilities arising from Retained Litigation;
and
(ix) Liabilities arising from Known Environmental
Conditions.
(c) Notwithstanding anything to the contrary in this Section
1.2, Liability and responsibility for Taxes shall be as set forth in Section
7.2.
1.3 Transfer Documentation and Possession. The parties hereto
agree that, in order to effect the transfer of the Assets and the assumption of
the Assumed Liabilities, the parties shall deliver the documents described in
Sections 3.2 and 3.3, and such other conveyance documents as are necessary to
convey (and as appropriate, record and perfect) title to the Assets to SJM or an
SJM Affiliate and for SJM or an SJM Affiliate to assume the Assumed Liabilities,
such other documents to be in form and substance mutually satisfactory to the
Sellers and SJM and as may be necessary under the laws of the jurisdiction where
such Assets and Assumed Liabilities are located to effect such transfer and
assumption. Coincident with the Closing, the Sellers shall deliver possession of
the Assets to SJM or the appropriate SJM Affiliate.
ARTICLE 2
CONSIDERATION
2.1 Consideration. Subject to Section 2.2, the consideration
paid for the Assets shall be $414,300,000 (the "Cash Consideration").
2.2 Cash Consideration Adjustment.
2.2.1 The Cash Consideration shall be subject to adjustment,
if any, after the Closing Date (as defined in Article 3) as specified in this
Section 2.2.
2.2.2 As soon as practicable (but in no event later than 90
calendar days following the Closing Date), Shareholder shall prepare and deliver
to SJM an audited balance sheet for the Business (the "Closing Balance Sheet"),
including the Company, the Subsidiaries and the Shareholder Affiliate, as of the
Closing Date, together with a supplementary statement adjusting the balance
sheet to exclude certain assets and liabilities which are not to be sold and to
include certain other assets and liabilities which are to be sold, all as set
forth on Schedule 2.2.2. In the preparation of the Closing Balance Sheet,
Shareholder shall in good faith consider all reasonable audit procedures
suggested by SJM, and to the extent such suggested procedures are acceptable to
Shareholder prepare the Closing Balance Sheet, in a manner consistent therewith.
The Deal Balance Sheet and the Closing Balance Sheet shall not include any
liability or reserve with respect to any future liabilities relating to or
arising out of the Settlement Agreement. The Closing Balance Sheet shall be
accompanied by the report thereon of Price Waterhouse, independent accountants
of Shareholder ("Shareholder's Accountants"), stating that the Closing Balance
Sheet fairly presents the financial position of the Business at the Closing Date
in conformity with Schedule 2.2.2 and otherwise in accordance with United States
generally accepted accounting principles (hereinafter referred to as "U.S.
GAAP"), which Schedule 2.2.2 and U.S. GAAP shall be applied on a basis
consistent with the preparation of the Deal Balance Sheet (as defined in Section
4.2). During the preparation of the Closing Balance Sheet by Shareholder and the
period of any dispute provided for in Section 2.2.4, SJM shall provide
Shareholder and Shareholder's Accountants reasonable access to the books,
records, facilities and employees of the Business, and SJM, the SJM Affiliates
and their respective successors, if any, shall cooperate fully with
Shareholder's Accountants, in each case to the extent required by Shareholder
and Shareholder's Accountants in order to prepare the Closing Balance Sheet and
to investigate the basis for any such dispute. SJM and its representatives shall
be given reasonable access to the books, records, facilities and employees of
Shareholder and the Shareholder Affiliate, including all supporting documents
and auditor's work papers used in the preparation of the Closing Balance Sheet,
as necessary for it to review the Closing Balance Sheet. SJM shall be permitted
to observe the physical count of inventory to be undertaken in preparation of
the Closing Balance Sheet.
2.2.3 Subject to the limitations set forth in Section 2.2.4,
within 30 Business Days after the date of receipt by SJM of the Closing Balance
Sheet:
(i) If the amount of Net Book Value shown on the
Closing Balance Sheet is less than $117,453,000 by at least $800,000
(the "Designated Amount"), Shareholder shall immediately pay to SJM, as
an adjustment to the Cash Consideration, in immediately available
funds, an amount equal to such excess over the Designated Amount; and
(ii) If the amount of Net Book Value shown on the
Closing Balance Sheet is greater than $117,453,000 by at least the
Designated Amount, SJM shall immediately pay, as an adjustment to the
Cash Consideration, in immediately available funds, to Shareholder an
amount equal to such excess over the Designated Amount.
2.2.4 If not disputed by SJM in accordance with this Section
2.2.4, the Closing Balance Sheet delivered by Shareholder to SJM shall be final,
binding and conclusive on the parties hereto. SJM may dispute any amounts
reflected on the Closing Balance Sheet to the extent that the net effect of such
disputed amounts in the aggregate would be to change the Net Book Value
reflected on the Closing Balance Sheet by more than the Designated Amount, but
only on the basis that the amounts reflected on the Closing Balance Sheet were
not arrived at in accordance with Schedule 2.2.2 and otherwise in accordance
with U.S. GAAP, or that the adjustments set forth in Schedule 2.2.2 or U.S. GAAP
were not applied on a basis consistent with the preparation of the Deal Balance
Sheet; provided, however, that SJM shall notify Shareholder and Shareholder's
Accountants in writing of each disputed item, specifying the amount thereof in
dispute and setting forth, in detail, the basis for such dispute, within 30
Business Days of SJM's receipt of the Closing Balance Sheet. In the event of
such a dispute, each of Shareholder and SJM shall negotiate in good faith to
reconcile their differences. If such dispute has not been resolved within 10
Business Days after the notice referred to in the preceding sentence has been
given, Ernst & Young ("SJM's Accountants") and Shareholder's Accountants shall
attempt to reconcile their differences, and any resolution by them as to any
disputed amounts shall be final, binding and conclusive on the parties hereto.
If any such resolution by SJM's Accountants and Shareholder's Accountants leaves
in dispute amounts the net effect of which in the aggregate (together with any
amounts originally disputed by SJM but no longer in dispute ("Non-Disputed
Amounts")) would not be to change the Net Book Value reflected on the Closing
Balance Sheet by at least the Designated Amount, all the amounts remaining in
dispute shall then be deemed to have been resolved in favor of the Closing
Balance Sheet, and such resolution shall be final, binding and conclusive on the
parties hereto. If SJM's Accountants and Shareholder's Accountants are unable to
reach a resolution, leaving in dispute amounts the net effect of which in the
aggregate (together with Non-Disputed Amounts) would change the Net Book Value
reflected in the Closing Balance Sheet by at least the Designated Amount, SJM's
Accountants and Shareholder's Accountants shall submit the items remaining in
dispute that SJM shall be entitled to dispute by the terms of this Section 2.2.4
for resolution to Deloitte & Touche or such other independent accounting firm of
international reputation as may be mutually acceptable to Shareholder and SJM
(the "Independent Accounting Firm"), which shall, within 30 Business Days of
such submission, determine and report to Shareholder and SJM upon such remaining
disputed items, and such report shall have the legal effect of an arbitral award
and shall be final, binding and conclusive on Shareholder and SJM. The fees and
disbursements of the Independent Accounting Firm shall be allocated between SJM
and Shareholder in the same proportion that the aggregate amount of such
remaining disputed items so submitted to the Independent Accounting Firm which
is unsuccessfully disputed by each such party (as finally determined by the
Independent Accounting Firm) bears to the total amount of such remaining
disputed items so submitted. No adjustment to any amount payable by SJM or
Shareholder pursuant to Section 2.2.3 shall be made with respect to amounts
disputed by SJM pursuant to this Section 2.2.4, unless the net effect of the
amounts successfully disputed by SJM in the aggregate (together with the
Non-Disputed Amounts) is to change the Net Book Value reflected on the Closing
Balance Sheet by at least the Designated Amount, in which case such adjustment
shall only be made in an amount equal to any excess over the Designated Amount.
Any amount that is payable under Section 2.2.3, including, without limitation,
any portion thereof that is subject to dispute under this Section 2.2.4 shall be
paid by Shareholder or SJM, as the case may be, in immediately available funds,
within five Business Days following the resolution of such dispute and in an
amount in accordance with such resolution.
2.2.5 In acting under this Agreement, Shareholder's
Accountants, SJM's Accountants and the Independent Accounting Firm shall be
entitled to the privileges and immunities of arbitrators.
2.2.6 Any payment required to be made by SJM or Shareholder
pursuant to Section 2.2.3 shall bear interest from the Closing Date through the
date of payment on the basis of the average of the daily rate of interest
publicly announced by Citibank, N.A. in New York, New York from time to time as
its base rate from the Closing Date to the date of such payment.
2.2.7 Within 15 Business Days of the date hereof, SJM and
Shareholder shall agree on a form of Escrow Agreement (the "Escrow Agreement")
with Citibank, N.A. (the "Escrow Agent"). On the Closing Date, SJM shall deposit
$13,000,000 of the Cash Consideration (the "Escrow Amount") into an account (the
Escrow Account") managed by the Escrow Agent. Pursuant to the terms of the
Escrow Agreement, the Escrow Agent shall release the Escrow Amount
simultaneously with a determination of a payment obligation by either SJM or
Shareholder, as the case may be, to the other in satisfaction of some or all of
the obligations due by one to the other under Section 2.2.3. If SJM is required
to make a payment to Shareholder under Section 2.2.3, some or all of the Escrow
Amount shall be released to Shareholder to the extent of the payment due to
Shareholder under Section 2.2.3 and credited against such payment. If
Shareholder is required to make a payment to SJM under Section 2.2.3, all of the
Escrow Amount shall be released to SJM. The fees and expenses of the Escrow
Agent shall be paid equally by SJM and Shareholder. Any interest earned on the
Escrow Amount while the Escrow Amount is held in the Escrow Account shall be
distributed to SJM and Shareholder, as the case may be, on the same pro rata
basis as SJM or Shareholder receives all or a portion of the Escrow Amount upon
the release thereof.
2.3 Allocation of Purchase Price. (a) As promptly as
practicable (but in no event later than 90 calendar days following the Closing
Date), SJM shall deliver to Shareholder a proposed allocation of the Cash
Consideration and the Assumed Liabilities among the Assets.
(b) SJM and Shareholder agree to negotiate in good faith
regarding the allocation referred to in subsection (a) above as promptly as
practicable. If SJM and Shareholder are unable (despite good faith negotiations)
to agree upon an allocation within 150 days after the Closing Date, SJM and
Shareholder shall each be individually responsible for performing its own
allocation.
ARTICLE 3
CLOSING
3.1 The Closing. The closing of the transactions contemplated
hereby (the "Closing") shall take place at the offices of Shearman & Sterling,
New York, New York, at 10:00 a.m. (New York City time) on the later of (i)
August 31, 1994 and (ii) the fifth Business Day after the satisfaction or waiver
of the conditions in Articles 8 and 9, or at such other time or place as the
parties may agree (the "Closing Date"). All matters at the Closing shall be
considered to take place simultaneously, and no delivery of any document shall
be deemed completed until all transactions and delivery of documents are
completed.
3.2 Deliveries of Shareholder and the Company. At the Closing,
Shareholder and the Company shall deliver or cause to be delivered to SJM or the
appropriate SJM Affiliates the following:
3.2.1 the Officers' Certificates from an executive officer of
each of Shareholder and the Company, in substantially the form of Exhibit 3.2.1
attached hereto;
3.2.2 the opinions of counsel for Shareholder and the Company,
in substantially the form of Exhibit 3.2.2 attached hereto;
3.2.3 copies of resolutions of the Company's Board of Directors
and of Shareholder's Board of Directors, each certified by the respective
Secretary (or other authorized officer) thereof as having been duly and validly
adopted and in full force and effect, authorizing execution and delivery of this
Agreement and performance respectively by the Company and Shareholder of the
transactions contemplated hereby;
3.2.4 an executed counterpart of the Medtronics Assignment and
Assumption Agreement, in substantially the form of Exhibit 3.2.4 attached hereto
(the "Medtronics Assignment");
3.2.5 a license agreement among St. Jude Medical
International, Inc., SJM and Siemens AG, in form and substance reasonably
satisfactory to each such party, whereby Siemens AG grants to SJM and its
Affiliates a non-exclusive short-term transition license to continue use of
those certain inventories of products and packaging and, for a certain period,
molds for production, bearing the trademark "SIEMENS" existing at the Closing
Date;
3.2.6 certificates evidencing securities of Angeion, Inc.
owned by the Company;
3.2.7 assignments necessary to assign the real property leases
being transferred hereunder to SJM;
3.2.8 the Bill of Sale and the Deeds;
3.2.9 an assignment of Proprietary Rights in form and
substance reasonably satisfactory to each of SJM and Shareholder;
3.2.10 an executed counterpart of the Canadian Transitional
Services Agreement in substantially the form of, and having substantially the
terms contained in, Exhibit 3.2.10 (the "Canadian Transitional Services
Agreement"); and.
3.2.11 an executed counterpart of the Escrow Agreement.
3.3 Deliveries of SJM. At the Closing, SJM shall deliver to
Shareholder, on behalf of the Sellers, the following:
3.3.1 the Cash Consideration by (x) wire transfer in
immediately available funds to a U.S. bank account designated by Shareholder to
SJM in writing at least two Business Days prior to the Closing Date and (y) to
the Escrow Agent pursuant to Section 2.2.7.;
3.3.2 the Officer's Certificate from an executive officer of
SJM, in substantially the form of Exhibit 3.3.2 attached hereto;
3.3.3 the opinion of counsel for SJM, in substantially the
form of Exhibit 3.3.3 attached hereto;
3.3.4 Certificates of Good Standing dated not more than thirty
(30) days prior to the Closing Date, with respect to SJM and Acquisition
Subsidiary issued by the Secretaries of State of Minnesota and Delaware,
respectively;
3.3.5 copies of resolutions of SJM's and Acquisition
Subsidiary's Boards of Directors, certified by the respective Secretaries
thereof as having been duly and validly adopted and in full force and effect,
authorizing execution and delivery of this Agreement and performance of the
transactions contemplated hereby;
3.3.6 an executed counterpart of the Medtronics Assignment;
3.3.7 an executed counterpart of the Assumption Agreement; and
3.3.8 an executed counterpart of the Canadian Transitional
Services Agreement; and
3.3.9 an executed counterpart of the Escrow Agreement.
3.4 Further Documents.
3.4.1 SJM, Shareholder and the Sellers shall execute and
deliver, or cause to be executed and delivered, such other powers of attorney,
instruments, documents or certificates as the other parties may reasonably
request to effect or evidence the consummation of the transactions contemplated
by this Agreement.
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF SHAREHOLDER
AND THE COMPANY
Shareholder and the Company represent and warrant to SJM and
agree with SJM that:
4.1 Authority; Organization, Capitalization and Qualification;
Effect of Agreement.
4.1.1 Authority. Each of Shareholder and the Company has full
corporate power and authority to execute and deliver this Agreement, perform its
obligations hereunder and to consummate the transactions contemplated hereby.
The execution and delivery of this Agreement, the performance by Shareholder and
the Company of their obligations under this Agreement and the consummation by
Shareholder and the Company of the transactions contemplated hereby have been
duly authorized by all necessary corporate action on the part of Shareholder and
the Company, and no other corporate proceedings on the part of Shareholder or
the Company are necessary to authorize the execution and delivery of this
Agreement and to consummate the transactions so contemplated. This Agreement has
been duly executed and delivered by Shareholder and the Company and constitutes
the valid and binding obligation of Shareholder and the Company and is
enforceable against Shareholder and the Company in accordance with its terms,
except to the extent that such enforceability (i) may be limited by bankruptcy,
insolvency, reorganization, moratorium or other similar laws relating to
creditors' rights generally, and (ii) is subject to general principles of equity
(regardless of whether such enforceability is considered in a proceeding in
equity or at law).
4.1.2 Organization and Qualification of the Company. Each of
the Company and the Shareholder Affiliate is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware
and Canada, respectively, and has full corporate power and authority to carry on
its business as it is now being conducted. Each of the Company and the
Shareholder Affiliate is duly qualified to do business as a foreign corporation
in good standing in each jurisdiction where the character of the property owned
or leased by it or the nature of its activities makes such qualification
necessary, except for those jurisdictions where the failure to be so qualified
would not, individually or in the aggregate, have a Material Adverse Effect (as
defined in Section 13.1). Shareholder has heretofore delivered, or caused to be
delivered, to SJM true and complete copies of the Company's certificate of
incorporation and bylaws.
4.1.3 Subsidiaries. Except as set forth in Schedule 4.1.3, the
Company has no subsidiaries, does not own, directly or indirectly, any stock,
partnership interest, joint venture interest or other equity interest in any
other Person, and does not have the power to vote, or to exercise a controlling
influence with respect to, any securities of any class of any Person, the
holders of which class are entitled to vote for the election of directors (or
persons serving similar functions) of such Person. Schedule 4.1.3 lists each
Subsidiary, and with respect to each Subsidiary, lists the number of shares of
its authorized capital stock, the number and class of shares thereof duly issued
and outstanding, the names of all stockholders and the number of shares of stock
owned by each stockholder. For the purposes of Article 1 and the representations
and warranties in this Article 4, "Subsidiary" shall mean BDL Holdings, Inc. and
Bio-Devices Laboratories, Inc.
4.1.4 Title to Stock. Shareholder holds all of the outstanding
capital stock of the Company free and clear of any Liens.
4.1.5. Officers and Directors. Schedule 4.1.5 contains an
accurate and complete list of all of the current directors and officers of the
Company.
4.1.6 Consents. Except as disclosed in Schedule 4.1.6 or as
would not, individually or in the aggregate, have a Material Adverse Effect, no
consent, approval, waiver or other action by any Person under any contract,
agreement, indenture, lease, instrument or other document to which Shareholder,
the Company, the Shareholder Affiliate or any Subsidiary is a party or by which
any of them or their Assets is bound is required or necessary for the execution,
delivery and performance of this Agreement or the other documents contemplated
hereby by Shareholder, the Shareholder Affiliate, any Subsidiary or the Company,
as the case may be, or the consummation of the transactions contemplated hereby
or thereby.
4.1.7 No Default. Except as disclosed in Schedule 4.1.7, the
execution, delivery and performance by Shareholder, the Shareholder Affiliate,
any Subsidiary and the Company of this Agreement or the other documents
contemplated hereby and the consummation by them of the transactions
contemplated hereby and thereby do not and will not (a) except as would not have
individually, or in the aggregate, a Material Adverse Effect, contravene or
constitute a default under or give rise to a right of termination, cancellation
or acceleration of any right or obligation of Shareholder or to a loss of any
benefit to which the Company, the Shareholder Affiliate or any Subsidiary is
entitled under (i) any provision of applicable law or regulation (assuming the
governmental consents referred to in Section 4.9 have been obtained); (ii) the
certificate of incorporation or bylaws of Shareholder or the Company; (iii) any
Commitment (as defined in Section 4.6); or (iv) any judgment, injunction, order,
decree, administrative interpretation, award or other instrument binding upon
Shareholder, the Company, any Subsidiary or the Shareholder Affiliate in respect
of the Business or (b) except as would not have individually, or in the
aggregate, a Material Adverse Effect, result in the creation or imposition of
any Lien on any Asset.
4.2 Financial Statements. Shareholder has delivered to SJM
copies of the audited balance sheets of the Business as of September 30, 1993
(together with a supplementary statement adjusting such financial statements to
exclude certain assets and liabilities, including certain reserves, which are
not to be sold and assumed and to include certain assets and liabilities which
are to be sold and assumed, all as set forth on Schedule 2.2.2 (the "Deal
Balance Sheet")), as well as an audited income statement and cash flow statement
for the Business for the fiscal year ended September 30, 1993, together with the
related notes and schedules thereto (collectively, the "Financial Statements").
The Financial Statements are attached as Schedule 4.2. The Financial Statements
have been prepared from the books and records of the Business in accordance with
U.S. GAAP applied on a consistent basis, subject to normal year-end adjustments,
and fairly present the financial condition of the Business as at the date
thereof and results of its operations for the periods covered thereby (subject
to the adjustments contained on the supplementary statement). The supplementary
statement has been subjected to the auditing procedures applied in the audit of
the Financial Statements and is fairly stated in all material respects in
relation to the Financial Statements. Schedule 2.2.2.1 sets forth for each of
the Financial Statements the intercompany eliminations between the Financial
Statements and each of the corresponding "Non-U.S. Financial Statements" (as
defined in the Non-U.S. Asset Purchase Agreement) (which the Sellers are
assuming have been prepared in accordance with U.S. GAAP) that are necessary to
prepare in accordance with U.S. GAAP combined financial statements for the
Financial Statements and the Non-U.S. Financial Statements. Shareholder has also
delivered to SJM unaudited profit and loss information for the Business for the
period from October 1, 1993 through May 31, 1994, based on financial information
normally prepared by the Company for delivery to Shareholder.
4.3 Absence of Certain Developments. Except as set forth in
Schedule 4.3, since September 30, 1993, the Business has been operated only in
the ordinary course, and neither the Company, any Subsidiary nor the Shareholder
Affiliate in respect of the Business, alone or in the aggregate, has:
4.3.1 mortgaged, pledged or subjected to any Lien, any of its
property or assets, tangible or intangible, other than in the ordinary course of
business, Permitted Liens and Liens that will be released at or prior to
Closing;
4.3.2 except as contemplated by this Agreement, (i) sold,
leased, assigned, transferred or otherwise disposed of any of its assets, except
for inventory sold in the ordinary course of business, or (ii) cancelled or
compromised any debt or claim, or waived or released any right, in the case of
both (i) and (ii) above, having a value of more than $250,000 or an aggregate
value in excess of $750,000;
4.3.3 except as contemplated by this Agreement, made any
material direct or indirect payments, dividends, sales or transfers of assets,
other than normal compensation, or made or granted any bonus or any wage, salary
increase, severance or severance arrangement to any director, manager, officer,
salesperson, distributor, agent, employee or group of employees or made or
granted any increase in any employee compensation or benefit plan or arrangement
(except in accordance with past practice), or amended or terminated any existing
employee benefit plan or arrangement or adopted any new employee benefit plan or
arrangement;
4.3.4 sold, assigned, transferred or licensed to any Person any
rights under any patents, trademarks, service marks, trade names, copyrights,
applications for registration with respect to any of the foregoing, trade
secrets or other intellectual property owned by, or licensed to, the Company,
any Subsidiary or the Shareholder Affiliate in respect of the Business;
4.3.5 entered into any settlement agreement regarding the
breach or infringement (or alleged breach or infringement) of any United States
or foreign intellectual property license, patent, copyright or trademark;
4.3.6 made any capital expenditures in excess of an aggregate
of $5,000,000;
4.3.7 suffered any extraordinary losses or waived any rights of
material value, whether or not in the ordinary course of business or consistent
with past practice;
4.3.8 suffered any damage, destruction or loss of any assets
owned by the Company or used in the operation of the Business which in the
aggregate have a replacement cost of more than $1,500,000 whether or not covered
by insurance;
4.3.9 modified, amended or terminated any Commitment (as
defined in Section 4.6) in a manner materially adverse to the Business;
4.3.10 suffered any Material Adverse Effect;
4.3.11 been the subject of any action taken by the United
States Food and Drug Administration (the "FDA") or any foreign regulatory
authority having jurisdiction over similar matters, excluding observations of
inspectors which have not resulted in any action, claim or investigation by the
FDA or other regulatory authority;
4.3.12 declared, set aside or paid any dividend or other
distribution with respect to any shares of capital stock of the Company, or made
any repurchase, redemption or other acquisition by the Company of any
outstanding shares of capital stock or other ownership interests in or other
securities of the Company, except as contemplated by Section 6.9;
4.3.13 altered any material term of any outstanding security of
the Company;
4.3.14 made any change in any method of accounting or
accounting practice or guideline by the Company, the Shareholder Affiliate in
respect of the Business or any Subsidiary, except for any such change required
by U.S. GAAP or similar rules and except for changes to obtain uniformity of
accounting policies and classifications;
4.3.15 entered into any foreign exchange hedging contracts or
any other financial derivative contracts;
4.3.16 undertaken any (i) incurrence, assumption or guarantee
by the Company or any Subsidiary of any indebtedness for borrowed money other
than in the ordinary course of business in amounts and on terms consistent with
past practices, (ii) issuance or sale of any securities convertible into or
exchangeable for debt securities of the Company or any Subsidiary, or (iii)
issuance or sale of options or other rights to acquire from the Company or any
Subsidiary, directly or indirectly, debt securities of the Company or any
Subsidiary or any securities convertible into or exchangeable for any such debt
securities;
4.3.17 failed to maintain its inventory in a normal and
customary manner materially consistent with its prior practice, or made any
material change in its selling, pricing or advertising practices or credit
terms, limits or durations inconsistent with its prior practice;
4.3.18 discharged or satisfied accounts payable other than in
the ordinary course of business consistent with past practice; or
4.3.19 entered into any agreement or made any commitment to
take any of the types of action described in subparagraphs 4.3.1 through 4.3.18
above.
4.4 Title to Personal Property and Assets. The Company, the
Shareholder Affiliate or a Subsidiary owns or has a valid leasehold interest in
all tangible personal property necessary for the conduct of the Business, and
owns or has a valid license or sublicense to use all computer software used
predominantly in the Business, free and clear of all Liens, except as set forth
in paragraph (a) of Schedule 4.4, Permitted Liens or as reflected on the
Financial Statements. Except as set forth in paragraph (b) of Schedule 4.4, the
equipment and fixed assets of the Business are in good condition and repair and
are usable in the ordinary course of business, ordinary wear and tear excepted.
Shareholder, the Shareholder Affiliate and the Company have furnished to SJM a
summary of tangible personal property, owned or leased by, in the possession of,
or used by the Company, the Shareholder Affiliate (but only to the extent used
in the Business) or the Subsidiaries. The Assets constitute all of the assets
and properties necessary for the conduct of the Business as currently conducted
in all material respects.
4.5 Patents, Trademarks and Copyrights. To the knowledge of
Shareholder, the Subsidiaries and the Company, (a) Schedule 4.5(a) lists all
patents, trademarks, service marks, trade names, copyrights, registrations and
and applications for registration with respect to any of the foregoing owned by
the Company or any Subsidiary; (b) Schedule 4.5(b) lists all license agreements
under which third party owned patents, trademarks, service marks, trade names,
copyrights, registrations and applications for registration of any of the
foregoing, know-how, technology or other intellectual property rights are
licensed to the Company, the Shareholder Affiliate or any Subsidiary; and (c)
Schedule 4.5(c) lists all claims and disputes pending or threatened (in writing)
with third parties alleging that the Company, the Shareholder Affiliate or any
Subsidiary, on the one hand, or such third party, on the other hand, infringes
on the other's patents, trademarks, service marks, trade names, copyrights,
trade secrets or other intellectual property rights. The Company has previously
furnished or made available to SJM all licenses listed on Schedules 4.5(a) and
4.5(b). On or before the Closing, the Company shall make available to SJM all
pending patent applications filed by the Company, the Shareholder Affiliate (in
respect of the Business) or any Subsidiary. Schedule 4.5(d) lists all
outstanding orders, judgments and decrees restricting the use by the Company,
the Shareholder Affiliate or any Subsidiary of the patents, trademarks, service
marks, trade names, copyrights, trade secrets or other intellectual property
rights owned or licensed by any of them. All of the license agreements listed on
Schedule 4.5(b) will be in full force and effect on the Closing Date, and
neither the Company, the Shareholder Affiliate nor any Subsidiary is in default
under any of them nor, to the knowledge of Shareholder or the Company, (i) is
any other party to any such license agreement in default thereunder, nor (ii)
does any condition exist that, with notice or lapse of time or both, would
constitute a default thereunder, except in each case for such failures to be in
full force and effect, defaults or conditions that would not have individually,
or in the aggregate, a Material Adverse Effect. The right, title and interest of
the Company, the Shareholder Affiliate and the Subsidiaries in and to the
Proprietary Rights and Proprietary Information are duly recorded (as applicable)
and free and clear of all Liens and rights of third parties other than Permitted
Liens and as otherwise described in Schedule 4.5(e). Each of the Company, the
Shareholder Affiliate and the Subsidiaries has established safeguards to
maintain the secrecy of its Proprietary Information that it considers to be
reasonable. To the knowledge of Shareholder and the Company, the information
which Shareholder, the Shareholder Affiliate, the Subsidiaries and the Company
believe is Proprietary Information has not been disclosed by the Company or any
of its Affiliates to any other person, entity or governmental agencies, except
pursuant to confidentiality agreements, protective orders or law and except as
would not have individually, or in the aggregate, a Material Adverse Effect. As
used herein, "Proprietary Information" means all know-how and technology owned
by the Company, the Shareholder Affiliate and the Subsidiaries and used in the
Business (except in the case of the Shareholder Affiliate, such term shall mean
know-how and technology used predominantly in the Business); and "Proprietary
Rights" means all patents, trademarks, service marks, copyrights, registrations
and applications therefor arising out of, and owned by the Company, the
Shareholder Affiliate and the Subsidiaries as part of, the Business. To the
knowledge of the Company, the Subsidiaries and the Shareholder Affiliate, no
interference actions are pending, and no notice has been received of an
intention to provoke an interference action or to otherwise challenge the
validity or priority of inventorship before the United States Patent and
Trademark Office or other similar authorities with respect to any patent or
application therefor included in the Assets.
4.6 Commitments. Paragraph (a) of Schedule 4.6 sets forth a
list of all of the following written contracts and other agreements to which the
Company or any Subsidiary, or the Shareholder Affiliate in respect of the
Business, is a party or by which the Company or any Subsidiary, or the
Shareholder Affiliate in respect of the Business or any Assets, bound or subject
(collectively, "Commitments"): (i) customer contracts and agreements for the
sale of materials or products which by their terms exceed one year or which are
in dollar amounts which equal or exceed $500,000 per annum; (ii) distributorship
agreements and manufacturer's representative agreements which provide for
payments in excess of $500,000 per annum; (iii) supply and vendor contracts for
sole source components or which provide for payments in excess of $350,000 per
annum; (iv) material research and development agreements; (v) employment,
consulting, independent contractor, severance, change in control, retention and
indemnification agreements, arrangements or understandings, and any other
agreements, arrangements or understandings, between the Company, any Subsidiary
or the Shareholder Affiliate in respect of the Business, and any current or
former stockholder, officer, director, employee, consultant, agent or other
representative, which provide for payments in excess of $100,000 per annum or
with respect to any such contract under which the total liability of the
Company, any Subsidiary or the Shareholder Affiliate in respect of the Business
equals or exceeds $500,000; (vi) contracts and other agreements with any labor
union or association representing any employee of the Company, any Subsidiary or
the Shareholder Affiliate in respect of the Business; (vii) joint venture
agreements; (viii) contracts or other agreements under which the Company agrees
to indemnify for or share Tax liability of any party; (ix) contracts and other
agreements relating to the borrowing of money; (x) any equipment leases
requiring payment of at least $100,000 within a given year which are not
cancelable without penalty upon 90 days' notice; (xi) agreements settling
pending or threatened Litigation which require continuing obligations after the
date hereof; (xii) any agreements between the Company, any Subsidiary or the
Shareholder Affiliate (in respect of the Business) and any of their Affiliates
(other than individuals); (xiii) agreements granting rights or options to
purchase the securities or assets (other than inventory in the ordinary course
of business) of other companies or entities; (xiv) agreements which limit the
Business from competing in any line of business or in any geographic area other
than distributorship or representation agreements which are exclusive as to
geographic area; or (xv) any other contract or other agreement (other than
contracts and agreements of the type specified in clauses (i) through (xiv)
above) that is material to the Business, whether or not made in the ordinary
course of business. There have been delivered or made available to SJM true and
complete copies of all such contracts and other agreements set forth in
paragraph (a) of Schedule 4.6. All of such Commitments are in full force and
effect, and none of the Company, any Subsidiary nor the Shareholder Affiliate is
in default under any of them, nor, to the knowledge of Shareholder or the
Company, (i) is any other party to any such contract or other agreement in
material default thereunder, nor (ii) does any condition exist that, with notice
or lapse of time or both, would constitute a default thereunder. The Company has
not received any notification of any change in its arrangements with customers
and suppliers that would individually, or in the aggregate, have a Material
Adverse Effect. Paragraph (b) of Schedule 4.6 indicates which of the Commitments
requires the consent of a third party to be transferred or to remain in full
force and effect following the consummation of the transactions contemplated by
this Agreement.
4.7 Litigation. Except as set forth in Schedule 4.7, there is
no Litigation pending or, to Shareholder's or the Company's knowledge,
threatened which seeks to enjoin or obtain damages in respect of the
consummation of the transactions contemplated hereby. Schedule 4.7 lists any
Litigation and, to Shareholder's or the Company's knowledge, any investigation
by a governmental entity, in each case that (i) involves a claim, or to
Shareholder's or the Company's knowledge, potential claim, of liability, in
excess of $2,000,000, against or affecting the Company, any Subsidiary or the
Shareholder Affiliate in respect of the Business or (ii) enjoins, or seeks to
enjoin, the operation of a portion of the Business or seeks declaratory judgment
if such injunction or judgment would, or if entered would, constitute a Material
Adverse Effect.
4.8 Compliance with Laws; Permits. Except as set forth in
paragraph (a) of Schedule 4.8, the Company, a Subsidiary or the Shareholder
Affiliate currently holds all permits, licenses, clearances, registrations,
consents, waivers, listings, exemptions, orders, certificates, authorizations or
approvals of any international, federal, provincial, state or local, domestic or
foreign, governmental authorities or regulatory agencies, including, without
limitation, those regulating safety, effectiveness and market clearance of
medical devices (the "Permits"), necessary to carry on the Business as it is
currently being conducted, except for such Permits the absence of which would
not, individually or in the aggregate, have a Material Adverse Effect. Except as
disclosed in paragraph (b) of Schedule 4.8, no approval or consent of any Person
is needed in order that any Permit shall continue in full force and effect
following the consummation of the transactions contemplated by this Agreement
and to assign such Permits to SJM or one of its Affiliates, except where the
failure to obtain such approvals or consents would not have individually, or in
the aggregate, a Material Adverse Effect. Except as set forth in paragraph (c)
of Schedule 4.8, or as would not have a Material Adverse Effect, the Company,
the Subsidiaries and the Shareholder Affiliate in respect of the Business have
complied with all applicable laws, regulations, Permits and orders of foreign,
federal, state and local governments and all agencies thereof (including,
without limitation, the FDA or any foreign regulatory authority having
jurisdiction over similar matters) that affect the Business and to which the
Company, the Subsidiaries or the Shareholder Affiliate are subject, and no
claims have been filed against the Company, the Subsidiaries or the Shareholder
Affiliate in respect of the Business alleging a violation of any such laws,
regulations or orders. Except as set forth in paragraph (d) of Schedule 4.8, no
notice, warning or other communication from any governmental authority in
respect of any failure or alleged failure by the Company, the Subsidiaries or
the Shareholder Affiliate in respect of the Business to comply with any law,
regulation or order has been received by the Company, the Subsidiaries or the
Shareholder Affiliate.
4.9 Governmental Consents. Except for the filing under the HSR
Act and otherwise as set forth in Schedules 4.8 and 4.9, the execution, delivery
and performance by Shareholder, the Shareholder Affiliate, the Subsidiaries and
the Company of this Agreement and the other documents contemplated hereby and
the consummation by Shareholder, the Shareholder Affiliate, the Subsidiaries and
the Company of the transactions contemplated by this Agreement require no action
by, or in respect of, or filing with, any governmental body, agency, official or
authority.
4.10 Employee Benefit Plans.
4.10.1 Schedule 4.10.1 sets forth a true and complete list of
each material Employee Benefit Plan covering any Employee (each as defined in
Section 4.10.5). With respect to each Employee Benefit Plan set forth on
Schedule 4.10.1:
(a) Each Company Employee Benefit Plan (and each
related trust, insurance contract, or fund) complies in form
and in operation in all material respects with its terms, and
with all applicable laws, regulations, ordinances, codes or
other legally binding rules and other requirements of all tax,
labor and other governmental authorities having jurisdiction
over the Company, and all applicable collective bargaining
agreements and works council rules, including the requirements
of ERISA, the Code, and other applicable laws.
(b) All employer and Employee contributions with
respect to Employees which are due and owing as of the Closing
Date pursuant to Employee Benefit Plans and Employee Benefit
Plans of the Shareholder Affiliate with respect to Employees
have been or will be made in accordance with local law and past
practice. Any liabilities for amounts accrued with respect to
Employees under any Employee Benefit Plan set forth in Schedule
4.10.1 as of the Closing Date have been appropriately reflected
on the books and records of such Employee Benefit Plan sponsor
in accordance with local law, past practice and generally
accepted accounting principles in the local jurisdiction.
(c) The Company or Shareholder has delivered to SJM
correct and complete copies of all plan documents and summary
plan descriptions, all material communications to Employees,
all related trust agreements, insurance contracts, and other
funding agreements which implement each Company Employee
Benefit Plan, and, where a plan document for a Company Employee
Benefit Plan does not exist, a detailed description of such
Company Employee Benefit Plan.
(d) No Company Employee Benefit Plan is either (i) a
Multiemployer Plan, or (ii) except as disclosed on Schedule
4.10.1, an Employee Welfare Benefit Plan (as defined in Section
4.10.5) providing medical, health, life insurance, or other
welfare-type benefits for current or future retired or
terminated Employees, their spouses or their dependents (other
than in accordance with Code Section 4980B).
(e) Except as disclosed on Schedule 4.10.1, to the
knowledge of the Company and its Subsidiaries, there has been
no amendment to, written interpretation of, or announcement
(whether or not written) relating to, or any change in employee
participation or coverage under, any Employee Benefit Plan that
is not reflected in the text of such Employee Benefit Plan
which would materially increase the expense (whether or not
such expense is recognized under generally accepted accounting
principles) to the employer whose Employees are covered by such
Employee Benefit Plan, other than as a function of the number
of plan participants or as a result of a change in the
applicable law.
(f) Except as disclosed on Schedule 4.10.1, or as
otherwise expressly provided with respect to a Company Employee
Benefit Plan or as otherwise required by applicable law, to the
knowledge of the Company and its Subsidiaries, no condition
exists that would prevent the amendment or termination of any
Company Employee Benefit Plan with respect to any Employee.
4.10.2 With respect to each Company Employee Benefit Plan that
any of the Company or its Subsidiaries, or any member of the Controlled Group
(as defined in Section 4.10.5) which includes the Company and its Subsidiaries,
maintains or has ever maintained for Employees, or to which any of them
contributes, has ever contributed, or has ever been required to contribute for
Employees, except as set forth on Schedule 4.10.2:
(a) neither SJM nor any SJM Affiliate has any direct
or indirect material liability: (i) with respect to any
complete or partial termination of any such Company Employee
Benefit Plan (including any Multiemployer Plan (as defined in
Section 4.10.5)) or any Company Employee Benefit Plan that has
been the subject of a Reportable Event (as defined in Section
13.1) as to which notices would be required to be filed with
the Pension Benefit Guaranty Corporation ("PBGC"), (ii) for any
breach of fiduciary duty or any failure to act or comply in
connection with the administration or investment of the assets
of any such Company Employee Benefit Plan, (iii) for any
transaction or holding of any asset under or in connection with
any Company Employee Benefit Plan that would result in
liability under Title I of ERISA or liability for any tax
pursuant to Section 4975 of the Code, or any Canadian tax laws,
(iv) to the PBGC (other than for PBGC premium payments) or
otherwise under Title IV of ERISA or under the Code with
respect to any such Company Employee Benefit Plan which is an
Employee Pension Benefit Plan, (v) arising out of or in
connection with any Multiemployer Plan (including withdrawal
liability), or (vi) under any Company Employee Benefit Plan
which is an Employee Welfare Benefit Plan providing medical,
health, life insurance, or other welfare type benefits for
current or future retired or terminated employees, their
spouses or their dependents (other than required by applicable
U.S. federal or state law or Canadian federal or provincial
law);
(b) no proceeding by the PBGC to terminate any such
Employee Benefit Plan has been instituted or threatened; and
(c) no action, suit, proceeding, hearing or
investigation with respect to the administration or the
investment of the assets of any such Company Employee Benefit
Plan (other than routine claims for benefits) that could
reasonably be expected to result in a material liability to SJM
or an SJM Affiliate pending or threatened, and neither
Shareholder, the Company, nor any members of the Controlled
Group that includes the Company, has any knowledge of any basis
for any such action, suit, proceeding, hearing, or
investigation.
4.10.3 Except as set forth on Schedule 4.10.3:
(a) the consummation of the transactions contemplated
by this Agreement will not (i) entitle any Employee to
severance pay, supplementary unemployment compensation or any
similar payment, (ii) accelerate the time of payment or
vesting, or increase the amount of any compensation due to any
such Employee, or (iii) constitute or involve a prohibited
transaction that is not otherwise covered by a statutory or
administrative exemption; and
(b) no collective bargaining agreement, employment
agreement or other agreement contains any "change in control"
or similar provisions which may be triggered by any of the
transactions contemplated in this Agreement.
4.10.4 Except as disclosed in Schedule 4.10.4, there have been
no statements by authorized representatives of the Company or its Subsidiaries,
Shareholder or the Shareholder Affiliate (in respect of the Business), whether
oral or in writing, regarding the Employee Benefit Plans to be maintained (or
not to be maintained) by SJM or the designated SJM Affiliate after the Closing
Date, which will result in material liability to SJM or the designated SJM
Affiliate, whether direct or indirect.
4.10.5 For purposes of this Agreement:
(a) "Company Employee Benefit Plan" means any
Employee Benefit Plan that exists immediately prior to the
Closing Date, is sponsored solely by or is primarily
administered by the Company or its Subsidiaries and covering
solely Employees, and any such Company Employee Benefit Plan
shall be identified as such on Schedule 4.10.1.
(b) "Controlled Group" has the meaning set forth in
Code Sec. 414.
(c) "Employee" means a current employee, including
both active employees (including light duty employees),
inactive employees (including employees on a leave of absence,
sick leave, short term disability or worker's compensation
disability on the Closing Date), and former employees
(including retirees and employees on long term disability), of
the Company or its Subsidiaries or any active employee of the
Shareholder Affiliate who is 100% engaged in the Business.
(d) "Employee Benefit Plan" means any agreement,
plan, program, fund, policy, contract or arrangement (either
written or unwritten) providing compensation, benefits,
pension, retirement, profit sharing, stock bonus, stock option,
stock purchase, phantom or stock equivalent, bonus, incentive,
deferred compensation, hospitalization, medical, dental,
vision, vacation, insurance, sick pay, disability, severance,
or similar employee benefits covering any Employee, and the
beneficiaries and dependents of the Employee, including without
limitation, (i) any Employee Welfare Benefit Plan (the "Welfare
Plan"), whether or not terminated, including but not limited to
any severance agreement or plan, any material fringe benefit
plan or program, any medical plan, life insurance plan,
short-term or long-term disability plan, dental plan, personnel
policy, vacation time, holiday pay, bonus program, service
award, moving expense reimbursement program or sick leave; (ii)
any deferred compensation or retirement plan or arrangement
which is an Employee Pension Benefit Plan, whether or not
terminated, including but not limited to any excess benefit
plan, top hat plan, or deferred compensation plan, any
Multiemployer Plan, defined contribution or defined benefit
arrangements which are Employee Pension Benefit Plans (the
"Pension Plans"); (iii) any other plan, program, policy,
contract or arrangement, including but not limited to any bonus
or incentive plan, stock options, restricted stock, stock
bonus, deferred bonus plan, salary reduction agreement,
change-of-control agreement, retention agreement, employment
agreement, or consulting agreement with former Employees.
(e) "Employee Pension Benefit Plan" has the meaning
set forth in ERISA Sec. 3(2).
(f) "Employee Welfare Benefit Plan" has the meaning
set forth in ERISA Sec. 3(1).
(g) "ERISA" means the Employee Retirement Income
Security Act of 1974, as amended.
(h) "Multiemployer Plan" has the meaning set forth in
ERISA Sec. 3(37).
4.11 Employees. Paragraph (a) of Schedule 4.11 sets forth a
true and complete list of all Employees (other than former employees),
indicating their position and base salary as of March 16, 1994. Except as
described in paragraph (b) of Schedule 4.11, none of the Employees is
represented by a union or other labor organization, nor are they covered by a
collective bargaining agreement, and no union organizing efforts have been
conducted within the last three years, or to the knowledge of Shareholder, the
Company and its Subsidiaries, are now being conducted with respect to the
Employees. The Company and its Subsidiaries are in material compliance with all
U.S. laws, regulations, ordinances, codes or other legally binding rules
applicable to the Business with respect to the Employees and its own policies
respecting employment and employment practices, terms and conditions of
employment, wages and hours, equal opportunity, civil rights, labor relations,
occupational health and safety and payroll taxes with respect to the Employees,
including, without limitation, the Immigration and Reform Control Act, Title VII
of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans
with Disabilities Act, the Federal Age Discrimination in Employment Act and any
federal, state or local law. None of the Company is in receipt of a complaint,
demand letter or charge issued by a U.S. or Canadian federal, state, provincial
or local agency which alleges a violation by the Company of any applicable law
or regulation respecting employment and employment practices, terms and
conditions of employment, wages and hours, equal opportunity, civil rights,
labor relations, occupational health and safety or payroll taxes with respect to
the Employees. Neither the Company nor its Subsidiaries has engaged in any plant
closing, work force reduction or other action which has resulted or would result
in material liability under the Workers Adjustment and Retraining Notification
Act or any other applicable U.S. or Canadian law or regulation with respect to
the Employees, has been issued any notice that any such action is to occur in
the future with respect to the Employees, and are in material compliance with
all applicable requirements of the Immigration Reform and Control Act and the
Consolidated Omnibus Budget Reconciliation Act of 1987 with respect to the
Employees. Paragraph (c) of Schedule 4.11 (which shall be delivered to SJM
within 20 days of the date hereof) shall set forth a true and complete list of
all inactive Employees and Employees who are receiving long-term disability,
including the expected duration of their disability or leave and the nature and
amount of any benefits provided by or through the Company, its Subsidiaries,
Shareholder or the Shareholder Affiliate during such period. Paragraph (d) of
Schedule 4.11 sets forth a true and complete list of all of the current
independent contractors of the Company and its Subsidiaries who in the past year
received aggregate payments in excess of $100,000.
4.12 Environmental Matters; OSHA.
4.12.1 The following terms used in this section are defined as
follows:
(a) "Environmental Laws" is defined as any and all
applicable federal, state and local treaties, laws, regulations,
ordinances, codes, standards or criteria, orders or decrees of any
court, agency, entity, organization or authority, or of any
jurisdiction where the Company or any Subsidiary is located or conducts
business pertaining to the public health and safety, workers, health
and safety and the pollution of or protection of the environment,
including but not limited to those related to air, water, noise, odor,
land, soil, pesticide, hazardous or toxic substances and wastes, in
effect at the Closing Date.
(b) "Regulated Substances" is defined as toxic,
radioactive or hazardous substances or wastes, pollutants or
contaminants, including but not limited to: asbestos; urea
formaldehyde; the group of organic compounds known as polychlorinated
biphenyls; petroleum products including gasoline, fuel oil, crude oil
and the various constituents of such products; and any substance or
material the generation, storage, handling, release, disposal or
cleanup of which is regulated by any Environmental Law.
(c) "Property" is defined as all real estate and
property now or formerly owned or leased by the Company or any
Subsidiary, including without limitation, as of the Closing, the real
property to be transferred to the Company pursuant to Section 6.8. For
purposes of this definition only, "Property" includes groundwater
underlying the surface.
4.12.2 Schedule 4.12.2 lists all environmental conditions known
to Shareholder, the Subsidiaries or the Company existing on or prior to the date
hereof and arising or resulting from (i) the noncompliance by the Company or any
Subsidiary with any applicable Environmental Law or (ii) the release of a
Regulated Substance into the environment at or from the Property and, in either
case, for which the Company or any Subsidiary would, or would reasonably be
expected to, be required to expend in excess of $100,000 in order to clean up
any such Regulated Substance or in order to bring the Company or any Subsidiary
into compliance with any such Environmental Law (collectively "Known
Environmental Conditions"). Prior to the Closing, Shareholder or the Company
may, from time to time, deliver to SJM a revised Schedule 4.12.2. Any
environmental conditions listed on any such revised Schedule 4.12.2 shall be
deemed to be included in the definition of "Known Environmental Conditions".
4.12.3 Except as disclosed on Schedule 4.12.3, to the knowledge
of Shareholder, the Subsidiaries and the Company, the Business has been operated
at all times in compliance with any and all applicable Environmental Laws,
except as would not have a Material Adverse Effect.
4.12.4 Except as disclosed on Schedule 4.12.4, to the knowledge
of Shareholder, the Subsidiaries and the Company, the Company or a Subsidiary
has all governmental licenses, permits and other authorizations required by any
and all Environmental Laws necessary to conduct and operate the Business as
currently conducted or operated, and none of the Company or any Subsidiary is in
violation of any terms or conditions of such licenses, permits or authorizations
as of the Closing Date, except as would not have a Material Adverse Effect.
4.12.5 Except as disclosed on Schedule 4.12.5, to the knowledge
of Shareholder, the Subsidiaries and the Company, none of the Company or a
Subsidiary is presently disposing of any Regulated Substance on the Property,
and none of the Company or a Subsidiary has in the past disposed of any
Regulated Substance on the Property.
4.12.6 Except as disclosed on Schedule 4.12.6, to the knowledge
of Shareholder, the Subsidiaries and the Company, the Property has not been
subject to any release or threatened release of any Regulated Substance, except
as individually or in the aggregate would not have a Material Adverse Effect.
4.12.7 Except as disclosed on Schedule 4.12.7, to the knowledge
of Shareholder, the Subsidiaries and the Company, there are and have been no
above-ground or underground storage tanks, sumps or clarifiers located on the
Property.
4.12.8 To the knowledge of Shareholder, the Subsidiaries and
the Company, the Business is not being operated in material violation of the
Occupational Safety and Health Act of 1970, or the regulations promulgated
thereunder or any similar laws or regulations of any other country.
4.13 Company Products; Regulation.
4.13.1 Except as disclosed in paragraph (a) of Schedule 4.13.1
and except as would not have a Material Adverse Effect, to the knowledge of the
Company and Shareholder, since January 1, 1992 there have been no written
notices, citations or decisions by any governmental or regulatory body that any
product produced, manufactured, marketed or distributed at any time by the
Business (the "Products") is defective or fails to meet any applicable standards
promulgated by any such governmental or regulatory body. To the knowledge of
Shareholder and the Company, the Business has complied in all material respects
with its policies, procedures and specifications with respect to design,
manufacture, labelling, testing and inspection of Products. Except as disclosed
in paragraph (b) of Schedule 4.13.1, since January 1, 1992 there have been no
recalls, field notifications or seizures ordered or, to the knowledge of the
Company or Shareholder, threatened by any such governmental or regulatory body
with respect to any of the Products. Except as has been disclosed to SJM, since
January 1, 1992, the Company, the Shareholder Affiliate and the Subsidiaries
have not received, and the Company and Shareholder do not have knowledge of any
reasonable basis for, any warning letter, or Section 305 notices from the FDA.
4.13.2 Except as would not have a Material Adverse Effect, the
Company, the Shareholder Affiliate and the Subsidiaries are in possession of and
will, upon SJM's request, make available to SJM, all supportive materials and
data substantiating representations made to the FDA or other domestic
governmental regulatory authority in its filings therewith, including any and
all testing data in the possession, or under the control, of the Company, the
Shareholder Affiliate (but only to the extent used in the Business) or any
Subsidiary, whether or not submitted to the FDA or other domestic or foreign
governmental regulatory authority. In addition, the Company, the Shareholder
Affiliate (but only to the extent used in the Business), has identified or will,
upon SJM's request, identify to SJM, to the knowledge of Shareholder and the
Company, all international locations where regulatory information and documents
are kept, except where the failure to identify any such locations would not have
a Material Adverse Effect. The Products perform in all material respects in
compliance with the representations and performance specifications as contained
in said filings.
4.14 Tax Matters.
4.14.1 United States Person. Each of the Sellers, except the
Shareholder Affiliate, is a United States person within the meaning of the Code.
4.14.2 Canadian Person. The Shareholder Affiliate is a Canadian
corporation and is a tax resident of Canada.
4.14.3 Permanent Establishment or Business Activity. Except as
set forth in Schedule 4.14.3, (i) neither the Company nor any Subsidiary has, or
has had, either a permanent establishment in any foreign country, as defined in
any applicable tax treaty or convention between the United States and such
foreign country, or business activity in any country other than the United
States that would subject it to a Tax in such country that would not apply to a
United States Person without a business activity in such country; and (ii) the
Shareholder Affiliate has no permanent establishment in any foreign country, as
defined in any applicable tax treaty or convention between Canada and such
foreign country and has no business activity in any country other than Canada
that would subject it to a Tax in such country that would not apply to a
Canadian corporation without business activity in such country.
4.14.4 Security for Tax-Exempt Obligations. None of the Assets
directly or indirectly secures any debt the interest on which is tax exempt
under Section 103(a) of the Code.
4.14.5 Tax-Exempt Use Property. None of the Assets is
"tax-exempt use property" within the meaning of Section 168(h) of the Code.
4.14.6 U.S. Real Property. None of the Assets being sold by the
Shareholder Affiliate constitutes an interest in real property located in the
United States or property that would constitute an investment in United States
property (as defined in Section 956(b) of the Code) if held by a controlled
foreign corporation (as defined in Section 957 of the Code).
4.15 Material Obligations. Except as would not have a Material
Adverse Effect individually or in the aggregate, neither the Company, the
Shareholder Affiliate in respect of the Business nor any Subsidiary has any
debts, liabilities or obligations of any nature (whether accrued, absolute,
contingent, direct, indirect, perfected, inchoate, unliquidated or otherwise and
whether due or to become due) arising out of transactions entered into at or
prior to the Closing, or any transaction, series of transactions, action or
inaction at or prior to the Closing, or any state of facts or condition existing
at or prior to the Closing (regardless of when such liability or obligation is
asserted) including, without limitation, any Liabilities arising from or
relating to the Prior Business, except (a) to the extent specifically reflected
and accrued for or reserved against in the Financial Statements, (b) for
liabilities set forth on Schedule 4.15 or (c) for liabilities and obligations
which have arisen after the date of the Deal Balance Sheet in the ordinary
course of business consistent with past practice.
4.16 Brokerage. Other than the fee payable by Shareholder to
Gleacher & Co., its investment banker, there are no claims for brokerage
commissions, finder's fees or similar compensation in connection with the
transactions contemplated by this Agreement based on any arrangement or
agreement made by Shareholder or the Company.
4.17 Affiliated Transactions. Except as listed and described in
paragraph (a) of Schedule 4.6 or in Schedule 4.17 hereto, neither the Company
nor any Subsidiary is a party to any transaction or Commitment with any of their
respective Affiliates, and has no obligation or liability owing thereunder in
respect of the Business in excess of $50,000 or which is not cancelable by the
Company or a Subsidiary on at least 60 days' notice without penalty.
4.18 Insurance. Schedule 4.18 constitutes a true and complete
description of all of the policies in force and effect and a description of
their respective coverage and limits presently applicable to or including the
operations and property of the Business. All such policies will terminate at the
Closing. Neither Shareholder, the Company nor the Shareholder Affiliate has
received any notice of cancellation in respect of insurance coverage for
operations, assets and properties relating to the Business. All premiums due and
payable in respect of such insurance have been paid. There are no pending or, to
Shareholder's or the Company's knowledge, threatened terminations or premium
increases with respect to any such policies and the Company, the Subsidiaries
and the Shareholder Affiliate are in compliance with all material conditions
contained therein.
4.19 Real Property.
4.19.1 Title to Owned Real Property and Interests as Tenant
Under Leased Real Property. One or more of the Sellers or SI-Pace Inc., a
California corporation, hold:
(a) fee simple title to all of the real property listed in
Paragraph A of Schedule 4.19 attached hereto (collectively, the "Owned
Real Property"), and
(b) valid leasehold interests under each of the leases described
in Paragraph B of Schedule 4.19 (collectively, the "Leased Real
Property") attached hereto and all of such leases are in full force and
effect,
in each case free and clear of all Liens except, in each case,
(i) liens for current property taxes (including supplemental
taxes) and assessments for the 1994-95 fiscal year not yet due and
payable,
(ii) as to the Owned Real Property referred to in Paragraph A.1
of Schedule 4.19, the title exceptions referred to in Exception Nos. 2
through 31, inclusive, appearing in that certain Preliminary Report No.
9410439-21 dated April 12, 1994 (a copy of which preliminary report is
attached hereto as part of Schedule 4.19), issued by First American
Title Company of Los Angeles, none of which title exceptions are
easements which could have a Material Adverse Effect on the operation of
the Business,
(iii) as to the Owned Real Property referred to in Paragraph A.2
of Schedule 4.19, the title exceptions referred to in Exception Nos. 2
through 10, and 13 appearing in that certain Preliminary Report No.
9410437-21 dated April 12, 1994 (a copy of which preliminary report is
attached hereto as Paragraph A.3 of Schedule 4.19), issued by First
American Title Company of Los Angeles, none of which title exceptions
are easements which could have a Material Adverse Effect on the
operation of the Business,
(iv) as to the Owned Real Property referred to in Paragraph A.3
of Schedule 4.19, the title exceptions referred to in Exception Nos. 3,
4 and 5 appearing in that certain Preliminary Report No. 9433648 dated
April 22, 1994 (a copy of which preliminary report is attached hereto as
part of Schedule 4.19), issued by First American Title Company of Los
Angeles, none of which title exceptions are easements which could have a
Material Adverse Effect on the operation of the Business,
(v) as to the Leased Real Property, minor imperfections of
title, if any,
(vi) zoning laws or other land use restrictions, and
(vii) Liens which are reflected on the Financial Statements.
4.19.2 Complete List and Description of all Owned Real Property
and Leased Real Property. The Owned Real Property and the Leased Real Property
(hereinafter collectively referred to as the "Real Property") together
constitute all real properties used or occupied in connection with the Business
or reflected on the Financial Statements. The Owned Real Property listed in
Paragraph A of Schedule 4.19 is all of the real property in which the Sellers
have an ownership interest in respect of the Business. The Leased Real Property
listed in Paragraph B of Schedule 4.19 is all of the real property leased by any
of the Sellers as tenant and which is used or occupied for the Business.
4.19.3 Delivery of all Title Insurance Policies, Surveys, Title
Reports, Leases and Property Reports. Copies of all title insurance policies,
title reports, surveys, leases, architectural or engineering reports, soils
tests and reports, seismic tests and reports and environmental tests and reports
in the possession or control of the Sellers and which relate to the Owned Real
Property have been delivered to SJM; and true, correct and complete copies of
all the leases relating to the Leased Real Property have been delivered to SJM.
4.19.4 Condemnation. To Sellers' Knowledge, Sellers have not
received written notice or any other notice of any pending or threatened
condemnation proceeding or other similar proceeding by any public authority with
respect to any of the Owned Real Property.
4.19.5 Violation of Ordinances. To Sellers' Knowledge, Sellers
have not received any written notice or any other notice of any claimed
violation of zoning, building, health, or similar ordinances, codes or
regulations.
4.19.6 Assessed Value. To Sellers' Knowledge, no written notice
or any other notice of any increase in the assessed valuation or of any
contemplated special assessment has been received by Sellers with respect to the
Owned Real Property.
4.19.7 Government Licenses. To Sellers' Knowledge, all
facilities situated on the Owned Real Property have received all material
approvals of government authorities (including licenses and permits) required in
connection with the ownership or operation thereof and, to Sellers' knowledge,
Sellers have not received written notice or any other notice of any violation of
applicable laws, rules and regulations with respect to the operation of the
same.
4.19.8 Subleases. There are no leases, subleases, licenses,
concessions or other agreements, written or oral, granting to any party or
parties the right of use or occupancy of any portion of any parcel of Real
Property, except for the subleases described in Paragraph C of Schedule 4.19.
4.19.9 Options. There are no outstanding options or rights of
first refusal to purchase any parcel of Owned Real Property, or any portion
thereof or interest therein.
4.19.10 Possession. There are no parties (other than Sellers) in
possession of any parcel of Real Property, other than tenants under leases of
the Real Property who are in possession of space pursuant to those subleases
listed in Paragraph C of Schedule 4.19.
4.19.11 Utilities. To Sellers' Knowledge, all facilities
located on each parcel of Owned Real Property are supplied with utilities and
other services necessary for the operation of such facilities including gas,
electricity, water, telephone, sanitary sewer and storm sewer, all of which
services are adequate for the operation of such facility as presently conducted
for the operation of the Business in all material respects.
4.19.12 Proceedings. To Sellers' Knowledge, Sellers have not
received notice of any pending or contemplated condemnation, assessments or
other proceeding or charge affecting the Real Property that would have a
Material Adverse Effect on the operation of the Business.
4.19.13 Knowledge. For purposes of this Section 4.19, the term
"Sellers' Knowledge" shall have the meaning set forth in Section 13.1.
4.20 Inventory. The Company has previously disclosed to SJM by a
letter dated June 22, 1994 the accounting guidelines used by the Company, the
Shareholder Affiliate (in respect of the Business) and the Subsidiaries (and
used in the preparation of the Deal Balance Sheet) for valuing Inventory (as
defined below), including, without limitation, the guidelines used to determine
whether Inventory is obsolete or damaged, or will be slow-moving or defective.
4.21 Accounts and Notes Receivable. The Company has previously
disclosed to SJM by a letter dated June 22, 1994 the accounting guidelines used
by the Company the Shareholder Affiliate (in respect of the Business) and the
Subsidiaries (and used in the preparation of the Deal Balance Sheet) for valuing
accounts receivable.
ARTICLE 5
REPRESENTATIONS AND WARRANTIES OF SJM
SJM represents and warrants to Shareholder and the Company and
agrees with Shareholder and the Company as follows:
5.1 Corporate Power and Authority; Effect of Agreement.
5.1.1 Each of SJM and Acquisition Subsidiary is a corporation
duly organized, validly existing and in good standing under the laws of
Minnesota and Delaware, respectively, and has full corporate power and authority
to carry on its business as it is now being conducted. All of the issued and
outstanding capital stock of Acquisition Subsidiary is owned by SJM.
5.1.2 Each of SJM and Acquisition Subsidiary has full corporate
power and authority to execute and deliver this Agreement, perform its
obligations hereunder and to consummate the transactions contemplated hereby.
The execution and delivery of this Agreement, the performance by SJM and
Acquisition Subsidiary of its obligations hereunder and the consummation by SJM
and Acquisition Subsidiary of the transactions contemplated hereby have been
duly authorized by all necessary corporate action on the part of SJM and
Acquisition Subsidiary, and no other corporate proceedings on the part of SJM or
Acquisition Subsidiary are necessary to authorize the execution and delivery of
this Agreement, or to consummate the transactions so contemplated.
5.1.3 This Agreement has been duly executed and delivered by
SJM and Acquisition Subsidiary and constitutes the legal, valid and binding
obligation of SJM and Acquisition Subsidiary, enforceable against each such
party in accordance with its terms, except to the extent that such
enforceability (a) may be limited by bankruptcy, insolvency, reorganization,
moratorium or other similar laws relating to creditors' rights generally, and
(b) is subject to general principles of equity (regardless of whether such
enforceability is considered in a proceeding in equity or at law).
5.1.4 The execution, delivery and performance by SJM and
Acquisition Subsidiary of this Agreement or the other documents contemplated
hereby and the consummation by them of the transactions contemplated hereby and
thereby do not and will not contravene or constitute a default under or give
rise to a right of termination, cancellation or acceleration of any right or
obligation of SJM or Acquisition Subsidiary or to a loss of any benefit to which
SJM or Acquisition Subsidiary is entitled under (i) except as would not be
materially adverse to the operations, results of operations, assets or financial
condition of SJM and the SJM Affiliates, taken as a whole, or have a material
adverse effect on the ability of SJM or Acquisition Subsidiary to consummate the
transactions contemplated by this Agreement, any provision of applicable law or
regulation (assuming the governmental consents referred to in Section 5.2 have
been obtained); (ii) the articles of incorporation or bylaws of SJM and
Acquisition Subsidiary; (iii) any judgment, injunction, order, decree,
administrative interpretation, award or other instrument binding upon SJM or
Acquisition Subsidiary; or (iv) result in the creation or imposition of any Lien
on any asset of SJM or Acquisition Subsidiary which would have a material
adverse effect on their ability to consummate the transactions contemplated
hereby.
5.2 Consents. Except for the filing under the HSR Act and
otherwise as set forth in Schedule 5.2, no consent, approval or authorization
of, or exemption by, or filing with, any governmental or regulatory authority or
any other third party is required in connection with the execution, delivery or
performance by SJM or Acquisition Subsidiary of this Agreement or the taking by
SJM or Acquisition Subsidiary of any other action contemplated hereby,
excluding, however, consents, approvals, authorizations, exemptions and filings,
if any, which any of Shareholder, the Shareholder Affiliate, any Subsidiary or
the Company is required to obtain or make.
5.3 Availability of Funds. SJM has available, or will have
available on the Closing Date, sufficient funds to enable it to consummate the
transactions contemplated by this Agreement.
5.4 Litigation. There is no Litigation pending or, to SJM's
knowledge, threatened, which seeks to enjoin or obtain damages in respect of the
consummation of the transactions contemplated hereby.
5.5 Brokerage. Other than the fee payable by SJM to CS First
Boston Corporation, its investment banker, there are no claims for brokerage
commissions, finder's fees or similar compensation in connection with the
transactions contemplated by this Agreement based on any arrangement or
agreement by SJM.
5.6 Certain Ownership Interests. SJM is not directly or
indirectly "significantly funded" (as that phrase is defined in Section
12(B)(c)(i) of the Settlement Agreement and Section 9.02(c)(i) of the License
Agreement), nor is there, directly or indirectly "significant voting common
stock or other voting equity ownership" (as that phrase is defined in Section
12(B)(c)(i) of the Settlement Agreement) in SJM, by the Japanese government or
investors of Japanese nationality; and (ii) it is not directly or indirectly
"significantly funded" (as that term is defined in Section 12(B)(c)(ii) of the
Settlement Agreement and Section 9.02(c)(ii) of the License Agreement), nor is
there, directly or indirectly "significant voting common stock or other voting
equity ownership" (as that phrase is defined in Section 12(B)(c)(ii) of the
Settlement Agreement and 9.02 (c)(ii) of the License Agreement) in SJM, by a
national government other than Japan.
ARTICLE 6
COVENANTS
6.1 Cooperation. Each of the parties hereto will use its
reasonable best efforts to cause the consummation of the transactions
contemplated hereby in accordance with the terms and conditions hereof and
applicable law. Each of the parties hereto will use its reasonable best efforts
to obtain all governmental consents and approvals necessary to consummate the
transactions contemplated by this Agreement and to cause the Closing to occur.
Each of Shareholder, the Company and the Shareholder Affiliate shall use its
reasonable best efforts to obtain the consent or approval of third Persons to
the transactions contemplated hereby with respect to the Commitments identified
on Schedule 4.6 and the Permits, if any, identified on paragraph (b) of Schedule
4.8 as requiring such consent or approval. The Company, Shareholder and SJM
agree that, in the event any consent or approval of any such third Person
necessary or desirable to preserve for the Business any right or benefit under
any such Commitment or Permit is not obtained prior to the Closing (and provided
that SJM waives any resulting failure of a condition under Article 8),
Shareholder will, subsequent to the Closing, cooperate with SJM and any SJM
Affiliate in attempting to obtain such consent or approval as promptly
thereafter as practicable. If such consent or approval cannot be obtained,
Shareholder shall use its reasonable best efforts, and cause the other Sellers
to use their reasonable best efforts, to provide SJM and any SJM Affiliate with
the rights and benefits of the affected Commitment or Permit for the term of
such Commitment or Permit and, if and to the extent that Shareholder or another
Seller provides the rights and benefits under any such Commitment or Permit or
any other contract for which consent or approval cannot be obtained, SJM shall
assume the obligations and burdens thereunder to such extent. After the Closing,
Shareholder and the other Sellers shall cooperate with SJM in the preparation of
any financial statements required to be filed by SJM with respect to the
Business pursuant to U.S. federal securities laws.
6.2 Conduct of Business. From the date hereof until the
Closing, the Company and the Shareholder Affiliate shall cause the Business to
be conducted in the ordinary course consistent with past practice. Without
limiting the generality of the foregoing, from the date hereof until the
Closing:
6.2.1 Each of Shareholder and the Company will use and will
cause the Shareholder Affiliate and the Subsidiaries to use all reasonable
efforts to:
(a) preserve the Business as a whole intact;
(b) keep available the services of the present officers,
employees and agents of the Business such that the Business will not
suffer a Material Adverse Effect;
(c) preserve the relationships with suppliers, customers,
distributors, licensors and licensees and others having business
dealings with it such that the Business will not suffer a Material
Adverse Effect;
(d) collect the receivables of the Business in a manner
consistent with past practice;
(e) maintain the assets, properties and interests of the
Business in customary repair, order and condition or, with respect to
the casualty, loss or damage of any assets of the Business that are
covered by insurance, transfer, at the Closing, to SJM the proceeds of
any insurance recovery with respect thereto (provided that SJM has
waived any failure of a condition under Article 8 resulting from the
casualty, loss or damage);
(f) continue to compensate the employees of the Business in a
manner consistent with past practice;
(g) maintain the books, accounts and records relating to the
Business in accordance with past practice as used in the preparation of
the Financial Statements described in Section 4.2 hereof; and
(h) promptly inform SJM in writing of any material variances
from the representations and warranties contained in Article 4 hereof.
6.2.2 Prior to the Closing, without the prior written consent
of SJM or unless otherwise contemplated or permitted by this Agreement, neither
the Company, the Shareholder Affiliate (in respect of the Business) nor the
Subsidiaries will:
(a) take any action described in Section 4.3 of this Agreement;
(b) except for the Shareholder Affiliate, amend its certificate
of incorporation or bylaws;
(c) except for the Shareholder Affiliate, merge or consolidate
with any person, acquire any stock or other ownership interest in any
Person or substantially all of the assets of any business as an entity
or liquidate, dissolve or otherwise reorganize or seek protection from
creditors;
(d) except as set forth in Schedule 6.2.2, enter into any other
agreements, commitments or contracts (including without limitation joint
venture agreements or material license agreements) which are material to
the Business, except agreements, commitments or contracts entered into
in the ordinary course for the purchase, sale or lease of goods or
services, consistent with past practice; or
(e) make any investment of a capital nature either by purchase
of stock or securities, contributions to capital, property transfers or
otherwise, or by the purchase of any property or assets of any other
individual, firm or corporation.
6.3 Intercompany Indebtedness. Prior to the Closing Date, all
intercompany indebtedness, liabilities and obligations owed by Shareholder or
any Affiliate of Shareholder (other than the Company, any Subsidiary or any
other Affiliate of Shareholder (in respect of the Cardiac Stimulation Device
business conducted by such Affiliate)) on the one hand, and the Company, the
Shareholder Affiliate (in respect of the Business) or any Subsidiary, on the
other hand, shall be netted, and if the Company, the Shareholder Affiliate or
any Subsidiary still has amounts owing, such amounts shall be dividended to
their respective shareholders and if Shareholder or any such Affiliate still has
amounts owing, such amounts shall be forgiven.
6.4 Access.
6.4.1 Shareholder and the Company shall provide, and shall
cause each of the Subsidiaries and the Shareholder Affiliate to provide, SJM,
its counsel, financial advisors, auditors and other authorized representatives,
with such information as SJM from time to time reasonably may request with
respect to the Company, the Assets, the Shareholder Affiliate (but only with
respect to the Business) and the Subsidiaries, and shall permit, and shall cause
each of the other Sellers to permit, SJM and its representatives reasonable
access, during regular business hours and upon reasonable notice, to the
offices, properties, books and records of the Company, the Shareholder Affiliate
(but only with respect to the Business), and the Subsidiaries, as SJM from time
to time reasonably may request, and will instruct the employees, counsel and
financial advisors of Shareholder, the Company, the Subsidiaries and the
Shareholder Affiliate to cooperate with the investigation of the Business;
provided that no investigation shall affect any warranties or representations
given by Shareholder or the Company to SJM in this Agreement and provided
further, however, that any such investigation shall be conducted in such a
manner so as not to interfere with the operations of the Business consistent
with past practice. This will include, without limitation, access promptly
following execution of this Agreement to information, books, records, and
personnel regarding product pricing, supplier costs, specifications for products
in development and U.S. patent applications. In addition, to the extent not
previously delivered or made available to SJM, Shareholder and the Company shall
cause to be delivered or made available to SJM all internal or third party
environmental and health and safety studies and reports with respect to the
Business, including without limitation, the audit report of Stat-a-matrix
supporting the certificate of compliance submitted to the FDA as well as any
other audit reports from Stat-a-matrix and correspondence between Stat-a-matrix
and the Company, in each case after January 1, 1992. If, in the course of SJM's
investigation of the Business, SJM learns of any fact or circumstance that may
make any of Shareholder's or the Company's representations or warranties in this
Agreement untrue in any material respect, SJM shall promptly inform Shareholder
of such fact or circumstance.
6.4.2 In order to facilitate the resolution of any claims made
by or against or incurred by Shareholder or Shareholder Affiliate with respect
to third parties prior to or after the Closing, upon reasonable notice, SJM
shall and shall cause its Affiliates to, after the Closing: (i) afford the
officers, employees and authorized agents and representatives of Shareholder
reasonable access, during regular business hours, to the offices, properties,
books and records of Acquisition Subsidiary (and any successor thereto) and its
Affiliates relating to the Business, (ii) furnish to the officers, employees and
authorized agents and representatives of Shareholder such additional financial
and other information regarding the Business as Shareholder may from time to
time reasonably request and (iii) make available to Shareholder, the employees
of Acquisition Subsidiary (and any successor thereto) and its Affiliates whose
assistance, testimony or presence is necessary to assist Shareholder in
evaluating any such claims and in defending such claims, including the presence
of such persons as witnesses in hearings or trials for such purposes; provided,
however, that such investigation shall not unreasonably interfere with the
businesses or operations of SJM, Acquisition Subsidiary or any of their
Affiliates; provided further, however, that neither SJM nor any of its
Affiliates shall be obligated to disclose any information which it holds under a
legally binding obligation of confidentiality or which is protected by any
privilege.
6.4.3 In order to facilitate the resolution of any claims made
by or against or incurred by SJM or any of its Affiliates with respect to third
parties after the Closing, upon reasonable notice, Shareholder and the
Shareholder Affiliate in respect of the Business shall, after the Closing: (i)
afford the officers, employees and authorized agents and representatives of SJM
reasonable access, during regular business hours, to the offices, properties,
books and records of the Seller with respect to the Business, (ii) furnish to
the officers, employees and authorized agents and representatives of SJM such
additional financial and other information regarding the Business for the period
prior to the Closing as SJM may from time to time reasonably request and (iii)
make available to SJM, the employees of the Sellers whose assistance, testimony
or presence is necessary to assist SJM in evaluating any such claims and in
defending such claims, including the presence of such persons as witnesses in
hearings or trials for such purposes; provided, however, that such investigation
shall not unreasonably interfere with the business or operations of Shareholder
or its Affiliates; provided further, however, that neither Shareholder nor any
of its Affiliates shall be obligated to disclose any information which they hold
under a legally binding obligation of confidentiality or which is protected by
any privilege.
6.5 Non-Disclosure Agreement. The terms of the Bilateral
Non-Disclosure Agreement (the "Non-Disclosure Agreement"), dated as of October
27, 1993, between the Company and SJM are hereby incorporated by reference,
except that Section 10 thereof shall be deemed amended to provide that New York
law shall govern the Non-Disclosure Agreement and that any disputes relating
thereto shall be brought before a federal court sitting in New York, New York.
Each of the parties hereto agrees to be bound by the terms of the Non-Disclosure
Agreement which is incorporated herein by reference. The NonDisclosure Agreement
shall remain in full force and effect until the Closing.
6.6 Antitrust, Competition Law Filings. As promptly as
practicable after the execution of this Agreement, each party to this Agreement
shall file or cause its Affiliates to file any reports or notifications that may
be required to be filed under the HSR Act and such other competition,
investment, foreign exchange, tax or other laws of such other jurisdictions as
may be necessary to effect the transactions contemplated by this Agreement.
6.7 Non-Foreign Person Affidavit. Shareholder and the Sellers
(other than the Shareholder Affiliate) shall furnish to SJM at or before the
Closing a non-foreign person affidavit, as provided for in Section 1445(b)(2) of
the Code.
6.8 Transfer of Real Property. Sellers shall take such actions
as are necessary to transfer, or cause to be transferred, to SJM (or such
Affiliates of SJM that SJM shall designate) on the Closing Date, all of the
Owned Real Property and the Leased Real Property, subject only to the title
exceptions referred to in Section 4.19.1 above.
6.9 Certain Dividends. From the date hereof until the Closing,
each of the Company and the Subsidiaries may declare and pay dividends to their
respective shareholders to reflect estimated pre-Tax earnings of the Company and
the Subsidiaries for the period from September 30, 1993 to the Closing Date.
6.10 Certain Actions Prior to the Closing Date. Prior to the
Closing Date, Shareholder shall cause the Company to transfer, whether in the
form of a dividend or otherwise, those assets listed on Schedule 6.10 out of the
Company. Shareholder shall not transfer to the Company or the Subsidiaries any
material assets, except as provided in Section 6.8.
6.11 Claims History. Without limiting the generality of Section
6.4, Shareholder, the Shareholder Affiliate and the Company shall promptly make
available and furnish access to SJM a products claims history with respect to
the Company, the Shareholder Affiliate (but only with respect to the Business)
and the Subsidiaries.
6.12 FDA Recertification. Without limiting the generality of
Section 6.4, Shareholder and the Company shall promptly furnish to SJM copies of
written communications with the FDA in respect of the Business made or received
by the Company pursuant to or in connection with the terms of that certain
Consent Decree of Permanent Injunction (captioned U.S. v. Siemens Medical
Systems, Inc. and dated March 23, 1994) (the "Consent Decree") including without
limitation certificates of compliance made to the FDA by or on behalf of the
Company or the Subsidiaries, and the responses, if any, by the FDA of such
certificates. Shareholder and the Company shall promptly furnish or make
available such other information as SJM may reasonably request regarding
compliance by the Company and the Subsidiaries with the applicable terms of the
Consent Decree.
6.13 Grant of License. SJM and the SJM Affiliates hereby grant
to Siemens Aktiengesellschaft ("Siemens AG"), effective at the Closing, a
worldwide, irrevocable, non-exclusive, perpetual, royalty free, paid up right
and license to use the patents, copyrights, trade secrets, designs, drawings,
software, know-how, technology and other intellectual property and proprietary
matters owned or used by the Company or any of its Subsidiaries or assigned or
transferred to SJM or one of its Affiliates, to make, have made, sell, have
sold, use, lease, license, or otherwise dispose of products intended for use in
or as products, other than Cardiac Stimulation Devices (including, without
limitation, the right and license to make, have made, sell, have sold, use,
lease, license or otherwise dispose of Cardiac Stimulation Devices or parts,
components, modules, subsystems or subassemblies thereof, in or as parts,
components, modules, subsystems or subassemblies of or for, products intended
for use other than as Cardiac Stimulation Devices), and to render services with
respect to any such products used or intended for use or uses other than as
Cardiac Stimulation Devices. The rights and licenses granted under this Section
6.13 may be freely sublicensed, assigned, transferred or disposed of, in whole
or in part, without the prior written consent of SJM, any of its Affiliates or
any of the successors in interest of any of the foregoing; any license,
assignment, transfer or other disposition by SJM, any of its Affiliates, the
Company, any of its Subsidiaries and any of the successors in interest of any of
the foregoing shall be subject to such rights and licenses granted to Siemens
AG.
6.14 Other Financial Statements. On or before the earlier of
(i) the date which is 30 days from the date hereof and (ii) the Closing Date,
the Company and Shareholder shall deliver to SJM an audited balance sheet for
the Business as of September 30, 1992, as well as an audited income statement
and cash flow statement for the fiscal year then ended, together with related
notes and schedules thereto, prepared from the books and records of the Business
in accordance with U.S. GAAP on a consistent basis. Upon the delivery by the
Company and Shareholder to SJM of the Closing Balance Sheet, the Company and
Shareholder shall also deliver to SJM an audited income statement and cash flow
statement for the Business for the period beginning October 1, 1993 and ending
on the Closing Date, together with related notes and schedules thereto. Within
30 calendar days after the end of June, 1994, and each calendar month
thereafter, Shareholder and the Company shall deliver to SJM unaudited profit
and loss information for the Business based on financial information normally
prepared by the Company for delivery to Shareholder. To the extent necessary to
permit SJM to comply with the rules and regulations of the Securities and
Exchange Commission, Shareholder shall provide to SJM financial information
prepared in accordance with U.S. GAAP consisting of an unaudited interim balance
sheet, dated as of the last day of, and an income statement and statement of
cash flow, for the period beginning January 1, 1994 and ending on the last day
of, such calendar quarter as required by the applicable rules and regulations of
the Securities and Exchange Commission. If the last day of such calendar quarter
is after the Closing Date, Shareholder shall cooperate in the preparation of
such interim unaudited financial statements.
ARTICLE 7
ADDITIONAL COVENANTS
7.1 Liability for Employee Benefit Plans.
7.1.1 In General. SJM or an Affiliate of SJM shall make
available to those Employees listed on Schedule 4.11, Employee Benefit Plans
that are no less favorable to such Employees, taken as a whole, than the
Employee Benefits Plans made available to similarly situated employees of SJM.
SJM shall, or shall cause an SJM Affiliate to, provide each Employee listed on
Schedule 4.11 who becomes an employee of SJM or an SJM Affiliate with service
credit as of the Closing Date for their years of service with Shareholder, the
Company, or any Affiliate of either the Company or Shareholder prior to the
Closing Date for purposes of eligibility to participate, eligibility for
benefits, calculation of benefits (other than the accrual of benefits under any
Employee Pension Benefit Plan as defined in Section 4.10.5) and vesting under
the Employee Benefit Plans made available to such Employee as provided in this
Section 7.1.1. SJM agrees to waive any pre-existing conditions (other than
pre-existing conditions recognized by the Company Employee Benefit Plan
immediately prior to the Closing Date) and credit the Employee for the current
plan year with any amounts paid toward the deductibles and the out-of-pocket
limits under such Employee Benefit Plans. SJM agrees to accept the transfer of
account balances in the Company's health care and dependent care reimbursement
Plans and to allow Employees to continue deductions and submitting claims
through year-end to the extent permitted by law. As of the Closing Date, SJM
shall offer employment to each Employee (other than a former employee).
7.1.2 Liability for Company Employee Benefit Plans. (a) On the
Closing Date, subject to the provisions in Section 7.1.4 and except as provided
in Sections 7.1.2(c) and 7.3, SJM shall assume, or cause a designated SJM
Affiliate to assume, each Company Employee Benefit Plans, and all liabilities
relating to such Company Employee Benefit Plan, whether arising before, on or
after the Closing Date except for any liabilities under the Employee Benefit
Plans for Employees in Canada arising prior to the Closing Date. SJM, or the
designated SJM Affiliate referred to in the immediately preceding sentence, also
shall assume on the Closing Date all liabilities of Shareholder, the Company or
any of their respective Subsidiaries to Employees for wages, incentive
compensation, vacations, perquisites, worker's compensation benefits, statutory
benefits and entitlements, including, without limitation, all obligations to
Employees under applicable federal or local law, including pursuant to the
Worker Adjustment and Retraining Notification Act and any COBRA Obligations.
(b) The Company or its third-party administrator, trustee or
insurance carrier shall assign to SJM any insurance policies or other assets
segregated for purposes of funding benefits pursuant to the Company Employee
Benefit Plans, the Executive Arrangements and any liabilities assumed pursuant
to Section 7.1.2(a).
(c) With respect to the Siemens-Pacesetter 401(k) Profit
Sharing Plan and Trust (the "Company 401(k) Plan"):
As of the Closing Date, SJM or the designated SJM Affiliate
shall adopt, as sole sponsoring employer, the Company 401(k) Plan and,
as of such adoption, shall assume all of the liabilities and
obligations of the Company 401(k) Plan and of Shareholder and the
Company (except for any breach of any duty or obligation occurring
prior to the Closing Date) with respect to the Company 401(k) Plan and
Shareholder and the Company shall be relieved of all liabilities and
obligations to the Plan's participants and their beneficiaries arising
under the Plan, except for any breach of any duty or obligation
occurring prior to the Closing Date. As of the Closing Date, the
Company shall cease to be a sponsoring employer, administrator or
fiduciary with respect to the Company 401(k) Plan and shall transfer
direction and control with respect to the Company 401(k) Plan and its
related trust and assets to SJM or its designated SJM Affiliate.
7.1.3 Nothing herein expressed or implied is intended or shall
be construed to confer upon or give to any person, firm or corporation, other
than the parties hereto and their respective permitted successors and assigns,
any rights or remedies under or by reason of this Agreement.
7.1.4 Shareholder, the Company, the Shareholder Affiliate and
the Controlled Group that includes Shareholder, shall indemnify, save and hold
harmless SJM, and the SJM Affiliates designated in Section 2.1 and the
Controlled Group of which SJM is a member from and against any and all Losses:
(a) arising under any Employee Pension Benefit Plan or any Employee Welfare
Benefit Plan maintained or contributed to by the Company, Shareholder or the
Shareholder Affiliate or any member of the Controlled Group of which the
Company, its Subsidiaries or the Shareholder Affiliate is a member, other than a
Company Employee Benefit Plan and obligations assumed by SJM and the SJM
Affiliates pursuant to Section 7.1.2 above, regardless of whether the Losses
relate to conditions or events arising out of transactions which occur prior to,
on or after the Closing Date; (b) arising out of the liabilities retained by
Shareholder, the Company or Shareholder Affiliate under Sections 7.1.2(a),
7.1.2(c) and 7.3; (c) attributable to Employees who do not become employees of
SJM or the designated Affiliate of SJM on the Closing Date. Subject to the
preceding sentence, SJM and the SJM Affiliates shall indemnify, save and hold
harmless Shareholder and the Shareholder Affiliate for any and all Losses
related to the Company Employee Benefit Plans and obligations assumed by SJM and
the SJM Affiliates pursuant to Section 7.1.2 above, regardless of whether such
Losses relate to conditions or events arising out of transactions that occur
prior to, on or following the Closing Date. The provisions of Sections 10.4,
10.6 and 10.7 shall apply, but the provisions of Section 10.5 shall not apply,
to the indemnification provided under this Section 7.1.4.
7.2 Tax Matters. The following provisions shall govern
the allocation of responsibility as between SJM and Shareholder for certain
Tax matters following the Closing Date:
7.2.1 Responsibility for Taxes. Except as otherwise provided in
Sections 7.2.2 and 7.2.3, Shareholder shall be solely responsible for all
Liabilities for any and all Taxes of Shareholder, the Sellers, their respective
Affiliates, any group of Persons or member of a group of Persons with which
Shareholder, any Seller and/or their respective Affiliates filed or files Tax
Returns on a combined basis and/or any Affiliated Group or member of an
Affiliated Group of which Shareholder, any Seller and/or their respective
Affiliates is, was or becomes a member. Except as otherwise provided in Sections
7.2.2 and 7.2.3, SJM shall be solely responsible for all Liabilities for any and
all Taxes of SJM, its Affiliates, any group of Persons or member of a group of
Persons with which SJM and/or its Affiliates files Tax Returns on a combined
basis, and/or any Affiliated Group or member of an Affiliated Group of which SJM
and/or its Affiliates is, was, or becomes a member, except for Liabilities for
Taxes imposed on Shareholder, the Sellers and/or their respective Affiliates for
which SJM or an SJM Affiliate becomes liable by virtue of its status as a
successor to the Assets and/or the Business.
7.2.2 Sales and Other Tax. SJM will pay, and shall indemnify
and hold the Company, Shareholder and their Affiliates harmless against, up to
$4,000,000 of (a) transfer, documentary, recording, notarial, sales, use,
registration, stamp and other similar taxes, fees and expenses (including, but
not limited to, all applicable stock transfer taxes and real estate transfer
taxes, however computed, including a tax based on the excess of sale price over
original cost) and including any penalties, interest and additions to such tax)
and (b) all expenses incurred in the transfer of intellectual property,
including, without limitation, the cost of all patent and trademark
registrations contemplated hereby, in each case incurred in connection with this
Agreement and the transactions contemplated hereby and each of Shareholder and
SJM will be responsible for the payment of, and shall indemnify and hold the
other party harmless against 50% of all such amounts in excess of $4,000,000
incurred in connection with this Agreement and the transactions contemplated
hereby; provided, however, that SJM will be solely responsible for the payment
of the Canadian Goods and Services Tax; and provided further that, if allowed by
Canadian law, SJM will be permitted to satisfy its obligation to pay the
Canadian Goods and Services Tax by assigning its claim for a refund of such
taxes to the Shareholder Affiliate. To the extent permitted under applicable
law, SJM shall satisfy its obligation under this Section 7.2.2 by paying
directly to the relevant tax authority (i) first, those taxes and expenses which
are imposed by applicable law solely on SJM or its Affiliates and which SJM
acknowledges at the time of the Closing are due and owing, and (ii) second,
those taxes and expenses which are imposed by applicable law jointly on
Shareholder or its Affiliates and SJM or its Affiliates and which SJM
acknowledges at the time of the Closing are due and owing.
7.2.3 Property Taxes. In the case of any taxable period that
includes (but does not end on) the Closing Date (a "Straddle Period"):
(a) Real, personal and intangible property Taxes and other
similar taxes ("Property Taxes") that are imposed by virtue of the ownership of
assets (as opposed to taxes that are imposed as a result of the transfer of
assets) with respect to the Assets for a Straddle Period shall be divided
between the Tax years (or portions thereof) ending on or prior to the Closing
Date (the "Pre-Closing Tax Period") and a Post-Closing Tax period that begins
the day following the Closing Date (a "Post-Closing Tax Period"), and the amount
of Taxes allocated to the Pre-Closing Tax Period or a Post-Closing Tax Period,
as the case may be, shall be equal to the amount of such Property Taxes accrued
(i.e., based upon the date of assessment of such Property Taxes and not upon the
date of payment thereof unless the Tax is related to a definite period of time,
in which case it will be treated as accruing ratably over that period) for the
entire Straddle Period multiplied by a fraction, the numerator of which is the
number of days during the Straddle Period that are in the Pre-Closing Tax Period
or a Post-Closing Tax Period, as the case may be, and the denominator of which
is the number of days in the Straddle Period.
(b) Shareholder shall satisfy its obligation in respect of
Taxes for the Straddle Period by paying to SJM the excess of (i) such Straddle
Period Taxes for the Pre-Closing Tax Period over (ii) the sum of such Straddle
Period Taxes paid by Shareholder, the Seller or their respective Affiliates.
Shareholder shall pay, or cause its Affiliate to pay, such excess, if any, to
SJM within thirty (30) days after the date of the Tax Return relating to such
Straddle Period Taxes is required to be filed (or, if later, is actually filed
but no earlier than the later of the date SJM pays its share of Straddle Period
Taxes or, if SJM or an Affiliate is responsible for filing the Tax Return in
question, thirty (30) days after Shareholder has received a copy of the Tax
Return with respect to which the Straddle Period Taxes are owing). If the sum of
such Straddle Period Taxes paid by Shareholder, the Sellers or their respective
Affiliates exceeds the Straddle Period Taxes for the Pre-Closing Tax Period, SJM
shall pay, or cause its Affiliate to pay, to Shareholder the amount of such
excess, if any, within thirty (30) days after the date of the Tax Return
relating to such Straddle Period Taxes is required to be filed (or, if later, is
actually filed but no earlier than the later of the date Shareholder pays its
share of Straddle Period Taxes or, if Shareholder or an Affiliate is responsible
for filing the Tax Return in question, thirty (30) days after SJM has received a
copy of the Tax Return with respect to which the Straddle Period Taxes are
owing). Payments to be made pursuant to this paragraph by Shareholder, SJM or
their affiliates with respect to any Straddle Period shall be appropriately
adjusted to reflect any final determination (which shall include the execution
of a Form 870-AD or successor form) with respect to Straddle Period Taxes.
7.2.4 Retention of Records. Each of SJM and Shareholder shall
retain (or cause to be retained) all books, records and other data pertaining to
Tax matters for all open periods or portions thereof ending on or before the
Closing Date other than books, records and data pertaining to Taxes based on or
measured by income, which neither party shall have an obligation to retain for
the benefit of the other. In particular, SJM and Shareholder shall retain (or
cause to be retained) all non-income-tax related Tax Returns, schedules and work
papers, and all material records and other documents relating thereto with
respect to the operations of the Sellers prior to the Closing Date, until the
expiration of the statute of limitations (and, to the extent notified by SJM or
Shareholder, any extension thereof) of the respective Tax periods and shall not
destroy any such documents thereafter without providing thirty (30) days'
written notice to Shareholder, or to SJM, as the case may be.
7.2.5 Notice; Cooperation. Nothing in this Section 7.2.5 shall
require any party to provide notices or cooperation with respect to matters
pertaining to Taxes that are based on or measured by income. Each of SJM and
Shareholder shall promptly provide written notice to the other upon receiving
(or upon an Affiliate receiving) notice from a taxing authority that additional
non-income Tax liabilities may exist or that any non-income-tax related books or
records have been requested by any taxing authority. SJM and Shareholder
covenant and agree that subsequent to the Closing, upon reasonable notice and
during normal business hours, they and their Affiliates will (i) give the other
party and its representatives information, books and records relevant to the
Sellers to the extent necessary to enable the other party to prepare its
non-income tax related Returns, and (ii) provide the other party or its
Affiliates with such information, books and records as may reasonably be
requested in connection with any non-income-tax related Tax Return, inquiry,
election, audit or other examination by any taxing authority, or judicial or
administrative proceeding relating to liability for Taxes. SJM and Shareholder
also shall make available to each other, as reasonably requested, and at the
expense of the requesting party, knowledgeable employees or advisors of the
party or its Affiliates of which the request is made and personnel responsible
for preparing and maintaining information, books, records and documents in
connection with non-income-tax related Tax filings, audits, disputes or
litigation. If Shareholder, SJM or any of their Affiliates pay any Taxes that,
pursuant to this Agreement, are to be borne by another party, such other party
shall promptly reimburse such paying party for the Taxes paid.
7.2.6 Refunds. Except as otherwise provided in this Section
7.2.6, any refunds or credits of Taxes of Shareholder, Sellers or their
Affiliates relating to taxable periods ending on or before the Closing Date
shall be for the account of Shareholder; provided, however, that any refunds or
credits of Taxes which are accrued on the Closing Balance Sheet or which result
from a payment of any Taxes by SJM or any Affiliate either directly or
indirectly, shall belong to SJM. Any refunds or credits of Taxes relating to any
Straddle Period shall be equitably apportioned between Shareholder, Sellers and
their Affiliates and SJM and its Affiliates consistently with Section 7.2.3. Any
amounts payable to Shareholder pursuant to this Section 7.2.6 shall be net of
any Tax cost or benefit to SJM or its Affiliates attributable to the receipt of
such refund and/or the payment by SJM of such amounts to Shareholder. Any
amounts payable to SJM pursuant to this Section 7.2.6 shall be net of any Tax
cost or benefit to Shareholder, Sellers or their Affiliates attributable to the
receipt of such refund and/or the payment by Shareholder of such amounts to SJM.
If any party receives any refunds or credits that, pursuant to this Agreement,
are the property of another party, such party shall promptly pay the amount of
such refunds or credits to the other party.
7.2.7 Certain Contest Rights. (a) Promptly after the receipt by
SJM or Shareholder or their respective Affiliates (the "Prospective Indemnitee")
of a written notice of any demand, claim or circumstance which, after the lapse
of time, would or might give rise to a claim or the commencement (or threatened
commencement) of any action, proceeding or investigation with respect to which
indemnity may be sought under this Section 7.2 (an "Asserted Tax Liability"),
the Prospective Indemnitee shall give notice thereof (the "Tax Claim Notice") to
the other party (the "Prospective Indemnitor"). The Tax Claim Notice shall
contain factual information (to the extent known to the Prospective Indemnitee)
describing the Asserted Tax Liability in reasonable detail and shall include
copies of any notice or other document received from any Taxing authority with
respect to any such Asserted Tax Liability. If the Prospective Indemnitee fails
to give the Prospective Indemnitor notice of an Asserted Tax Liability as
required by this Section 7.2.3, and if such failure to give notice results in a
detriment to the Prospective Indemnitor, then any amount to which the
Prospective Indemnitor is otherwise required to pay pursuant to Section 7.2 with
respect to the Asserted Tax Liability shall be reduced by the amount of such
detriment.
(b) The Prospective Indemnitor may elect to direct, through
counsel of its own choosing and at its own expense, the compromise or contest,
either administratively or in the courts, of any Asserted Tax Liability. If the
Prospective Indemnitor elects to direct the compromise or contest of such
Asserted Tax Liability, it shall within 30 calendar days (or sooner, if the
nature of the Asserted Tax Liability so requires) notify the Prospective
Indemnitee of its intent to do so, and the Prospective Indemnitee shall
cooperate and shall cause its Affiliates to cooperate, at the Prospective
Indemnitor's expense, in the compromise or contest of such Asserted Tax
Liability. The Prospective Indemnitor may not enter into on behalf of the
Prospective Indemnitee or its Affiliates a settlement agreement with respect to
any Asserted Tax Liability without the written consent of the Prospective
Indemnitee; provided, however, that, if the Prospective Indemnitee does not
grant such consent to the Prospective Indemnitor with respect to the settlement
of an Asserted Tax Liability, the Prospective Indemnitor may satisfy its
indemnity obligation under this Section 7.2 with respect to the Asserted Tax
Liability by paying to the Prospective Indemnitee (or its Affiliates) the amount
which the Prospective Indemnitor (or its Affiliate) would have paid if such
consent had been granted and the Asserted Tax Liability settled pursuant to such
settlement agreement. If the Prospective Indemnitor elects not to direct the
compromise or contest of the Asserted Tax Liability, fails to notify the
Prospective Indemnitee of its election, contests its obligation to indemnify
under this Section 7.2 or if the Prospective Indemnitee refuses to grant consent
to the Prospective Indemnitor to enter into a settlement agreement with respect
to an Asserted Tax Liability, the Prospective Indemnitee or its Affiliates may
pay, compromise or contest such Asserted Tax Liability, and the Prospective
Indemnitor shall cooperate (including granting any necessary powers of attorney)
in such contest. The Prospective Indemnitee's settlement or compromise of an
Asserted Tax Liability under the conditions set forth in the preceding sentence
shall not affect the Prospective Indemnitor's indemnity obligation pursuant to
Section 7.2; provided, however, that the Prospective Indemnitor will not be
obligated to indemnify the Prospective Indemnitee (or its Affiliates) for any
amounts in excess of the amount the Prospective Indemnitor would have paid
pursuant to a settlement agreement if the Prospective Indemnitee had given its
written consent to the Prospective Indemnitor with respect to such settlement
agreement. In any event, the Prospective Indemnitor (or its Affiliates) and the
Prospective Indemnitee (or its Affiliates) may participate, at its own expense,
in the contest of such Asserted Tax Liability. If the Prospective Indemnitor
chooses to direct the compromise or contest of any Asserted Tax Liability, the
Prospective Indemnitee shall promptly empower and shall cause its Affiliates to
promptly empower (by power of attorney and such other documentation as may be
appropriate) such representative of the Prospective Indemnitee as it may
designate to represent the Prospective Indemnitor or its Affiliates in any
audit, claim for refund or administrative or judicial proceeding insofar as such
audit, claim for refund or proceeding involves an Asserted Tax Liability for
which the Prospective Indemnitor would be liable under Section 7.2.
7.2.8 Indemnification. Shareholder agrees to indemnify and hold
SJM, Acquisition Subsidiary and their respective Affiliates harmless from and
against any and all Taxes resulting from any breach of any of the
representations, warranties, covenants or other agreements of the Shareholder or
its Affiliates contained in this Section 7.2. SJM agrees to indemnify and hold
Shareholder, the Sellers and their respective Affiliates harmless from and
against any and all Taxes resulting from any breach of any of the
representations, warranties, covenants or other agreements of SJM or its
Affiliates contained in this Section 7.2. In addition to Taxes, this indemnity
obligation extends to (i) the reasonable costs incurred by the indemnified party
in collecting under this indemnity agreement and (ii) legal fees, but only if
the Prospective Indemnitor fails to acknowledge its indemnity obligation under
this Section 7.2 within 30 days after notification by the Prospective Indemnitee
of the Asserted Tax Liability.
7.3 Liability for Executive Arrangements.
7.3.1 SJM shall on the Closing Date assume any and all
liability directly or indirectly related to the Supplemental Executive
Retirement Plan ("SERP"), Employment Agreements, Split Dollar Life Insurance
Agreement, Executive Life Insurance Agreements and Executive Savings Plan listed
on Schedule 7.3 (together, the "Executive Arrangements") and SJM shall assume
all liabilities and perform all obligations of the Company and Shareholder under
the Executive Arrangements; provided, however, that Shareholder shall remain
liable and shall pay directly to such executive the excess, if any, of (i) the
Enhanced Benefit, over (ii) the Alternative Benefit payable under Section 5.2 of
the SERP and, if any interest payable under Section 5.2 or additional amounts
payable pursuant to Section 5.3 of the SERP are due, the portion of the interest
and additional amount that is attributable solely to such excess. On or prior to
the Closing Date, Shareholder shall inform SJM of whether the transactions
contemplated by this Agreement constitute a Target Sale of the Company, as
defined in the SERP. SJM shall provide Shareholder with prior written notice of
any claim under the SERP that would give rise to a Shareholder obligation
hereunder and shall provide Shareholder with an opportunity to review, at its
own expense, the calculation of benefits under the SERP.
7.4 Non-Competition.
7.4.1 During the period from the date of this Agreement to and
including the fourth anniversary of the date hereof (or, if not enforceable for
such period in any country, for such shorter period as shall be enforceable in
such country), Shareholder shall not, nor shall it permit any of its Affiliates
to, directly or indirectly, engage in the development, marketing, production,
sale or distribution anywhere in the world of Competitive Products (as defined
below).
7.4.2 As used in Section 7.4.1 hereof, the phrase "directly or
indirectly, engage in" includes any direct or indirect ownership, profit
participation or other interest by Shareholder or its Affiliates, whether as
owner, stockholder, partner, joint venturer, beneficiary or otherwise, in any
Person; provided, however, that the foregoing provisions shall not prevent
Shareholder or any of its Affiliates from (a) investing in businesses that
compete with the Competitive Products where such investments are incidental
investments in public companies and constitute, in the aggregate, less than 5%
of the outstanding securities or voting interest of each of such companies, (b)
acquiring businesses an incidental portion (such portion being deemed to be
incidental if the assets, revenues or income relating to the business which
competes with the Competitive Products is less than 5% of the assets, revenues
or income, respectively, of the business being acquired) of the business of
which competes with the Competitive Products (unless the excess over 5% of the
competing portion of such business is divested within six months from the date
of such acquisition) or (c) investing in investment funds or investment
partnerships which in turn invest in companies or entities which may be engaged
in the production, sale or distribution of Competitive Products so long as
neither Shareholder nor any of its Affiliates exercise control over such
investment decisions.
7.4.3 As used in this Section 7.4, (i) "Competitive Products"
means "Cardiac Stimulation Devices" (as defined in Section 13.1) and other
devices performing the same purpose or function as, or that are competitive
with, Cardiac Stimulation Devices, and shall include products intended for use
in or as products that are Cardiac Stimulation Devices (including, without
limitation, parts, components, modules, subsystems or subassemblies thereof, or
parts, components, modules, subsystems or subassemblies of and for, products
intended for use as or products that are Cardiac Stimulation Devices) except to
the extent that they are intended for use in or as products other than Cardiac
Stimulation Devices and (ii) "Affiliate" does not include any Person once it is
no longer an Affiliate of Siemens AG.
7.5 Non-Solicitation. For thirty-six months from the Closing
Date, neither Shareholder nor the Shareholder Affiliate, on the one hand, nor
SJM nor any of its Affiliates, on the other hand, shall specifically solicit to
hire any current employees of the other party without the prior written consent
of such latter party, provided that nothing herein shall restrict or preclude
the rights of either party to make generalized searches for employees by use of
advertisements in the media (including without limitation, trade media) or by
engaging search firms to engage in searches which are not targeted or focused on
the employees of the other party.
7.6 Siemens Name. Immediately after the Closing, except as
otherwise permitted under the License Agreement referred to in Section 3.2.5,
SJM will take all action necessary to cease the use of the name "Siemens" (or
any variant thereof) and related trademarks, corporate names, and trade names
incorporating the name "Siemens", and any "Siemens" logos and trade dress, in
each case in connection with the conduct of the Business. On the Closing Date,
Shareholder shall take all necessary action to change the name of the Company to
exclude the word "Pace-Setter".
7.7 Confidentiality. Except as otherwise provided in this
Agreement, after the Closing, the Sellers and their Affiliates shall not use or
disclose to third Persons any information disclosed to and transferred and
assigned, licensed or otherwise made available to SJM or its Affiliates in
connection with the Business and transfer of Assets hereunder. Without
limitation, this obligation of confidentiality shall apply to information
related to the Products, business plans, strategies, technologies, and future
business relationships of the Business. This obligation of confidentiality shall
not apply to the extent any such information (a) is or becomes part of the
public domain through no fault of the Sellers (but only after and only to the
extent that it is published or otherwise becomes part of the public domain); (b)
after the Closing, comes into the possession of the Sellers from a third Person
who was not, to the Sellers' knowledge, under a continuing obligation of
confidence to the disclosing party; or (c) is disclosed by the Sellers pursuant
to any judicial compulsion, provided that SJM is notified at the time such
judicial action is initiated. Disclosures relating to the Products, business
plans, strategies and future business relationships of SJM or the Company shall
not be deemed to be in the public domain or in the possession of the receiving
party merely because they are embraced (but not disclosed) by general
disclosures in the public domain or in the possession of the receiving party.
7.8 Bulk Sales Laws. The Company shall comply with the
provisions of the "bulk sales" law of the State of California, and otherwise
each of the parties waives compliance by the other parties with the provisions
of the "bulk sales" laws of any jurisdiction which may be applicable to the
transactions contemplated by this Agreement.
7.9 Guarantee. SJM hereby unconditionally guarantees the
obligations of the SJM Affiliates and Acquisition Subsidiary hereunder.
7.10 Real Estate Inspections. Commencing from the date of this
Asset Purchase Agreement and continuing through the date of Closing, SJM, its
agents, contractors and subcontractors shall have the right to enter upon the
Owned Real Property, at reasonable times (during ordinary business hours) upon
not less than 48 hours' prior notice to the Company, to make such inspections,
surveys and tests of the Real Property and the improvements situated thereon as
SJM may require.
7.11 Real Estate Related Reports. Promptly after the execution
of this Asset Purchase Agreement, Seller shall deliver to SJM, or cause to be
delivered to SJM, copies of all insurance claims and reports relating to the
Owned Real Property which have been submitted to insurance companies since
January 1, 1994, insuring all or portions of the Real Property and all letters,
correspondence and/or reports prepared by or at the request of such insurance
companies that have been delivered to any of Sellers or which Sellers are
entitled to obtain from such insurance companies.
7.12 Reimbursement for Certain Damages. Shareholder shall
reimburse Acquisition Subsidiary for the out-of-pocket costs incurred by the
Business after the Closing Date to repair the damage to the floor in the "clean
room" at the Company's Valley View Court Facility as a result of the January 17,
1994 earthquake, including costs of employees who are idled for a period of time
as a result of the repair of such damage, to the extent that such costs are not
covered by insurance proceeds. After the Closing Date, SJM shall, and shall
cause Acquisition Subsidiary to, use its reasonable best efforts to mitigate the
Losses incurred by the Business as a result of such damage that are not covered
by insurance. After the Closing Date, SJM shall pay to the Shareholder its
allocable portion of any insurance proceeds received by SJM or its Affiliates
under Section 1.1(a)(xxii) for expenses paid by the Company prior to the Closing
Date to repair any damage resulting from such earthquake prior to the Closing
Date to the extent that SJM or its Affiliates receive insurance proceeds after
the Closing Date for such expenses.
ARTICLE 8
CONDITIONS TO SJM'S OBLIGATIONS
The obligations of SJM to consummate the transactions contemplated by this
Agreement shall be subject to the satisfaction (or waiver by SJM in writing), on
or prior to the Closing Date, of all of the following conditions:
8.1 Representations, Warranties and Covenants of Shareholder
and the Company. The Sellers shall each have in all material respects performed
and complied with all of their agreements and covenants contained herein to be
performed at or prior to the Closing Date, and the representations and
warranties of Shareholder and the Company contained herein shall be true on and
as of the Closing Date in all material respects.
8.2 Prohibition. No statute, rule or regulation or order of any
court or administrative agency shall be in effect which prohibits consummation
of the transactions contemplated hereby.
8.3 Deliveries. Shareholder and the Company shall each have
made or caused to be made delivery to SJM of the items set forth in Section 3.2
hereof.
8.4 No Material Adverse Effect. No occurrences or events which,
individually or in the aggregate, have a Material Adverse Effect shall have
occurred following the date of this Agreement and be continuing.
8.5 HSR Compliance. The waiting period specified by the HSR Act
shall have expired or shall have been terminated.
8.6 Other Governmental Approvals. All governmental filings,
authorizations and approvals which are identified on Schedules 4.9 and 5.2 that
are required for the consummation of the transactions contemplated hereby or to
permit SJM and its Affiliates, after consummation of the transactions
contemplated hereby, to carry on the Business in the manner now conducted, and
any of the consents and approvals identified on Schedule 4.6 or Schedule 4.8(b)
the absence of which would have individually, or in the aggregate, a Material
Adverse Effect, will have been made or obtained.
8.7 Non-U.S. Asset Purchase Agreement. The closing of the
purchase and sale under the Non-U.S. Asset Purchase Agreement (as defined in
Section 13.1) shall have occurred.
ARTICLE 9
CONDITIONS TO SHAREHOLDER'S
AND THE COMPANY'S OBLIGATIONS
The obligations of the Company and Shareholder to consummate the transactions
contemplated by this Agreement shall be subject to the satisfaction (or waiver
by the Company and Shareholder in writing), on or prior to the Closing Date, of
all of the following conditions:
9.1 Representations, Warranties and Covenants of SJM. SJM and
Acquisition Subsidiary each shall have in all material respects performed and
complied with all of their agreements and covenants contained herein to be
performed at or prior to the Closing Date, and all of the representations and
warranties of SJM and Acquisition Subsidiary contained herein shall be true on
and as of the Closing Date in all material respects.
9.2 No Prohibition. No statute, rule or regulation or order of
any court or administrative agency shall be in effect which prohibits
consummation of the transactions contemplated hereby.
9.3 Deliveries. SJM shall have made or caused to be made
delivery to the Company and Shareholder of the items set forth in Section 3.3
hereof.
9.4 HSR Compliance. The waiting period specified by the HSR Act
shall have expired or shall have been terminated.
9.5 Other Governmental Approvals. All governmental filings,
authorizations and approvals which are identified on Schedules 4.9 and 5.2 that
are required for the consummation of the transactions contemplated hereby will
have been made or obtained.
9.6 Non-U.S. Asset Purchase Agreement. The closing of the
purchase and sale under the Non-U.S. Asset Purchase Agreement shall have
occurred.
ARTICLE 10
INDEMNIFICATION AND RELATED MATTERS
10.1 Survival. Subject to the limitations and other provisions
of this Agreement, the representations and warranties of SJM, the Company and
Shareholder contained herein shall survive the Closing and shall remain in full
force and effect, regardless of any investigation made by or on behalf of SJM,
the Company or Shareholder, as the case may be, for a period of one year after
the Closing Date; provided, however, that (A) the representations and warranties
in Sections 4.1.1, 4.1.2, 4.1.3, 4.1.4, 4.1.5, 4.3.1, 4.3.12, 4.3.13, 4.14 and
4.17 shall survive for a period of two years after the Closing Date, (B) the
representations and warranties in Sections 4.2, 4.3.17 and 4.3.18 shall only
survive until the adjustment to the Cash Consideration has been resolved
pursuant to Section 2.2, and (C) the representations and warranties in Sections
4.7 and 4.18 shall not survive the Closing.
10.2 Indemnification by Shareholder. Subject to the terms and
conditions of this Article 10, Shareholder agrees to indemnify and hold SJM,
Acquisition Subsidiary and their respective Affiliates, including, in each case,
any of their respective directors, officers, employees and representatives,
harmless from and against:
10.2.1 Any and all Losses resulting from any breach of any of
the representations and warranties (as of the Closing Date), covenants or other
agreements of the Company or Shareholder contained in this Agreement (other than
Sections 7.1 and 7.2, it being understood that the sole remedy for breach
thereof shall be pursuant to Sections 7.1 and 7.2, as the case may be); and
10.2.2 Losses resulting from Excluded Liabilities.
10.3 Indemnification by SJM. Subject to the terms and
conditions of this Article 10, SJM agrees to indemnify and hold Shareholder and
its Affiliates, including, in each case, any of its or their respective
directors, officers, employees and representatives, harmless from and against:
10.3.1 Any and all Losses resulting from any breach of any
representations and warranties (as of the Closing Date), covenants or agreements
of SJM contained in this Agreement (other than Sections 7.1 and 7.2, it being
understood that the sole remedy for breach thereof shall be pursuant to Sections
7.1 and 7.2, as the case may be); and
10.3.2 Losses resulting from Assumed Liabilities.
10.4 Determination of Damages and Related Matters. In
calculating any amounts payable to SJM, Acquisition Subsidiary and their
respective Affiliates pursuant to Section 10.2 or payable to Shareholder or its
respective Affiliates pursuant to Section 10.3, such amounts shall be limited to
the amount of any Losses that remain after deducting therefrom any insurance
proceeds or any indemnity, contribution or similar payment recoverable from the
indemnified Person from any third party with respect thereto. Any indemnity
payment made pursuant to this Section 10 shall be decreased by the amount of the
indemnified Person's Tax benefit (as defined below), and increased by the amount
of the indemnified Person's Tax cost (as defined below). The amount of the
indemnified Person's Tax benefit shall be equal to the amount of the deduction
(or the present value of any increased depreciation or amortization deductions)
resulting from the indemnified Loss, multiplied by the highest marginal federal
income tax rate imposed on the indemnified Person. The amount of the indemnified
Person's Tax cost shall be equal to the amount of the income (or the present
value of any decreased depreciation or amortization deductions) resulting from
the receipt of the indemnity payment, multiplied by the highest marginal federal
tax rate imposed on the indemnified person. For purposes of this Section 10.4,
present values will be computed using the Applicable Federal Rate as the
discount rate. To the extent permitted by law, the parties will treat all
indemnity payments as adjustments to the purchase price and liabilities for
indemnified Losses as having been in existence at the time of the Acquisition.
10.5 Limitation on Indemnification Liabilities. The
indemnification obligations of Shareholder contained in Section 10.2 hereof
shall not be effective until the aggregate dollar amount of all Losses which
would otherwise be indemnifiable under Section 10.2 exceeds $8,000,000 (the
"Threshold Amount"), and then only to the extent such aggregate amount exceeds
the Threshold Amount. The indemnification obligations of Shareholder under
Section 10.2 shall be effective only until the dollar amount paid in respect of
the Losses indemnified against under such Section aggregates to an amount equal
to $120,000,000 (the "Liability Cap"). The Threshold Amount and the Liability
Cap contained in this Section 10.5 shall not apply to any obligations arising
under Sections 2.2.4 and 2.3 regarding fees and expenses, Section 6.1, 6.4.2,
6.5, 6.6, 6.14, Article 7 or Article 12 or to any Losses arising from Excluded
Liabilities.
10.6 Notice of Indemnification. In the event any legal
proceeding shall be threatened or instituted or any claim or demand shall be
asserted by any person in respect of which payment may be sought by one party
hereto from the other party under the provisions of this Agreement, the party
seeking indemnification (the "Indemnitee") shall promptly cause written notice
of the assertion of any such claim of which it has knowledge which is covered by
this indemnity to be forwarded to the other party (the "Indemnitor") which
notice, in the case of a claim arising under Section 7.1, 7.2, 10.2 or 10.3,
must be received by the Indemnitor before the expiration of the relevant
survival period set forth in Section 10.1 or if no such period is specified,
until the applicable period under the statute of limitations therefor has
expired. Any notice of a claim by reason of any of the representations,
warranties, covenants or agreements contained in this Agreement shall state
specifically the representation, warranty, covenant or agreement with respect to
which the claim is made, the facts giving rise to an alleged basis for the
claim, and the amount of the liability asserted against the Indemnitor by reason
of the claim.
10.7 Indemnification Procedure for Third-Party Claims. In the
event that an Indemnitee receives written notice of the commencement of any
action or proceeding, the assertion of any claim by a third party or the
imposition of any penalty or assessment for which indemnity may be sought
pursuant to this Article 10 (a "Third Party Claim"), and such Indemnitee intends
to seek indemnity pursuant to this Article 10, the Indemnitee shall promptly
provide the Indemnitor with notice of such action, proceeding, claim, penalty or
assessment, and the Indemnitor shall, upon receipt of such notice, be entitled
to participate in or, at the Indemnitor's option, assume the defense, appeal or
settlement of such action, proceeding, claim, penalty or assessment with respect
to which such indemnity has been invoked with counsel of its own choosing, and
the Indemnitee will cooperate fully with the Indemnitor in connection therewith.
In the event that the Indemnitor fails to assume the defense, appeal or
settlement of such action, proceeding, claim, penalty or assessment within 30
days after receipt of notice thereof from the Indemnitee, the Indemnitee shall
have the right to undertake the appeal of such action, proceeding, claim,
penalty or assessment at the Indemnitor's expense, subject to the rights of the
Indemnitor in the immediately succeeding sentence. If the Indemnitee assumes
such defense and proposes to settle or compromise any such action, proceeding,
claim, penalty or assessment then the Indemnitee shall give written notice
thereof and the Indemnitor shall have the right to participate in the settlement
or assume or reassume the defense of such action, proceeding, claim, penalty or
assessment.
ARTICLE 11
TERMINATION PRIOR TO CLOSING
11.1 Termination. This Agreement may be terminated at any time
prior to the Closing:
11.1.1 by the mutual written consent of the parties; or
11.1.2 by either Shareholder and the Company, on the one hand,
or SJM and Acquisition Subsidiary, on the other hand, if there has been a breach
of a material representation or breach of a material covenant on the part of the
other party in the representations, warranties and covenants contained herein,
unless such breach is cured within 30 days of receipt of notice of such breach;
or
11.1.3 by either Shareholder and the Company, on the one hand,
or SJM and Acquisition Subsidiary, on the other hand, if the Closing has not
occurred by October 31, 1994; provided that no party may terminate this
Agreement pursuant to this clause if such party's failure to fulfill any of its
obligations under this Agreement shall have been the reason that the Closing
Date shall not have occurred on or before said date; and provided further that
such date shall be extended until December 31, 1994, if the Closing did not
occur by such date because of the failure of SJM, Shareholder or the Company to
receive one of the governmental approvals or authorizations contemplated by this
Agreement because of the failure of any applicable waiting period to expire; or
11.1.4 by either Shareholder and the Company, on the one hand,
or SJM and Acquisition Subsidiary, on the other hand, if there shall be any law
or regulation that makes consummation of the Acquisition or any other material
component of the transactions contemplated hereby illegal or otherwise
prohibited or if any judgment, injunction, order or decree enjoining SJM, the
Company or Shareholder from consummating the transactions contemplated hereby is
entered and such judgment, injunction, order or decree shall become final and
nonappealable.
11.2 Effect of Termination. If this Agreement is terminated
pursuant to Section 11.1, this Agreement shall become void and of no effect with
no liability on the part of any party hereto, except (i) as set forth in
Sections 6.5 and 12.6 and (ii) that nothing shall relieve any party hereto for
liability for any breach of this Agreement.
ARTICLE 12
MISCELLANEOUS
12.1 Entire Agreement. This Agreement (including the exhibits
hereto, the Schedules and the documents referred to herein and the other
documents executed by the parties on the date hereof) and the Non-Disclosure
Agreement contain the entire understanding of the parties hereto in respect of
the subject matter contained herein and supersede all prior agreements and
understandings between the parties with respect to such subject matter. There
are no restrictions, promises, representations, warranties, covenants, or
undertakings, other than those expressly set forth or referred to herein or
therein. Notwithstanding anything to the contrary contained herein, the parties
hereto agree that the Company and Shareholder shall not be deemed to have made
herein any representations and warranties with respect to the "Business" or
"Assets" (as such terms are defined in the NonU.S. Asset Purchase Agreement).
12.2 Amendment; Waiver. No waiver and no modification or
amendment of any provision of this Agreement shall be effective unless
specifically made in writing and duly signed by the parties to be bound thereby.
Waiver by a party of any breach of or failure to comply with any of the
provisions of this Agreement by any other party shall not be construed as, or
constitute, a continuing waiver of, or a waiver of any other breach of, or
failure to comply with, any other provision of this Agreement.
12.3 Assignment. This Agreement and all of the provisions
hereof shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns, but neither this Agreement
nor any of the rights, interests or obligations hereunder shall be assigned by
any of the parties hereto without the prior written consent of the other
parties; provided, however, that SJM may assign this Agreement and its rights,
interests and obligations in whole or in part hereunder to one or more directly
or indirectly wholly owned subsidiaries of SJM without the consent of
Shareholder or the Company; provided, however, that such assignment shall not
relieve SJM of any of its obligations hereunder.
12.4 Headings; Usage. The paragraph headings contained herein
are for the purposes of convenience only and are not intended to define or limit
the contents of said paragraphs. The meanings of any terms defined herein are
equally applicable to both the singular and plural forms of the terms defined.
12.5 Cooperation. Each party hereto shall cooperate, shall take
further action and shall execute and deliver such further documents as may be
reasonably requested by the other party in order to carry out the provisions and
purposes of this Agreement.
12.6 Expenses. Except as provided in Section 7.2.2, SJM shall
bear its and Acquisition Subsidiary's, and Shareholder shall bear its, the
Company's, the Shareholder Affiliate's and the Subsidiaries' costs and expenses
in connection with the negotiation, preparation, performance and consummation of
the transactions contemplated by this Agreement, including all taxes of any
type, the fees and disbursements of all attorneys, accountants, appraisers,
investment bankers and advisors retained by or representing them in connection
with the preparation and performance of this Agreement.
12.7 Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of New York applicable to
contracts made and to be performed therein.
12.8 Disputes. (a) Any dispute between SJM and Shareholder
arising out of or in connection with this Agreement (or any agreements or
documents delivered by the parties hereto pursuant to the terms of this
Agreement) or any alleged breach hereof may, at the option of either SJM or
Shareholder, be submitted for discussion and possible resolution by senior
officers of SJM and Shareholder, as designated by their respective chief
executive officers.
(b) Except as provided in Article 2, all disputes arising,
relating to or arising in connection with this Agreement, including those
pertaining to the validity, interpretation, construction or breach hereof or of
any legal obligation owed or claimed to be owed by any party hereto to any other
party hereto or its Affiliates, that is not otherwise amicably settled between
the parties shall exclusively be resolved by arbitration between SJM and
Shareholder pursuant to the Commercial Arbitration Rules of the American
Arbitration Association (the "Rules"), with the arbitration to be conducted in
the English language and taking place in New York, New York.
(c) The arbitral tribunal shall be composed of three
arbitrators appointed in accordance with the Rules. The Chairman of the arbitral
tribunal shall be nominated by the two arbitrators nominated respectively by
Shareholder and SJM, and if they fail to agree upon such Chairman within 30 days
after the second arbitrator has been appointed, such Chairman shall be appointed
by the American Arbitration Association. No arbitrator shall be or have been a
present or past employee, officer, director, legal counsel, consultant or agent
of either party or its Affiliates. All arbitrators shall be of legal education,
unless the parties agree otherwise at the time. Unless prohibited or restricted
by applicable law, each party agrees to provide to the arbitrators and the other
party, subject to a strict confidentiality agreement, such documents, other
evidence, witness testimony as may reasonably be requested by the other party
and as are relevant to the issues being arbitrated. The arbitrators may restrict
or terminate discovery requests which they conclude are unreasonable, unduly
burdensome or not relevant to the issues being arbitrated. Such discovery shall
occur during a reasonable time period. The arbitrators shall not have the power
to act as "amiable compositeurs" with respect to any dispute submitted to such
arbitration, but rather shall make their decision based on their understanding
and interpretation of the applicable law and facts. SJM expressly acknowledges
and agrees that Siemens AG has not in any way agreed to or consented to the
jurisdiction of the federal, state or local courts of the United States for any
purpose whatsoever and shall not be so treated hereunder, and SJM hereby waives
all rights to claim that Siemens AG is subject to such jurisdiction. The fees
and disbursements of the arbitrators shall be allocated between the disputing
party and the other party to the dispute in the same proportion that the
disputed items so submitted to the arbitrators that are unsuccessfully disputed
by each (as finally determined by the arbitrators) bears to the total amount of
all disputed items so submitted. Notwithstanding any provision of this Agreement
to the contrary, (i) any party shall be entitled to seek a judicial order for
interim relief to the extent necessary to safeguard the property that is the
subject matter of an arbitration proceeding hereunder, and (ii) judgment upon
the award rendered in any arbitration proceeding hereunder may be entered in any
court having jurisdiction or application may be made to such court in a judicial
acceptance of the award and an order by enforcement, as the case may be. The
parties hereto agree that the arbitrators appointed pursuant to this Section
12.8 shall have the power to grant equitable relief, including temporary and
permanent injunctive relief and specific performance.
12.9 Severability. Whenever possible, each provision of this
Agreement will be interpreted in such manner as to be effective and valid under
the applicable law, but if any provision of this Agreement is held to be
prohibited by or invalid under applicable law, such provision will be
ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this
Agreement.
12.10 Counterparts. This Agreement may be executed in one
or more counterparts, all of which taken together will constitute one and the
same instrument.
12.11 Interpretation. This Agreement has been fully negotiated
by the parties through their legal counsel. Accordingly, in interpreting this
Agreement, the rule of the interpretation requiring that documents be construed
against the draftsman shall be inapplicable.
12.12 Notices. All notices, requests and other communications
to any party hereunder shall be in writing and shall be given or made (and shall
be deemed to have been duly given or made upon receipt) by delivery in person,
by courier service, by cable, by facsimile transmission, by telegram or by
registered or certified mail (postage prepaid, return receipt requested) to the
respective parties at the following addresses (or at such other address for a
party as shall be specified in a notice given in accordance with this Section
12.12):
if to Shareholder
or the Company, to:
Siemens Medical Systems, Inc.
186 Wood Avenue South
Iselin, NJ 08830
Facsimile No.: (908) 321-3441
Attention: Robert V. Dumke and
David Machlowitz
with a copy to:
Siemens Corporation
1301 Avenue of the Americas
New York, NY 10019-6022
Facsimile No.: (212)258-4945
Attention: E. Robert Lupone
and
Shearman & Sterling
599 Lexington Avenue
New York, NY 10022
Facsimile No.: (212)848-7179
Attention: Peter D. Lyons
if to SJM to:
St. Jude Medical, Inc.
One Lillehei Plaza
St. Paul, Minnesota 55117
Attention: Ronald Matricaria, President
and Chief Executive Officer
Attention: Diane M. Johnson,
Vice President and
General Counsel
with a copy to:
Lindquist & Vennum
4200 IDS Center
80 South Eighth Street
Minneapolis, MN 55402
Attention: Joel H. Green
12.13 Publicity. Upon execution of this Agreement, the parties
shall jointly issue a press release, as agreed upon by them. Neither party
shall, without the prior written consent of the other, issue any statement or
communication to the public or to the press regarding this Agreement, or any of
the terms, conditions or other facts with respect to the Agreement, except as
required by law or the rules of any recognized stock exchange.
12.14 No Third Party Beneficiary. The provisions of this
Agreement are for the sole benefit of the parties to this Agreement and are not
for the benefit of any third party.
ARTICLE 13
DEFINITIONS
13.1 Definitions. For purposes of this Agreement, the following
terms have the meaning set forth below:
"Affiliate" means as to any Person controlling, controlled by,
or under common control with, such Person, any officer, director or executive
employee of such Person, and any Employee Benefit Plan maintained by such Person
(including, without limitation, related trusts and the fiduciaries thereof).
"Affiliated Group" means an affiliated group as defined in
Section 1504 of the Code (or any analogous combined, consolidated or unitary
group defined under state, local or foreign income tax law) of which the Company
is or has been a member.
"Assets" shall have the meaning given to it in Section 1.1(a).
"Assumption Agreement" means the Assumption Agreement to be
executed by SJM and the Sellers on the Closing Date substantially in the form of
Exhibit 3.3.7
"Assumed Liabilities" shall have the meaning given to it in
Section 1.2(a).
"Bill of Sale" means the Bill of Sale and Assignment to be
executed by the Sellers on the Closing Date substantially in the form of Exhibit
3.2.8A.
"Business" means the research, development, manufacturing,
marketing, assembly, sales, maintenance and service of Current Cardiac
Stimulation Devices by the Company and the Subsidiaries and shall exclude all
Prior Business.
"Business Day" means any day that is not a Saturday, a Sunday
or a day on which banks are required or permitted to be closed in the State of
New York. For purposes of Section 2.2 and 3.1, "Business Day" also means any day
that is not a Saturday, a Sunday or a day on which banks are required to be
closed in the Kingdom of Sweden.
"Cardiac Stimulation Devices" means devices for electrically
stimulating or shocking the heart and internal (but not external) holter
monitors which, in each case, are suitable for use by human patients, including,
without limitation: cardiac pacemakers, antitachycardia pacemakers,
cardioverters and defibrillators, including combinations thereof, whether
implantable or not; pulse generators and other waveform generators specially
designed for, and used with, such devices; leads, electrodes and sensors
specially designed for, and used with, such devices; mechanisms designed for
coupling such generators in a stimulating, shocking or sensing relationship to
the heart; data dispensing, processing and gathering systems designed for such
devices, including programmers, pacing system analyzers, defibrillation system
analyzers, testers, encoders, decoders, transmitters, receivers and computer
software-controlled systems (including the software) specially designed for use
with or as part of such devices.
"Cash Consideration" shall have the meaning given to it in
Section 2.1.
"Closing" shall have the meaning given to it in Section 3.1.
"Closing Balance Sheet" shall have the meaning given to it in
Section 2.2.2.
"Closing Date" shall have the meaning given to it in Section
3.1.
"COBRA Obligation" means the obligation imposed upon any
Company Employee Benefit Plan to meet the requirements of Section 4980(B) of the
Code, Part 6 of Title 1 of ERISA or any applicable state law requiring
continuation coverage.
"Code" means the Internal Revenue Code of 1986, as amended.
"Commitments" shall have the meaning given to it in Section4.6.
"Company Employee Benefit Plan" shall have the meaning given it
in Section 4.10.5.
"Company 401(k) Plan" has the meaning given to it in Section
7.1.2(c).
"Competitive Products" shall have the meaning given to it in
Section 7.4.3.
"Controlled Group" shall have the meaning given to it in
Section 4.10.5.
"Current Cardiac Stimulation Devices" means Cardiac Stimulation
Devices as are under research or development, or manufactured or marketed by the
Company, the Shareholder Affiliate and the Subsidiaries at the Closing Date.
"Deal Balance Sheet" shall have the meaning given to it in
Section 4.2.
"Deeds" means the deeds to be executed by the Company on the
Closing Date substantially in the form of Exhibit 3.2.8B in order to convey
title to SJM or an SJM Affiliate of each parcel of Owned Real Property.
"Designated Amount" shall have the meaning given to it in
Section 2.2.3.
"Employee" shall have the meaning given to it in Section
4.10.5.
"Employee Benefit Plan" shall have the meaning given to it in
Section 4.10.5.
"Employee Pension Benefit Plan" has the meaning given to it in
Section 4.10.5.
"Employee Welfare Benefit Plan" shall have the meaning given to
it in Section 4.10.5.
"Environmental Laws" shall have the meaning given to it in
Section 4.12.1(a).
"ERISA" has the meaning given to it in Section 4.10.5.
"Escrow Agent" shall have the meaning given to it in Section
2.2.7.
"Escrow Agreement" shall have the meaning given to it is
Section 2.2.7.
"Excluded Assets" shall have the meaning given to it in Section
1.1(b).
"Excluded Liabilities" shall have the meaning given to it in
Section 1.2(b).
"Executive Arrangements" has the meaning given to it in Section
7.3.1.
"FDA" shall have the meaning given to it in Section 4.3.11.
"Financial Statements" shall have the meaning given to it in
Section 4.2.
"HSR Act" means the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended, and the rules and regulations promulgated thereunder.
"knowledge" means, with respect to the Company, the knowledge
of the following persons: G. Jaensch, M. Novack, R. Sandler, P. Palmer, J.
Aldrich, and D. Morley and, with respect to any other company, the knowledge of
the executive officers of such company.
"Known Environmental Condition" shall have the meaning given to
it in Section 4.12.2.
"Liabilities" means any and all debts, liabilities and
obligations, whether accrued or fixed, absolute or contingent or matured or
unmatured.
"License Agreement" means the License Agreement, dated August
26, 1992, between Siemens AG and Medtronics, Inc.
"Lien" means any mortgage, claim, lien, pledge, charge,
security interest, option, preemptive right, assessment, security interest,
restriction on transfer or encumbrance of any kind.
"Litigation" means any claim, action, suit or proceeding in any
court or before any arbitrator or governmental body, agency or official.
"Losses" means any and all Liabilities, obligations, duties,
demands, claims, actions, causes of action, assessments, losses, costs, damages,
deficiencies, taxes, fines or expenses, including, without limitation, interest,
penalties, reasonable attorneys' fees and all amounts paid in investigation,
defense or settlement of any of the foregoing; provided, however, that the
foregoing shall not include consequential damages.
"Material Adverse Effect" means any change in, or effect on,
the Business as currently conducted that is, or is reasonably likely to be,
materially adverse to the operations, results of operations, assets or financial
condition of the Business, taken as a whole, except for such changes or effects
that are the result of changes in general economic conditions or changes that
generally affect the industry in which the Business is operated.
"Medtronics Assignment" shall have the meaning given to it in
Section 3.2.7.
"Multiemployer Plan" shall have the meaning given to it in
Section 4.10.5.
"Net Book Value" means the assets minus the liabilities
reflected on the applicable balance sheet, as adjusted.
"Non-Disclosure Agreement" shall have the meaning given to it
in Section 6.5.
"Non-U.S. Asset Purchase Agreement" means the Asset Purchase
Agreement dated as of June 26, 1994 among St. Jude Medical Inc., St. Jude
Medical International, Inc. and Siemens-Elema AB.
"PBGC" shall have the meaning given to it in Section 4.10.2(a).
"Permits" shall have the meaning given to it in Section 4.8.
"Permitted Liens" mean (i) Liens for inchoate mechanics' and
materialmen's liens for construction in progress and workmen's, repairmen's,
warehousemen's and carriers' liens arising in the ordinary course of the
Business which in the aggregate have a value of less than $100,000, (ii) Liens
for Taxes not yet payable and for Taxes being contested in good faith, and (iii)
Liens and imperfections of title the existence of which would not materially
affect the use of the property subject to such lien, consistent with past
practice.
"Person" means any individual, sole proprietorship,
partnership, joint venture, trust, unincorporated association, corporation or
other such entity or government (whether domestic, foreign, Federal, state,
county, city or otherwise, including, without limitation, any instrumentality,
division, agency or department thereof).
"Post-Closing Litigation Losses" means all Losses resulting
from any Litigation against the Company or the Business that are not Pre-Closing
Litigation Losses.
"Post-Closing Products Liability Losses" means any Losses
resulting from any product liability claims for Products implanted or otherwise
used with a patient on, before or after the Closing Date arising from a death,
injury, explant or other similar occurrence happening or alleged to have
happened after the Closing Date.
"Pre-Closing Litigation Losses" means any Losses resulting from
any Litigation pending or threatened against the Company or the Business on the
Closing Date.
"Pre-Closing Products Liability Losses" means any Losses
resulting from any product liability claims for Products implanted or otherwise
used with a patient on or before the Closing Date arising from a death, injury,
explant or other similar occurrence happening or alleged to have happened on or
before the Closing Date.
"Pre-Closing Tax Period" shall have the meaning given to it in
Section 7.2.3.
"Prior Business" means the research, development, manufacture,
marketing, assembly, sales, maintenance and service of Cardiac Stimulation
Devices by each of the Company and the Subsidiaries or the Shareholder Affiliate
which has taken place and has been discontinued by the Company, the Subsidiaries
or the Shareholder Affiliate prior to the date hereof.
"Products" shall have the meaning given to it in Section
4.13.1.
"Property" shall have the meaning given to it in Section
4.12.1(c).
"Property Taxes" shall have the meaning given to it in Section
7.2.3.
"Regulated Substances" shall have the meaning given to it in
Section 4.12.1(b).
"Reportable Event" shall have the meaning given to it in ERISA
Section 4043.
"Retained Litigation" means the Wilson class action suit.
"Rules" shall have the meaning given to it in Section 12.8.
"Sellers" has the meaning given to it in Section 1.1.
"Settlement Agreement" means the Settlement Agreement dated
September 9, 1992 between Siemens AG and Medtronics, Inc.
"Shareholder Affiliate" shall have the meaning given to it in
Section 1.1(a).
"Siemens AG" has the meaning given to it in Section 6.13.
"SJM's Accountants" shall have the meaning given to it in
Section 2.2.4.
"SJM Affiliates" shall have the meaning given to it in Section
1.1(a).
"Straddle Period" shall have the meaning given to it in Section
7.2.3.
"Subsidiary" means any corporation of which the securities
having a majority of the ordinary voting power in electing the board of
directors are, at the time as of which any determination is being made, owned by
the Company either directly or through one or more Subsidiaries.
"Tax" or "Taxes" means with respect to any person any federal,
state, county, local or foreign income, gross receipts, profits, capital,
franchise, estimated, alternative minimum, add-on minimum, estimated, sales,
use, occupancy, transfer, registration, value added, ad valorem, excise, natural
resources, severance, stamp, occupation, premium, windfall profit, environmental
(including taxes under Section 59A of the Code), customs, duties, levies, real
property, personal property, capital stock, mercantile, social security (or
similar), unemployment, disability, payroll, license, employment, employee or
other withholding, or other tax, governmental fee or like assessment or charge
of any kind whatsoever, including any interest, penalties or additions to tax or
additional amounts in respect of the foregoing, whether disputed or not and
whether computed on a separate, consolidated, unitary, combined or any other
basis; the foregoing shall include any transferee or secondary liability for a
Tax and any liability assumed by agreement or arising as a result of being (or
ceasing to be) a member of any Affiliated Group (or being included (or required
to be included) in any Tax Return relating thereto) or as a result of any
spin-off, distribution or other reorganization related to the disposition of any
assets or business of the Company or any other member of the Shareholder
Consolidated Group.
"Tax Returns" means returns, amendments, statements, forms,
information, elections, declarations, reports, claims for refund, information
returns or other documents (including any related or supporting schedules,
statements or information) filed or required to be filed in connection with the
determination, assessment or collection of any Taxes of any party or the
administration of any laws, regulations or administrative requirements relating
to any Taxes.
"U.S. GAAP" shall have the meaning given to it in Section
2.2.2.
IN WITNESS WHEREOF, the parties hereto have executed this
Agreement as of the date first written above.
ST. JUDE MEDICAL, INC.
By /s/ Ronald A. Matricaria
Ronald A. Matricaria
Its: President and Chief Executive Officer
SJM ACQUISITION CORP.
By /s/ Ronald A. Matricaria
Ronald A Matricaria
Its: President and Chairman
SIEMENS-PACESETTER, INC.
By /s/ Guenter Jaensch
Guenter Jaensch
Its: Chairman and Chief Executive Officer
By /s/ Michael E. Novack
Michael E. Novack
Its: Executive Vice President and Chief
Financial Officer
SIEMENS MEDICAL SYSTEMS, INC.
By /s/ Robert V. Dumke
Robert V. Dumke
Its: President and Chief Executive Officer
By /s/ David Machlawitz
David Machlawitz
Its: Secretary
ASSET PURCHASE AGREEMENT
AMONG
ST. JUDE MEDICAL, INC.,
SJM ACQUISITION CORP.,
SIEMENS-PACESETTER, INC.
AND
SIEMENS MEDICAL SYSTEMS, INC.
dated as of
June 26, 1994
TABLE OF CONTENTS
ARTICLE 1
TRANSFER OF ASSETS
1.1 Assets to Be Sold 1
1.2 Assumption and Exclusion of Liabilities 5
1.3 Transfer Documentation and Possession 6
ARTICLE 2
CONSIDERATION
2.1 Consideration 6
2.2 Cash Consideration Adjustment 6
2.3 Allocation of Purchase Price 9
ARTICLE 3
CLOSING
3.1 The Closing 10
3.2 Deliveries of Shareholder and the Company 10
3.3 Deliveries of SJM 11
3.4 Further Documents 12
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF SHAREHOLDER
AND THE COMPANY
4.1 Authority; Organization, Capitalization
and Qualification; Effect of Agreement 12
4.2 Financial Statements 14
4.3 Absence of Certain Developments 14
4.4 Title to Personal Property and Assets 17
4.5 Patents, Trademarks and Copyrights 17
4.6 Commitments 18
4.7 Litigation 19
4.8 Compliance with Laws; Permits 19
4.9 Governmental Consents 20
4.10 Employee Benefit Plans 20
4.11 Employees 24
4.12 Environmental Matters; OSHA 25
4.13 Company Products; Regulation 27
4.14 Tax Matters 28
4.15 Material Obligations 28
4.16 Brokerage 29
4.17 Affiliated Transactions 29
4.18 Insurance 29
4.19 Real Property 29
4.20 Inventory 32
4.21 Accounts and Notes Receivable 32
ARTICLE 5
REPRESENTATIONS AND WARRANTIES OF SJM
5.1 Corporate Power and Authority; Effect of Agreement 32
5.2 Consents 33
5.3 Availability of Funds 34
5.4 Litigation 34
5.5 Brokerage 34
5.6 Certain Ownership Interests 34
ARTICLE 6
COVENANTS
6.1 Cooperation 34
6.2 Conduct of Business 35
6.3 Intercompany Indebtedness 36
6.4 Access 36
6.5 Non-Disclosure Agreement 38
6.6 Antitrust, Competition Law Filings 38
6.7 Non-Foreign Person Affidavit 38
6.8 Transfer of Real Property 38
6.9 Certain Dividends 39
6.10 Certain Actions Prior to the Closing Date 39
6.11 Claims History 39
6.12 FDA Recertification 39
6.13 Grant of License 39
6.14 Other Financial Statements 40
ARTICLE 7
ADDITIONAL COVENANTS
7.1 Liability for Employee Benefit Plans 40
7.2 Tax Matters 42
7.3 Liability for Executive Arrangements 47
7.4 Non-Competition 48
7.5 Non-Solicitation 49
7.6 Siemens Name 49
7.7 Confidentiality 49
7.8 Bulk Sales Laws 49
7.9 Guarantee 49
7.10 Real Estate Inspections 50
7.11 Real Estate Related Reports 50
ARTICLE 8
CONDITIONS TO SJM'S OBLIGATIONS
8.1 Representations, Warranties and
Covenants of Shareholder and the Company 50
8.2 No Prohibition 51
8.3 Deliveries 51
8.4 No Material Adverse Effect 51
8.5 HSR Compliance 51
8.6 Other Governmental Approvals 51
8.7 Non-U.S. Asset Purchase Agreement 51
ARTICLE 9
CONDITIONS TO SHAREHOLDER'S
AND THE COMPANY'S OBLIGATIONS
9.1 Representations, Warranties and Covenants of SJM 51
9.2 No Prohibition 52
9.3 Deliveries 52
9.4 HSR Compliance 52
9.5 Other Governmental Approvals 52
9.6 Non-U.S. Asset Purchase Agreement 52
ARTICLE 10
INDEMNIFICATION AND RELATED MATTERS
10.1 Survival 52
10.2 Indemnification by Shareholder 52
10.3 Indemnification by SJM 53
10.4 Determination of Damages and Related Matters 53
10.5 Limitation on Indemnification Liabilities 54
10.6 Notice of Indemnification 54
10.7 Indemnification Procedure for Third-Party Claims 54
ARTICLE 11
TERMINATION PRIOR TO CLOSING
11.1 Termination 55
11.2 Effect of Termination 55
ARTICLE 12
MISCELLANEOUS
12.1 Entire Agreement 56
12.2 Amendment; Waiver 56
12.3 Assignment 56
12.4 Headings; Usage 56
12.5 Cooperation 57
12.6 Expenses 57
12.7 Governing Law 57
12.8 Disputes 57
12.9 Severability 58
12.10 Counterparts 58
12.11 Interpretation 58
12.12 Notices 58
12.13 Publicity 60
12.14 No Third Party Beneficiary 60
ARTICLE 13
DEFINITIONS
13.1 Definitions 60
3.2.1 Form of Shareholder Officers' Certificates
3.2.2 Form of Opinions of Counsel for Shareholder and the Company
3.2.4 Form of Medtronics Assignment and Assumption Agreement
3.2.8A Form of Bill of Sale and Assignment
3.2.8B Form of Deed
3.2.10 Form of Canadian Transitional Services Agreement
3.3.2 Form of SJM Officer's Certificate
3.3.3 Form of Opinion of Counsel for SJM
3.3.7 Form of Assumption Agreement
[NON-U.S.] ASSET PURCHASE AGREEMENT
THIS ASSET PURCHASE AGREEMENT is entered into as of June 26,
1994, among Siemens-Elema AB, a company organized under the laws of Sweden
("SiemensElema"), St. Jude Medical, Inc., a Minnesota corporation ("SJM"), and
St. Jude Medical International, Inc., a Delaware corporation and a wholly owned
subsidiary of SJM ("SJM International").
WHEREAS, Siemens-Elema and the Shareholder Affiliates are
engaged in the Business (each as defined herein); and
WHEREAS, each of SJM, SJM International and Siemens-Elema
desire that the Sellers sell, assign, transfer, convey and deliver to SJM or its
Affiliates all of the Assets, and that SJM or its Affiliates purchase and
acquire the same, subject to the assumption by SJM or its Affiliates of the
Assumed Liabilities (each such term being used as defined herein), all upon the
terms and subject to the conditions set forth in this Agreement;
The parties hereto agree as follows:
ARTICLE 1
TRANSFER OF ASSETS
1.1 ASSETS TO BE SOLD. (a) On the terms and subject to the
conditions of this Agreement, Siemens-Elema shall, and shall cause certain of
its Affiliates (the names and domiciles of incorporation of which are listed on
Schedule 1.1(a); collectively, the "Shareholder Affiliates" and, together with
Siemens-Elema, the "Sellers") to, on the Closing Date, sell, assign, transfer,
convey and deliver to SJM, or to such Affiliate or Affiliates of SJM, as SJM may
designate in writing to Siemens-Elema (collectively, "SJM Affiliates"), and SJM
shall purchase or shall cause one or more of the SJM Affiliates to purchase from
the Sellers on the Closing Date, all of the right, title and interest of the
Sellers in the assets, properties, rights and goodwill of every kind and
description and wherever located, whether tangible or intangible, real, personal
or mixed, owned by the Sellers which are predominantly used or held for use in
the Business, other than the Excluded Assets, and to the extent legally
transferable (the assets to be purchased by SJM or the SJM Affiliates pursuant
to this Section 1.1 being referred to as the "Assets"), including, without
limitation, the following:
(i) all furniture, fixtures, equipment, machinery and other
tangible personal property, used or held for use by a Seller and
predominantly used in the Business or otherwise owned or held by a
Seller on the Closing Date predominantly for use in the Business,
including the furniture, fixtures, equipment, machinery and other
tangible personal property described on Schedule 1.1(a)(i);
(ii) all vehicles predominantly used in the Business on the
Closing Date, including the vehicles listed on Schedule 1.1(a)(ii);
(iii) all inventories sold as part of the Business and all
merchandise, supplies or other personal property predominantly used in
the Business, including the inventories described on Schedule
1.1(a)(iii);
(iv) all third-party accounts and notes receivable of the
Sellers arising from the conduct of the Business before the Closing
Date, including the accounts receivable listed on Schedule 1.1(a)(iv);
(v) all books of account, personnel records, invoices, shipping
records, supplier lists, device history records, manufacturing records,
traceability records, regulatory documents, records, reports and
correspondence, lab notebooks, research records, correspondence and
other documents, data files and service manuals and any rights thereto
(and copies of financial and tax records) predominantly used in, or
relating predominantly to, the Business on the Closing Date;
(vi) all claims (excluding any Tax claims), causes of action,
choses in action, rights of recovery and rights of set-off of any kind
(including rights to insurance proceeds and rights under and pursuant
to all warranties, representations and guarantees made by suppliers of
products, materials or equipment, or components thereof), pertaining
to, arising out of, and enuring to the benefit, of any Seller and
predominantly relating to the Business;
(vii) all sales and promotional literature, customer lists and
other sales-related materials owned, used, associated with or employed
by and predominantly used or held for use in the Business on the
Closing Date, and all customer lists owned, used, associated with or
employed by the Business on the Closing Date;
(viii) all rights of each Seller under all contracts, licenses,
sublicenses, agreements, leases, commitments, and sales and purchase
orders, and under all bids and offers predominantly relating to the
Business on the Closing Date, including those contracts, licenses,
sublicenses, agreements, leases, commitments, sales and purchase orders
and bids and offers listed on Schedule 1.1(a)(viii);
(ix) all patents, trademarks, service marks, trade names,
copyrights, and registrations and applications for registration with
respect to any of the foregoing, pertaining to the Business, including
all such items listed on Schedule 1.1(a)(ix); and all trade secrets,
know-how and other intellectual property owned by any Seller and used
predominantly in the Business on the Closing Date;
(x) all goodwill of the Sellers with respect to the Business on
the Closing Date;
(xi) all permits, licenses, agreements, waivers and
authorizations held or used by any Seller in connection with the
Business;
(xii) all product approvals, clearances, registrations,
permits, consents, waivers, certificates, listings, and exemptions
submitted to or granted by a regulatory authority, foreign or domestic,
for the purpose of allowing the manufacture, sale or distribution of a
product of the Business, and all other permits, orders, certificates,
authorizations or approvals of any supranational, national, federal,
state, provincial or local, domestic or foreign, governmental authority
or regulatory agency held by a Seller in respect of the Business;
(xiii) all advances, deposits, loans, prepaid interest and
other prepaid expenses of all kinds of the Business, including all
advances, deposits, loans, prepaid interest and other prepaid expenses
listed on Schedule 1.1(a)(xiii);
(xiv) computer software and firmware used predominantly in the
Business, including the software used in connection with production,
inventory tracking, and work in process testing;
(xv) any and all interests in real property leases (including
leases for warehouse space) used or held for use in the Business by
each Seller and described in Schedule 1.1(a)(xv) attached hereto,
including without limitation, the benefit of any prepaid rent, security
deposits and options to renew or purchase in connection therewith,
which schedule shall set forth basic information with respect to each
lease including landlord's name, commencement date, expiration date,
square footage of the premises, monthly rent (including maintenance and
tax obligations), offsets, free and prepaid rent, security deposits,
and information concerning any options to renew, expand or purchase the
premises; and
(xvi) all Employee Benefit Plans listed on Schedule 7.1.2, and
all insurance contracts and other assets the Sellers are obligated to
transfer to SJM or the SJM Affiliates pursuant to Section 7.1.2.
(b) Notwithstanding any provision of Section 1.1(a) to the
contrary, the Assets shall exclude the following assets owned by one or more of
the Sellers (the "Excluded Assets"):
(i) all cash, cash equivalents and bank accounts owned by each
Seller at the Closing Date;
(ii) all assets and properties of each Seller (other than
customer lists specified in Section 1.1(a)(vii)), whether tangible or
intangible, that are not predominantly used or held for use in the
conduct of the Business;
(iii) all rights of each Seller under this Agreement; and
(iv) financial records and tax records.
(c) Schedules referenced above in this Section 1.1 more
specifically describe the foregoing generally described Assets as of September
30, 1993, being sold to SJM or the SJM Affiliates and the Excluded Assets as of
September 30, 1993. As soon as practicable (but in no event later than 90
calendar days following the Closing Date), Siemens-Elema shall prepare and
deliver to SJM, which shall have the right to review (with disputes to be
resolved if necessary by the Independent Accounting Firm specified in Section
2.2.4), revised Schedules for this Section 1.1 which shall more specifically
describe the Assets and the Excluded Assets as of the Closing Date.
1.2 ASSUMPTION AND EXCLUSION OF LIABILITIES. (a) Except for the
Assumed Liabilities expressly provided for in Section 1.2(b) below, the Sellers
shall retain, pay, perform and discharge when due all Liabilities known or
unknown (the "Excluded Liabilities"):
(i) arising out of or relating to the conduct or condition of
the Business or the Assets or the Excluded Assets existing or occurring
on or prior to the Closing Date whether accrued or arising before or
after the Closing Date; and
(ii) except as specifically provided in Section 7.2, for Taxes
now or hereafter owed by any Seller or any of their Affiliates,
relating to any Tax period, or any portion of any Tax period, including
Taxes imposed on any Seller or any of their Affiliates for which SJM or
any of its Affiliates becomes liable, under the laws of the relevant
jurisdiction, by virtue of being a successor to the Business.
(b) On the terms and subject to the conditions of this
Agreement, on the Closing Date, SJM shall, or shall cause the appropriate SJM
Affiliate to, assume and pay, perform and discharge when due only the following
Liabilities (the "Assumed Liabilities");
(i) all Liabilities of the Business, to the extent reflected or
reserved against on the Closing Balance Sheet;
(ii) all Liabilities to the extent they arise out of or relate
to the conduct or condition of the Business or the Assets after the
Closing Date;
(iii) all Liabilities accruing after the Closing Date under all
Commitments and other contracts, licenses, sublicenses, agreements,
leases, commitments, sales and purchase orders transferred to SJM or an
SJM Affiliate under this Agreement, and, in respect of any Commitment,
or other contract, license, sublicense, agreement, lease, commitment,
sales or purchase order not transferred because a consent or approval
required for the transfer thereof has not been obtained, Liabilities
thereunder to the extent that a Seller or any of its Affiliates
provides SJM or an SJM Affiliate the rights and benefits thereof;
(iv) all Liabilities relating to employees and employee
benefits and Taxes assumed by SJM or an SJM Affiliate pursuant to
Sections 7.1 and 7.2;
(v) all Post Closing Products Liability Losses; and
(vi) all Post Closing Litigation Losses.
1.3 TRANSFER DOCUMENTATION AND POSSESSION. The parties hereto
agree that, in order to effect the transfer of the Assets and the assumption of
the Assumed Liabilities, the parties shall deliver the documents described in
Sections 3.2 and 3.3, and such other conveyance documents as are necessary to
convey and, as appropriate, record and perfect title to the Assets to SJM or SJM
Affiliates and for SJM or SJM Affiliates to assume the Assumed Liabilities, such
other documents to be in form and substance mutually satisfactory to
Siemens-Elema and SJM and as may be necessary under the laws of the jurisdiction
where such Assets and Assumed Liabilities are located to effect such transfer
and assumption. Coincident with the Closing, the Sellers shall deliver
possession of the Assets to SJM or the appropriate SJM Affiliate.
1.4 TRANSITIONAL SERVICES.
1.4.1 In order to allow for a transition of those portions of
the Business that are conducted at certain facilities of Siemens-Elema and the
Shareholder Affiliates, SiemensElema shall and shall cause certain Shareholder
Affiliates and other of its Affiliates to enter into one or more transitional
services agreements, containing the terms set forth in Exhibit 1.4.1 hereto,
including the terms relating to the lease of space at the Solna, Sweden facility
(the "Siemens Transitional Services Agreements").
1.4.2 In order to allow for a transition of those portions of
the Business that are predominantly used in the Business, but are partially used
by Siemens-Elema or another Seller in other businesses, SJM shall, or shall
cause an SJM Affiliate to, enter into one or more transitional services
agreements in a form to be agreed upon by Siemens-Elema and SJM (the "SJM
Transitional Services Agreements").
ARTICLE 2
CONSIDERATION AND MANNER OF PAYMENT
2.1 CONSIDERATION AND PAYMENT. Subject to Section 2.2, the
aggregate cash consideration paid for the Assets shall be US$110,000,000 (the
"Cash Consideration"). The Cash Consideration shall be paid in full in
immediately available dollar funds at the Closing.
2.2 CASH CONSIDERATION ADJUSTMENT.
2.2.1 The Cash Consideration shall be subject to adjustment, if
any, after the Closing Date (as defined in Article 3) as specified in this
Section 2.2.
2.2.2 As soon as practicable (but in no event later than 90
calendar days following the Closing Date), Siemens-Elema shall prepare and
deliver to SJM an audited combined balance sheet for the Business (the "Closing
Balance Sheet") as of the Closing Date, together with a supplementary statement
adjusting the combined balance sheet to exclude certain assets and liabilities
which are not to be sold and to include certain other assets and liabilities
which are to be sold, all as set forth on Schedule 2.2.2. In preparation of the
Closing Balance Sheet, Siemens-Elema shall in good faith consider all reasonable
audit procedures suggested by SJM, and to the extent such suggested procedures
are acceptable to Siemens-Elema, prepare the Closing Balance Sheet in a manner
consistent therewith. The Deal Balance Sheet and the Closing Balance Sheet shall
not include any liability or reserve with respect to any future liabilities
relating to or arising out of the Settlement Agreement. The Closing Balance
Sheet shall be accompanied by the report thereon of Coopers & Lybrand, the
independent accountants of Siemens-Elema ("Siemens-Elema's Accountants"),
stating that the Closing Balance Sheet fairly presents the combined financial
position of the Business at the Closing Date in conformity with Schedule 2.2.2
and otherwise in accordance with United States generally accepted accounting
principles (hereinafter referred to as "U.S. GAAP") which Schedule 2.2.2 and
U.S. GAAP shall be applied on a basis consistent with the preparation of the
Deal Balance Sheet as defined in Section 4.2. During the preparation of the
Closing Balance Sheet by Siemens-Elema and the period of any dispute provided
for in Section 2.2.4, SJM shall provide Siemens-Elema and Siemens-Elema's
Accountants reasonable access to the books, records, facilities and employees of
the Business, and SJM, the SJM Affiliates and their respective successors, if
any, shall cooperate fully with SiemensElema's Accountants, in each case to the
extent required by Siemens-Elema and Siemens-Elema's Accountants in order to
prepare the Closing Balance Sheet and to investigate the basis for any such
dispute. SJM and its representatives shall be given reasonable access during
regular business hours and upon reasonable notice to the books, records,
facilities and employees of Siemens-Elema and the Shareholder Affiliates
pertaining to the Business including all supporting documents and auditor's work
papers used in the preparation of the Closing Balance Sheet, as necessary for it
to review the Closing Balance Sheet; provided, however, that any such
investigation shall be conducted in such manner so as not to interfere with the
operations of the Sellers. SJM shall be permitted to observe the physical count
of inventory to be undertaken in preparation of the Closing Balance Sheet.
2.2.3 Subject to the limitations set forth in Section 2.2.4,
within 30 Business Days after the date of receipt by SJM of the Closing Balance
Sheet:
(i) If the amount of Net Book Value shown on the Closing
Balance Sheet is less than US$58,158,000 by at least US$200,000 (the
"Designated Amount"), Siemens-Elema shall immediately pay to SJM, as an
adjustment to the Cash Consideration, in immediately available dollar
funds, an amount equal to such excess over the Designated Amount; and
(ii) If the amount of Net Book Value shown on the Closing
Balance Sheet is greater than US$58,158,000 by at least the Designated
Amount, SJM shall immediately pay, as an adjustment to the Cash
Consideration, in immediately available dollar funds, to Siemens-Elema
an amount equal to such excess over the Designated Amount.
2.2.4 If not disputed by SJM in accordance with this Section
2.2.4, the Closing Balance Sheet delivered by Siemens-Elema to SJM shall be
final, binding and conclusive on the parties hereto. SJM may dispute any amounts
reflected on the Closing Balance Sheet to the extent that the net effect of such
disputed amounts in the aggregate would be to change the Net Book Value
reflected on the Closing Balance Sheet by more than the Designated Amount, but
only on the basis that the amounts reflected on the Closing Balance Sheet were
not arrived at in accordance with Schedule 2.2.2 and otherwise in accordance
with U.S. GAAP, or that the adjustments set forth in Schedule 2.2.2 or U.S. GAAP
were not applied on a basis consistent with the preparation of the Deal Balance
Sheet; provided, however, that SJM shall notify Siemens-Elema and
Siemens-Elema's Accountants in writing of each disputed item, specifying the
amount thereof in dispute and setting forth, in detail, the basis for such
dispute, within 30 Business Days of SJM's receipt of the Closing Balance Sheet.
In the event of such a dispute, each of Siemens-Elema and SJM shall negotiate in
good faith to reconcile their differences. If such dispute has not been resolved
within 10 Business Days after the notice referred to in the preceding sentence
has been given, Ernst & Young ("SJM's Accountants") and Siemens-Elema's
Accountants shall attempt to reconcile their differences, and any resolution by
them as to any disputed amounts shall be final, binding and conclusive on the
parties hereto. If any such resolution by SJM's Accountants and Siemens-Elema's
Accountants leaves in dispute amounts the net effect of which in the aggregate
(together with any amounts originally disputed by SJM but no longer in dispute
("Non-Disputed Amounts")) would not be to change the Net Book Value reflected on
the Closing Balance Sheet by at least the Designated Amount, all the amounts
remaining in dispute shall then be deemed to have been resolved in favor of the
Closing Balance Sheet, and such resolution shall be final, binding and
conclusive on the parties hereto. If SJM's Accountants and Siemens-Elema's
Accountants are unable to reach a resolution, leaving in dispute amounts the net
effect of which in the aggregate (together with Non-Disputed Amounts) would
change the Net Book Value reflected on the Closing Balance Sheet by at least the
Designated Amount, SJM's Accountants and Siemens-Elema's Accountants shall
submit the items remaining in dispute that SJM shall be entitled to dispute by
the terms of this Section 2.2.4 for resolution to Deloitte & Touche or such
other independent accounting firm of international reputation as may be mutually
acceptable to Siemens-Elema and SJM (the "Independent Accounting Firm"), which
shall, within 30 Business Days of such submission, determine and report to
Siemens-Elema and SJM upon such remaining disputed items, and such report shall
have the legal effect of an arbitral award and shall be final, binding and
conclusive on Siemens-Elema and SJM. The fees and disbursements of the
Independent Accounting Firm shall be allocated between SJM and Siemens-Elema in
the same proportion that the aggregate amount of such remaining disputed items
so submitted to the Independent Accounting Firm which is unsuccessfully disputed
by each such party (as finally determined by the Independent Accounting Firm)
bears to the total amount of such remaining disputed items so submitted. No
adjustment to any amount payable by SJM or Siemens-Elema pursuant to Section
2.2.3 shall be made with respect to amounts disputed by SJM pursuant to this
Section 2.2.4, unless the net effect of the amounts successfully disputed by SJM
in the aggregate (together with the Non-Disputed Amounts) is to change the Net
Book Value reflected on the Closing Balance Sheet by at least the Designated
Amount, in which case such adjustment shall only be made in an amount equal to
any excess over the Designated Amount. Any amount that is payable under Section
2.2.3, including, without limitation, any portion thereof that is subject to
dispute under this Section 2.2.4 shall be paid by Siemens-Elema or SJM, as the
case may be, in immediately available dollar funds, within five Business Days
following the resolution of such dispute and in an amount in accordance with
such resolution.
2.2.5 In acting under this Agreement, Siemens-Elema's
Accountants, SJM's Accountants and the Independent Accounting Firm shall be
entitled to the privileges and immunities of arbitrators.
2.2.6 Any payment required to be made by SJM or Siemens-Elema
pursuant to Section 2.2.3 shall bear interest from the Closing Date through the
date of payment on the basis of the average of the daily rate of interest
publicly announced by Citibank, N.A. in New York, New York from time to time as
its base rate for dollars from the Closing Date to the date of such payment.
2.3 ALLOCATION OF PURCHASE PRICE. (a) As promptly as
practicable (but in no event later than ten (10) days prior to the Closing Date,
SJM shall deliver to SiemensElema a preliminary proposed allocation of the Cash
Consideration and Assumed Liabilities among the countries in which the Business
is conducted and the respective Sellers are located.
(b) As promptly as practicable (but in no event later than the
later of (i) 90 calendar days following the Closing Date and (ii) thirty days
after the Closing Balance Sheet is finally resolved), SJM shall deliver to
Siemens-Elema a proposed allocation of the Cash Consideration and the Assumed
Liabilities reflected in the Closing Balance Sheet among the countries in which
the Business is conducted and the Sellers are located and, where appropriate,
among the Assets located in such countries.
(c) SJM and Siemens-Elema agree to negotiate in good faith
regarding the allocation referred to in subsections (a) and (b) above as
promptly as practicable. If SJM and Siemens-Elema are unable (despite good faith
negotiations) to agree upon an allocation within 150 days after the Closing
Date, SJM and Siemens-Elema shall each be individually responsible for
performing its own allocation.
ARTICLE 3
CLOSING
3.1 THE CLOSING. The closing of the transactions contemplated
hereby (the "Closing") shall take place at the offices of Baker & McKenzie,
Eriksbergsgatan 46, 100 41, Stockholm, Sweden, and at such other locations as
the parties may agree at 10:00 a.m. (New York City time) on the later of (i)
August 31, 1994, and (ii) the fifth Business Day after the satisfaction or
waiver of the conditions in Articles 8 and 9, or at such other time or place as
the parties may agree (the "Closing Date"). All matters at the Closing shall be
considered to take place simultaneously, and no delivery of any document shall
be deemed completed until all transactions and delivery of documents are
completed. At the Closing, the purchase of the Assets shall be, as between SJM
and the SJM Affiliates, on the one hand, and SiemensElema and the Shareholder
Affiliates, on the other hand, deemed to have occurred at and as of 24:00 local
time in the respective jurisdictions on the Closing Date.
3.2 DELIVERIES OF SIEMENS-ELEMA. At the Closing, Siemens-Elema
shall deliver or cause to be delivered to SJM or the appropriate SJM Affiliates
the following:
3.2.1 copies of resolutions of Siemens-Elema's and Shareholder
Affiliates' Boards of Directors (or equivalent corporate body) showing that all
required corporate action, if any, on the part of each Seller, has been duly and
validly adopted and in full force and effect, authorizing execution and delivery
of this Agreement and performance respectively by each Seller of the
transactions contemplated hereby and by the Ancillary Documents;
3.2.2 an executed counterpart of the Medtronics Assignment and
Assumption Agreement, in substantially the form of Exhibit 3.2.2 attached hereto
(the "Medtronics Assignment");
3.2.3 a license agreement among SJM, SJM International and
Siemens AG, in a form to be agreed by Siemens-Elema and SJM, whereby Siemens AG
grants to SJM, SJM International and their Affiliates a non-exclusive short-term
transition license to continue use of those certain inventories of products and
packaging, and for a certain period molds for production bearing the trademark
"SIEMENS" existing at the Closing Date;
3.2.4 counterparts, executed by each Seller of the Business
Transfer Agreements;
3.2.5 counterparts, executed by Siemens-Elema, Siemens AG and
such of their Affiliates as may be appropriate, of a General Assignment of
Intangibles in a form to be agreed upon by Siemens-Elema and SJM, and an
Intellectual Property Assignment Agreement in a form to be agreed upon by
Siemens-Elema and SJM, and such other conveyance documents as are necessary to
convey and record title in any intangibles, including any patents, patent
applications, trademark registrations and applications for trademark
registrations, such other documents to be in a form and substance reasonably
satisfactory to SJM and/or its counsel and as may be necessary under the laws of
the jurisdiction where such intangibles are located to effect and record such a
transfer (collectively, the "Assignments"); and
3.2.6 counterparts, executed by Siemens-Elema, the other
Sellers and their Affiliates (as appropriate), of the Siemens Transitional
Services Agreements and the SJM Transitional Services Agreements.
3.3 DELIVERIES OF SJM. At the Closing, SJM shall deliver to
Siemens- Elema on its behalf and on behalf of the other Sellers, the following:
3.3.1 the Cash Consideration, in accordance with Section 2.1
hereof, to a U.S. bank account designated by Siemens-Elema to SJM in writing at
least two Business Days prior to the Closing Date;
3.3.2 Certificates of Good Standing dated not more than thirty
(30) days prior to the Closing Date, with respect to SJM and SJM International
issued by the Secretaries of State of Minnesota and Delaware, respectively;
3.3.3 copies of resolutions of SJM's and SJM International's
Boards of Directors, certified by the respective Secretaries thereof as having
been duly and validly adopted and in full force and effect, authorizing
execution and delivery of this Agreement and performance of the transactions
contemplated hereby;
3.3.4 an executed counterpart of the Medtronics Assignment;
3.3.5 counterparts, executed by SJM International or other SJM
Affiliates (as appropriate), of the Business Transfer Agreements; and
3.3.6 counterparts, executed by SJM International or other SJM
Affiliates (as appropriate), of the Siemens Transitional Services Agreements and
the SJM Transitional Services Agreements.
3.4 FURTHER DOCUMENTS.
3.4.1 SJM, SJM International, and the Sellers shall execute and
deliver, or cause to be executed and delivered, such other notarial and other
deeds, assignments, recordations, powers of attorney, instruments, documents or
certificates as the other parties may reasonably request to effect or evidence
the consummation of the transactions contemplated by this Agreement.
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF SIEMENS-ELEMA
Subject to Section 6.12, Siemens-Elema represents and warrants
to SJM and agrees with SJM that, on and as of the date of this Agreement and on
and as of the Closing Date:
4.1 AUTHORITY, ORGANIZATION, CAPITALIZATION AND QUALIFICATION;
EFFECT OF AGREEMENT.
4.1.1 Authority. Siemens-Elema has full corporate power and
authority to execute and deliver this Agreement, perform its obligations
hereunder and to consummate the transactions contemplated hereby. The execution
and delivery of this Agreement, the performance by Siemens-Elema of its
obligations under this Agreement and the consummation by Siemens-Elema of the
transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of Siemens-Elema, and no other corporate
proceedings on the part of Siemens-Elema are necessary to authorize the
execution and delivery of this Agreement and to consummate the transactions so
contemplated. This Agreement has been duly executed and delivered by
Siemens-Elema and constitutes the valid and binding obligation of Siemens-Elema
and is enforceable against Siemens-Elema in accordance with its terms, except to
the extent that such enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to creditors' rights
generally.
4.1.2 Organization and Qualification of Siemens-Elema.
Siemens-Elema is a corporation (aktiebolag) duly organized and validly existing
under the laws of Sweden and has full corporate power and authority to carry on
its business as it is now being conducted. Each of the Shareholder Affiliates is
a corporation duly organized and validly existing under the laws of the
jurisdiction of its incorporation and has full corporate power and authority to
carry on its business as it is now being conducted. Each of Siemens-Elema and
the Shareholder Affiliates is, in respect of the Business, duly qualified to do
business in each jurisdiction where the character of the property owned or
leased by it or the nature of its activities makes such qualification necessary,
except for those jurisdictions where the failure to be so qualified would not,
individually or in the aggregate, have a Material Adverse Effect (as defined in
Section 13.1). Siemens-Elema has heretofore delivered, or caused to be
delivered, to SJM true and complete copies of Siemens-Elema's certificate of
incorporation and bylaws (or equivalent organizational documents).
4.1.3 Subsidiaries. Neither Siemens-Elema nor any Shareholder
Affiliate, in each case in respect of the Business, has any Subsidiary, owns,
directly or indirectly, any stock, partnership interest, joint venture interest
or other equity interest in any other Person, or has the power to vote, or to
exercise a controlling influence with respect to, any securities of any class of
any Person, the holders of which class are entitled to vote for the election of
directors (or persons serving similar functions) of such Person.
4.1.4 Consents. Except as disclosed in Schedule 4.1.4 or as
would not, individually or in the aggregate, have a Material Adverse Effect, no
consent, approval, waiver or other action by any Person under any contract,
agreement, indenture, lease, instrument or other document to which Siemens-Elema
or any Shareholder Affiliate is a party or by which any of them or their assets
is bound is required or necessary for the execution, delivery and performance of
this Agreement or any Ancillary Agreement by Siemens-Elema or any Shareholder
Affiliate, as the case may be, or the consummation of the transactions
contemplated hereby or thereby.
4.1.5 No Default. Except as disclosed in Schedule 4.1.5 the
execution, delivery and performance by Siemens-Elema of this Agreement and by
each Shareholder Affiliate of the Ancillary Agreements and the consummation by
them of the transactions contemplated hereby and thereby do not and will not (a)
except as would not have, individually or in the aggregate, a Material Adverse
Effect, contravene or constitute a default under or give rise to a right of
termination, cancellation or acceleration of any right or obligation of
Siemens-Elema or any Shareholder Affiliate or to a loss of any benefit to which
Siemens-Elema or the Business is entitled under (i) any provision of applicable
law or regulation (assuming the governmental consents referred to in Section 4.9
have been obtained); (ii) the certificate of incorporation or bylaws (or similar
organizational documents) of Siemens-Elema or any Shareholder Affiliate; (iii)
any Commitment (as defined in Section 4.6); or (iv) any judgment, injunction,
order, decree, administrative interpretation, award or other instrument binding
upon Siemens-Elema, any Shareholder Affiliate or the Business or (b) except as
would not have, individually or in the aggregate, a Material Adverse Effect,
result in the creation or imposition of any Lien on any of the Assets.
4.2 FINANCIAL STATEMENTS. Siemens-Elema has delivered to SJM
copies of the audited combined balance sheets of the Business as of September
30, 1993 (together with a supplementary statement adjusting such financial
statements to exclude certain assets and liabilities, including certain
reserves, which are not to be sold and assumed and to include certain assets and
liabilities which are to be sold and assumed, all as set forth on Schedule 2.2.2
(the "Deal Balance Sheet")) as well as an audited income statement and cash flow
statement for the Business for the fiscal year ended September 30, 1993,
together with the related notes and schedules thereto (collectively, the
"Financial Statements"). The financial statements are attached as Schedule 4.2.
The Financial Statements have been prepared from the books and records of the
Business in accordance with U.S. GAAP applied on a consistent basis, subject to
normal year-end adjustments, and fairly present the financial condition of the
Business as at the date thereof and the results of its operations for the
periods covered thereby (subject to the adjustments contained on the
supplementary statement). The supplementary statement has been subjected to the
auditing procedures applied in the audit of the Financial Statements and is
fairly stated in all material respects in relation to the Financial Statements.
Schedule 2.2.2.1 sets forth for each of the Non-U.S. Financial Statements the
intercompany eliminations between the Non-U.S. Financial Statements and each of
the corresponding U.S. Financial Statements as defined in the U.S. Asset
Purchase Agreement (which the Sellers are assuming have been prepared in
accordance with U.S. GAAP), that are necessary to prepare in accordance with
U.S. GAAP combined financial statements for the Financial Statements and the
Non-U.S. Financial Statements. Siemens-Elema has also delivered to SJM unaudited
profit and loss information for the Business for the period from October 1, 1993
through May 31, 1994, based on financial information normally prepared by
Siemens-Elema for delivery to Siemens AG.
4.3 ABSENCE OF CERTAIN DEVELOPMENTS. Except as set forth in
Schedule 4.3, since September 30, 1993, the Business has been operated in a
manner consistent with past practice, and neither Siemens-Elema nor any
Shareholder Affiliate, in each case with respect to the Business, has, alone or
in the aggregate:
4.3.1 mortgaged, pledged or subjected to any Lien, any of its
property or assets, tangible or intangible, other than in the ordinary course of
business, Permitted Liens and Liens that will be released at or prior to
Closing;
4.3.2 except as contemplated by this Agreement, sold, leased,
assigned, transferred or otherwise disposed of any of its assets, except for
inventory sold in the ordinary course of business, having a value of more than
US$50,000 or an aggregate value in excess of US$250,000;
4.3.3 except as contemplated by this Agreement, made or granted
any bonus or any wage, salary increase, severance or severance arrangement to
any director, manager, officer, salesperson, employee or group of employees or
made or granted any increase in any employee compensation or benefit plan or
arrangement (except in accordance with past practice), or amended or terminated
any existing employee benefit plan or arrangement or adopted any new employee
benefit plan or arrangement;
4.3.4 sold, assigned, transferred or licensed to any Person any
rights under any patents, trademarks, service marks, trade names, copyrights,
registrations or applications for registration with respect to any of the
foregoing, trade secrets or other intellectual property owned by, or licensed
to, Siemens-Elema or any Shareholder Affiliate;
4.3.5 entered into any settlement agreement regarding the
breach or infringement (or alleged breach or infringement) of any domestic or
foreign intellectual property license, patent, copyright or trademark;
4.3.6 made any capital expenditures in Scotland and Sweden in
excess of an aggregate of US$2,000,000;
4.3.7 suffered any extraordinary losses or waived any rights of
material value, whether or not consistent with past practice;
4.3.8 suffered any damage, destruction or loss of any assets
owned by Siemens-Elema or the Shareholder Affiliate in Scotland or used by them
in the operation of the Business or any inventory owned or held for use by any
Shareholder Affiliate which in the aggregate have a replacement cost of more
than US$500,000 whether or not covered by insurance;
4.3.9 modified, amended or terminated any Commitment (as
defined in Section 4.6) in a manner materially adverse to the Business;
4.3.10 [Reserved];
4.3.11 been the subject of any action taken by the United
States Food and Drug Administration (the "FDA") or any other domestic or foreign
regulatory authority having jurisdiction over similar matters, excluding
observations of inspectors which have not resulted in any action, claim or
investigation by the FDA or other such regulatory authority;
4.3.12 made any change in any of the accounting methods or
accounting practices or guidelines of Siemens-Elema or any Shareholder
Affiliate, except for any such change required by Siemens-Elema's or
Shareholders Affiliates accounting policies and except for changes to obtain
uniformity of accounting policies and classifications;
4.3.13 entered into any foreign exchange hedging contracts or
any other financial derivative contracts;
4.3.14 undertaken any incurrence, assumption or guarantee by
SiemensElema or any Shareholder Affiliate of any indebtedness for borrowed money
other than consistent with past practices;
4.3.15 failed to maintain its inventory or collect its
receivables in a normal and customary manner materially consistent with its
prior practice, or made any material change in its pricing practices or credit
terms, limits or durations inconsistent with its prior practice;
4.3.16 discharged or satisfied accounts payable other than
consistent with past practice; or
4.3.17 entered into any agreement or made any commitment to
take any of the types of action described in subparagraphs 4.3.1 through 4.3.16
above.
4.4 TITLE TO PERSONAL PROPERTY AND ASSETS. Either Siemens-Elema
or a Shareholder Affiliate owns or has a valid leasehold interest in all
tangible personal property necessary for the conduct of the Business, free and
clear of all Liens, except as set forth in paragraph (a) of Schedule 4.4,
Permitted Liens or as reflected on the Financial Statements. Except as set forth
in paragraph (b) of Schedule 4.4, the equipment and fixed assets of the Business
are in good condition and repair and are usable in the ordinary course of
business, ordinary wear and tear excepted. The Assets constitute all of the
assets and properties necessary for the conduct of the Business as currently
conducted in all material respects.
4.5 PATENTS, TRADEMARKS AND COPYRIGHTS. To the knowledge of
Siemens-Elema, (a) Schedule 4.5(a) lists all patents, trademarks, service marks,
trade names, copyrights, registrations and applications for registration with
respect to any of the foregoing, owned by Siemens-Elema or any Shareholder
Affiliate or other Affiliate of Siemens-Elema with respect to the Business; (b)
Schedule 4.5(b) lists all license agreements under which third party owned
patents, trademarks, copyrights, registrations and applications for registration
of any of the foregoing, know how, technology or other intellectual property
rights are licensed to Siemens-Elema or any Shareholder Affiliate with respect
to the Business; and (c) Schedule 4.5(c) lists all claims and disputes pending
or threatened (in writing) with third parties alleging that Siemens-Elema or any
Shareholder Affiliate with respect to the Business, on the one hand, or such
third party, on the other hand, infringes on the other's patents, trademarks,
service marks, trade names, copyrights, trade secrets or other intellectual
property rights. Siemens-Elema has previously furnished or made available to SJM
all licenses listed on Schedules 4.5(a) and 4.5(b). On or before the Closing,
Siemens-Elema shall make available to SJM all pending patent applications filed
by SiemensElema or any Shareholder Affiliate with respect to the Business in
Sweden, the United States or elsewhere. Schedule 4.5(d) lists all outstanding
orders, judgments and decrees restricting the use by Siemens-Elema or any
Shareholder Affiliate with respect to the Business of the patents, trademarks,
copyrights, trade secrets or other intellectual property rights owned or
licensed by any of them. All of the license agreements listed on Schedule 4.5(b)
will be in full force and effect on the Closing Date, and none of Siemens-Elema
or any Shareholder Affiliate is in default under any of them nor, to the
knowledge of Siemens-Elema or any Shareholder Affiliate, (i) is any other party
to any such license agreement in default thereunder, nor (ii) does any condition
exist that, with notice or lapse of time or both, would constitute a default
thereunder, except in each case for such failures to be in full force and
effect, defaults or conditions that would not have, individually or in the
aggregate, a Material Adverse Effect. The right, title and interest of
Siemens-Elema and the Shareholder Affiliates in and to the Proprietary Rights
and Proprietary Information are duly recorded (as applicable) and free and clear
of all Liens and rights of third parties other than Permitted Liens and as
otherwise described in Schedule 4.5(e). As used herein, "Proprietary
Information" means all know-how and technology owned by Siemens-Elema or any of
the Shareholder Affiliates and used predominantly in the Business; and
"Proprietary Rights" means all patents, trademarks, service marks, trade names,
copyrights, registrations and applications for registration with respect to any
of the foregoing, arising out of, and owned by Siemens-Elema or any of the
Shareholder Affiliates as part of, the Business.
4.6 COMMITMENTS. Paragraph (a) of Schedule 4.6 sets forth a
list of all of the following written contracts and other agreements to which
Siemens-Elema or any Shareholder Affiliate in respect of the Business is a party
or by which Siemens-Elema or any Shareholder Affiliate in respect of the
Business or any of the Assets is bound or subject (collectively, "Commitments"):
(i) customer contracts and agreements for the sale of materials or products
which by their terms exceed one year or which are in dollar amounts which equal
or exceed US$500,000 per annum; (ii) distributorship agreements and
manufacturer's representative agreements, which provide for payments in excess
of US$500,000 per annum; (iii) supply and vendor contracts for sole source
components or which provide for payments in excess of US$350,000 per annum; (iv)
material research and development agreements; (v) employment, consulting,
independent contractor, severance, change in control, retention and
indemnification agreements, arrangements or understandings, and any other
agreements, arrangements or understandings, between Siemens-Elema or Shareholder
Affiliate, and any current or former stockholder, officer, director, employee,
consultant, agent or other representative, which provide for payments in excess
of US$100,000 per annum or with respect to any such contract under which the
total liability of Siemens-Elema or any Shareholder Affiliate equals or exceeds
US$500,000; (vi) contracts and other agreements with any labor union or
association representing any employee of Siemens-Elema or any Shareholder
Affiliate; (vii) joint venture agreements; (viii) contracts or other agreements
under which Siemens-Elema or any Shareholder Affiliate agrees to indemnify for
or share Tax liability of any party; (ix) contracts and other agreements
relating to the borrowing of money; (x) any equipment leases requiring payment
of at least US$100,000 within a given year which are not cancelable without
penalty upon 90 days' notice; (xi) agreements settling pending or threatened
Litigation which require continuing obligations after the date hereof; (xii) any
agreements between Siemens-Elema or any Shareholder Affiliate, on the one hand,
and any Affiliate of Siemens-Elema, on the other hand, material, individually or
in the aggregate, to the continued operation of the Business consistent with
past practice; (xiii) agreements granting rights or options to purchase the
securities or assets (other than inventory in the ordinary course of business)
of other companies or entities; (xiv) agreements which limit the Business from
competing in any line of business or in any geographic area, other than
distributorship or representation agreements which are exclusive as to
geographic territory; or (xv) any other contract or other agreement (other than
contracts and agreements of the type specified in clauses (i) through (xiv)
above) that is material to the Business. There have been delivered or made
available to SJM true and complete copies of all such contracts and other
agreements set forth in paragraph (a) of Schedule 4.6. All of such Commitments
are in full force and effect, and none of SiemensElema or any Shareholder
Affiliate is in material default under any of them. None of Siemens-Elema or any
Shareholder Affiliate has received any notification of any change in its
arrangements with customers and suppliers that would individually, or in the
aggregate, have a Material Adverse Effect. Paragraph (b) of Schedule 4.6
indicates which of the Commitments requires the consent of a third party to be
transferred or to remain in full force and effect following the consummation of
the transactions contemplated by this Agreement.
4.7 LITIGATION. Except as set forth in Schedule 4.7, there is
no Litigation pending or, to Siemens-Elema's or any Shareholder Affiliate's
knowledge, threatened which seeks to enjoin or obtain damages in respect of the
consummation of the transactions contemplated hereby. Schedule 4.7 lists any
Litigation and, to Siemens-Elema's or any Shareholder Affiliate's knowledge, any
investigation by a governmental entity, in each case that (i) involves a claim,
or to Siemens-Elema's or any Shareholder Affiliate's knowledge, potential claim,
of liability, in excess of US$2,000,000, against or affecting Siemens-Elema or
any Shareholder Affiliate in respect of the Business or (ii) enjoins, or seeks
to enjoin, the operation of a portion of the Business or seeks declaratory
judgment if such injunction or judgment would, or if entered would, constitute a
Material Adverse Effect.
4.8 PERMITS. Except as set forth in Schedule 4.8, Siemens-Elema
or a Shareholder Affiliate currently holds all permits, licenses, clearances,
registrations, consents, waivers, listings, exemptions, orders, certificates,
authorizations or approvals of any international, federal, provincial, state or
local, domestic or foreign, governmental authorities or regulatory agencies,
including, without limitation, those regulating safety, effectiveness and market
clearance of medical devices (the "Permits"), necessary to carry on the Business
as it is currently being conducted, except for such Permits the absence of which
would not, individually or in the aggregate, have a Material Adverse Effect.
4.9 GOVERNMENTAL CONSENTS. Except for the filing with the
Austrian Cartel Court, with the Treasury Department of the French Ministry of
Economy, Finance and Budget and otherwise as set forth in Schedule 4.9, the
execution, delivery and performance by Siemens-Elema of this Agreement and the
consummation by Siemens-Elema of the transactions contemplated by this Agreement
and the consummation by the Shareholder Affiliates of the transactions
contemplated by the Ancillary Agreements require no action by, or in respect of,
or filing with, any governmental body, agency, official or authority.
4.10 EMPLOYEE BENEFIT PLANS.
4.10.1 Schedule 4.10.1 sets forth a true and complete list of
each material Employee Benefit Plan covering any Employee (each as defined in
Section 4.10.5). With respect to each Employee Benefit Plan set forth on
Schedule 4.10.1:
(a) Each Employee Benefit Plan (and each related trust,
insurance contract, or fund) complies in form and in operation in all
material respects with its terms, and with all applicable laws,
regulations, ordinances, codes or other legally binding rules and other
requirements of all tax, labor and other governmental authorities
having jurisdiction over Siemens-Elema or any Shareholder Affiliate,
and all applicable collective bargaining agreements and works council
rules.
(b) All employer and Employee contributions which are due and
owing as of the Closing Date with respect to Employee Benefit Plans
have been or will be made in accordance with local law and past
practice. Any Benefit Obligations under any Employee Benefit Plan as of
the Closing Date have been appropriately reflected on the books and
records of such Employee Benefit Plan sponsor in accordance with local
law, past practice and generally accepted accounting principles in the
local jurisdiction. Except as disclosed in Schedule 4.10.1, all Benefit
Obligations under any Employee Benefit Plan as of the Closing Date will
be, on the Closing Date, fully covered by insurance contracts, special
assets or other provisions established for this purpose.
(c) Siemens-Elema has delivered to SJM correct and complete
copies of all plan documents and summary plan descriptions, all
material communications to Employees, all related trust agreements,
insurance contracts, and other funding agreements which implement each
Employee Benefit Plan, and, where a plan document for an Employee
Benefit Plan does not exist, a detailed description of such Employee
Benefit Plan.
(d) Except as disclosed on Schedule 4.10.1, no Employee Benefit
Plan provides medical, health, life insurance, or other welfare-type
benefits for current or future retired or terminated Employees, their
spouses or their dependents.
(e) Except as disclosed on Schedule 4.10.1, to the best
knowledge of Siemens-Elema, there has been no amendment to, written
interpretation of, or announcement (whether or not written) relating
to, or any change in employee participation or coverage under, any
Employee Benefit Plan that is not reflected in the text of such
Employee Benefit Plan which would materially increase the expense
(whether or not such expense is recognized under generally accepted
accounting principles) to the employer whose Employees are covered by
such Employee Benefit Plan, other than as a function of the number of
plan participants.
(f) Except as disclosed on Schedule 4.10.1, or as otherwise
expressly provided with respect to an Employee Benefit Plan or as
otherwise required by applicable law, to the best knowledge of
Siemens-Elema, no condition exists that would prevent the amendment or
termination of any Employee Benefit Plan with respect to any Employee.
4.10.2 No action, suit, proceeding, hearing or investigation
with respect to the administration or the investment of the assets of any
Employee Benefit Plan (other than routine claims for benefits) that could
reasonably be expected to result in a material liability to Siemens-Elema or any
Shareholder Affiliate is pending or threatened, and neither SiemensElema nor any
Shareholder Affiliate has any knowledge of any basis for any such action, suit,
proceeding, hearing, or investigation.
4.10.3 Except as set forth on Schedule 4.10.3:
(a) the consummation of the transactions contemplated by this
Agreement will not (i) entitle any Transferred Employee of the Business
to severance pay, termination indemnities, supplementary unemployment
compensation or any similar payment, (ii) accelerate the time of
payment or vesting, or increase the amount of any compensation due to
any such Employee, or (iii) constitute or involve a prohibited
transaction that is not otherwise covered by a statutory or
administrative exemption; and
(b) no collective bargaining agreement, employment agreement or
other agreement contains any "change in control" or similar provisions
which may be triggered by any of the transactions contemplated in this
Agreement.
4.10.4 Except as disclosed in Schedule 4.10.4, there have been
no statements by authorized representatives of Siemens-Elema or any Shareholder
Affiliate, whether oral or in writing, regarding any Employee Benefit Plans to
be maintained (or not to be maintained) by SJM or an SJM Affiliate after the
Closing Date, which will result in material liability to SJM or such SJM
Affiliate, whether direct or indirect.
4.10.5 For purposes of this Agreement:
(a) "Employee" means a current employee, including both active
employees (including light duty employees), and inactive employees
(including employees on a leave of absence, sick leave, short term
disability, long term disability or worker's compensation disability on
the Closing Date), of the Business employed outside of North America.
(b) "Employee Benefit Plan" means any agreement, plan, program,
fund, policy, contract or arrangement (either written or unwritten)
providing compensation, benefits, pension, retirement, superannuation,
profit sharing, stock bonus, stock option, stock purchase, phantom or
stock equivalent, bonus, thirteenth month, incentive, deferred
compensation, hospitalization, medical, dental, vision, vacation,
insurance, sick pay, disability, severance, termination indemnity,
redundancy pay, educational assistance, holiday pay, housing
assistance, moving expense reimbursement, fringe benefit or similar
employee benefits covering any Employee, and the beneficiaries and
dependents of the Employee, regardless of whether it is mandated under
local law, private, funded, unfunded, financed by the purchase of
insurance, contributory or non-contributory.
(c) For purposes of this Agreement, the term "Benefit
Obligations" means the actual liability to provide all current and
projected benefits to Employees, regardless of whether an amount less
than such actual liability is reported on the employer's financial
statements under applicable tax or accounting rules. For example, the
"Benefit Obligations" of an unfunded book reserve pension plan in
Austria or Germany is greater than the amount credited to the
employer's bookkeeping reserve.
4.11 EMPLOYEES. Paragraph (a) of Schedule 4.11 sets forth a
true and complete list of all Employees (other than former employees),
indicating their position and base salary. Paragraph (b) of Schedule 4.11 sets
forth a true and complete list of each works council, union or other labor
organization, which has to be notified or consulted or with which negotiations
need to be conducted in connection with the transactions contemplated by this
Agreement and each collective bargaining agreement which has any impact on the
terms and conditions of employment with respect to the Employees. Where required
under local law, Siemens-Elema or the relevant Shareholder Affiliate will have,
prior to the Closing Date, properly notified, or where appropriate consulted or
negotiated with, the local works council, union, labor board or relevant
government agency concerning the transactions contemplated by this Agreement and
the Ancillary Agreements. Other than as described on Schedule 4.11(c), each of
Siemens-Elema and the Shareholder Affiliates is in material compliance with all
domestic and foreign laws, regulations, ordinances, codes or other legally
binding rules applicable to the Business and its own policies respecting
employment and employment practices, terms and conditions of employment, wages
and hours, equal opportunity, civil rights, labor relations, occupational health
and safety and payroll taxes, and any federal, state, provincial or local human
rights act. Other than as described on Schedule 4.11(d), (i) none of
Siemens-Elema or any Shareholder Affiliate is in receipt of a complaint, demand
letter or charge issued by a federal, state, provincial or local agency which
alleges a violation by Siemens-Elema or any Shareholder Affiliate in respect of
the Business of any applicable law or regulation respecting employment and
employment practices, terms and conditions of employment, wages and hours, equal
opportunity, civil rights, labor relations, occupational health and safety or
payroll taxes; and (ii) since September 30, 1993, none of Siemens-Elema or any
Shareholder Affiliate has engaged in any plant closing, work force reduction or
other action which has resulted or would result in material liability under any
applicable domestic or foreign law or regulation, have not issued any notice
that any such action is to occur in the future, and are in material compliance
with all applicable requirements of all applicable immigration laws and
regulations.
4.12 [RESERVED]
4.13 COMPANY PRODUCTS; REGULATION.
4.13.1 Except as disclosed in paragraph (a) of Schedule 4.13.1
and except as would not have a Material Adverse Effect, to the knowledge of
Siemens-Elema, since January 1, 1992 there have been no written notices,
citations or decisions by any governmental or regulatory body that any product
produced, manufactured, marketed or distributed at any time by the Business (the
"Products") is defective or fails to meet any applicable standards promulgated
by any such governmental or regulatory body. To the knowledge of Siemens-Elema,
Siemens-Elema is in compliance with the Consent Decree applicable to the
Products of the Business. Except as disclosed in paragraph (b) of Schedule
4.13.1, since January 1, 1992 there have been no recalls, field notifications or
seizures ordered or, to the knowledge of Siemens-Elema, threatened by any such
governmental or regulatory body with respect to any of the Products. Except as
has been disclosed to SJM, since January 1, 1992, Siemens-Elema has not received
and does not have knowledge of any reasonable basis for, any warning letter, or
Section 305 or other similar notices from the FDA or any other domestic or
foreign regulatory authority having jurisdiction over similar matters.
4.13.2 Except as would not have a Material Adverse Effect,
Siemens-Elema is in possession of and will, upon SJM's request, make available
to SJM, all supportive materials and data with respect to the Business
substantiating representations made to the FDA or other domestic or foreign
governmental regulatory authority in its filings therewith, including any and
all testing data in the possession, or under the control, of Siemens-Elema,
whether or not submitted to the FDA or other domestic or foreign governmental
regulatory authority. In addition, Siemens-Elema has identified or will, upon
SJM's request, identify to SJM, to the knowledge of Siemens-Elema, all
international locations where regulatory information and documents are kept,
except where the failure to identify any such locations would not have a
Material Adverse Effect. The Products perform in all material respects in
compliance with the representations and performance specifications as contained
in said filings.
4.14 TAX MATTERS.
4.14.1 U.S. Real Property. Except as set forth in Schedule
4.14.1, none of Siemens-Elema or the Shareholder Affiliates own, with respect to
the Business, any interest in real property located in the United States or any
property which would constitute an investment in United States property (as
defined in Section 956(b) of the Code) if held by a controlled foreign
corporation (as defined in Section 957 of the Code).
4.14.2 Permanent Establishment. Except as set forth in Schedule
4.14.2, none of Siemens-Elema or the Shareholder Affiliates has, or has had, in
respect of the Business, a permanent establishment or other presence subjecting
it to taxation, in any foreign country, as defined under any applicable law, tax
treaty or convention.
4.15 [RESERVED]
4.16 BROKERAGE. Other than the fee payable by Siemens Medical
Systems, Inc. to Gleacher & Co., its investment banker, there are no claims for
brokerage commissions, finder's fees or similar compensation in connection with
the transactions contemplated by this Agreement based on any arrangement or
agreement made by SiemensElema or any of its Affiliates.
4.17 AFFILIATED TRANSACTIONS. Except as listed and described in
paragraph (a) of Schedule 4.6 or in Schedule 4.17 hereto, as relates to the
Business, neither SiemensElema nor any Shareholder Affiliate is a party to any
transaction or Commitment with, and has no obligation or liability owing to or
from, any Affiliate of Siemens-Elema in excess of US$50,000 or which is not
cancelable by Siemens-Elema or such Shareholder Affiliate on at least 60 days'
notice without penalty.
4.18 INSURANCE. Schedule 4.18 constitutes a true and complete
description of all of the policies in force and effect and a description of
their respective coverage and limits presently applicable to or including the
operations and property of the Business. None of Siemens-Elema nor any
Shareholder Affiliate has received any notice of cancellation in respect of
insurance coverage for operations, assets and properties relating to the
Business. All premiums due and payable in respect of such insurance have been
paid. There are no pending or, to Siemens-Elema's knowledge, threatened
terminations or premium increases with respect to any such policies and
Siemens-Elema and the Shareholder Affiliates are in compliance with all material
conditions contained therein.
4.19 [RESERVED]
4.20 INVENTORY. Siemens-Elema has previously disclosed to SJM
by letter dated June 22, 1994, the accounting guidelines used by Siemens-Elema
in respect of the Business (and used by Siemens-Elema in the preparation of the
Deal Balance Sheet) for valuing Inventory (as defined below), including without
limitation the guidelines used to determine whether Inventory is obsolete or
damaged, or will be slow-moving or defective.
4.21 ACCOUNTS AND NOTES RECEIVABLE. Siemens-Elema has
previously disclosed to SJM by letter dated June 22, 1994, the accounting
guidelines used by SiemensElema in respect of the Business (and used by
Siemens-Elema in the preparation of the Deal Balance Sheet) for valuing accounts
receivable. All accounts and notes receivable reflected on the Deal Balance
Sheet for sales to customers (other than Affiliates of Siemens-Elema and the
Shareholder Affiliates) outside the United States and all such accounts and
notes receivable arising subsequent to the Deal Balance Sheet Date, have arisen
in the manner consistent with past practice of the Business, represent valid
obligations due to SiemensElema or the Shareholder Affiliates, and have been
documented by invoices and accompanying documentation as required to permit and
support collection in accordance with national, provincial and local law or
regulation.
ARTICLE 5
REPRESENTATIONS AND WARRANTIES OF SJM
SJM represents and warrants to Siemens-Elema and agrees with
SiemensElema as follows:
5.1 CORPORATE POWER AND AUTHORITY; EFFECT OF AGREEMENT.
5.1.1 Each of SJM and SJM International is a corporation duly
organized, validly existing and in good standing under the laws of Minnesota and
Delaware, respectively, and has full corporate power and authority to carry on
its business as it is now being conducted. All of the issued and outstanding
capital stock of SJM International is owned by SJM.
5.1.2 Each of SJM and SJM International has full corporate
power and authority to execute and deliver this Agreement, perform its
obligations hereunder and to consummate the transactions contemplated hereby.
The execution and delivery of this Agreement, the performance by SJM and SJM
International of its obligations hereunder and the consummation by SJM and SJM
International of the transactions contemplated hereby have been duly authorized
by all necessary corporate action on the part of SJM and SJM International, and
no other corporate proceedings on the part of SJM or SJM International are
necessary to authorize the execution and delivery of this Agreement, or to
consummate the transactions so contemplated. On the Closing Date each of the SJM
Affiliates will have full corporate power and authority to execute and deliver
the Ancillary Agreements to which it is a party, perform its obligations
thereunder and consummate the transactions contemplated thereby. On the Closing
Date the execution and delivery of the Ancillary Agreements, the performance by
each SJM Affiliate of its obligations thereunder and the consummation by each
SJM Affiliate of the transactions contemplated thereby will have been duly
authorized by all necessary corporate action on the part of each SJM Affiliate,
and no other corporate proceedings on the part of any SJM Affiliate will be
necessary to authorize the execution and delivery of this Ancillary Agreement,
or to consummate the transactions contemplated thereby.
5.1.3 This Agreement has been duly executed and delivered by
SJM and SJM International and constitutes the legal, valid and binding
obligation of SJM and SJM International, enforceable against each such party in
accordance with its terms, except to the extent that such enforceability may be
limited by bankruptcy, insolvency, reorganization, moratorium or other similar
laws relating to creditors' rights generally. At the Closing, the Ancillary
Agreements to which SJM and any SJM Affiliate is a party, will be duly executed
and delivered by SJM and the respective SJM Affiliate and will constitute the
legal, valid and binding obligation of SJM and the respective SJM Affiliate,
enforceable against each such party in accordance with its terms, except to the
extent that such enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to creditors' rights
generally.
5.1.4 The execution, delivery and performance by SJM and SJM
International of this Agreement and by each SJM Affiliate of the Ancillary
Agreements and the consummation by them of the transactions contemplated hereby
and thereby do not and will not contravene or constitute a default under or give
rise to a right of termination, cancellation or acceleration of any right or
obligation of SJM, SJM International or any such SJM Affiliate or to a loss of
any benefit to which SJM, SJM International or any such SJM Affiliate is
entitled under (i) except as would not be materially adverse to the operations,
results of operations, assets or financial condition of SJM and the SJM
Affiliates, taken as a whole, or have a material adverse effect on the ability
of SJM or SJM International to consummate the transactions contemplated by this
Agreement, any provision of applicable law or regulation (assuming the
governmental consents referred to in Section 5.2 have been obtained); (ii) the
articles of incorporation or bylaws (or similar organizational documents) of
SJM, SJM International or any such SJM Affiliate; (iii) any judgment,
injunction, order, decree, administrative interpretation, award or other
instrument binding upon SJM, SJM International or any such SJM Affiliate; or
(iv) result in the creation or imposition of any Lien on any asset of SJM, SJM
International or any such SJM Affiliate which would have a material adverse
effect on their ability to consummate the transactions contemplated hereby.
5.2 CONSENTS. Except for the filing with the Austrian Cartel
Court, with the Treasury Department of the French Ministry of Economy, Finance
and Budget and otherwise as set forth in Schedule 5.2, no consent, approval or
authorization of, or exemption by, or filing with, any governmental or
regulatory authority or any other third party is required in connection with the
execution, delivery or performance by SJM or SJM International of this Agreement
or the taking by SJM or SJM International of any other action contemplated
hereby, excluding, however, consents, approvals, authorizations, exemptions and
filings, if any, which Siemens-Elema or any of its Affiliates is required to
obtain or make.
5.3 AVAILABILITY OF FUNDS. SJM has available, or will have
available on the Closing Date, sufficient funds to enable it to consummate the
transactions contemplated by this Agreement.
5.4 LITIGATION. There is no Litigation pending or, to SJM's
knowledge, threatened, which seeks to enjoin or obtain damages in respect of the
consummation of the transactions contemplated hereby.
5.5 BROKERAGE. Other than the fee payable by SJM to CS First
Boston Corporation, its investment banker, there are no claims for brokerage
commissions, finder's fees or similar compensation in connection with the
transactions contemplated by this Agreement based on any arrangement or
agreement by SJM.
5.6 CERTAIN OWNERSHIP INTERESTS. SJM is not directly or
indirectly "significantly funded" (as that phrase is defined in Section
12(B)(c)(i) of the Settlement Agreement and Section 9.02(c)(i) of the License
Agreement), nor is there, directly or indirectly, "significant voting common
stock or other voting equity ownership" (as that phrase is defined in Section
12(B)(c)(i) of the Settlement Agreement) in SJM, by the Japanese government or
investors of Japanese nationality; and (ii) it is not directly or indirectly,
"significantly funded" (as that term is defined in Section 12(B)(c)(ii) of the
Settlement Agreement and Section 9.02(c)(ii) of the License Agreement), nor is
there, directly or indirectly "significant voting common stock or other voting
equity ownership" (as that phrase is defined in Section 12(B)(c)(ii) of the
Settlement Agreement and 9.02(c)(ii) of the License Agreement) in SJM, by a
national government other than Japan.
ARTICLE 6
COVENANTS
6.1 COOPERATION. Each of the parties hereto will use its
reasonable best efforts to cause the consummation of the transactions
contemplated hereby in accordance with the terms and conditions hereof and
applicable law. Each of the parties hereto will use its reasonable best efforts
to obtain all governmental consents and approvals necessary to consummate the
transactions contemplated by this Agreement and to cause the Closing to occur.
Siemens-Elema shall use, and shall cause each Shareholder Affiliate to use, its
reasonable best efforts to obtain the consent or approval of third Persons to
the transactions contemplated hereby or by any of the Ancillary Agreements with
respect to the Commitments identified in Schedule 4.6 and the Permits.
Siemens-Elema and SJM agree that, in the event any consent or approval of any
such third Person necessary or desirable to preserve for the Business any right
or benefit under any such Commitment or Permit is not obtained prior to the
Closing (and provided that SJM waives any resulting failure of a condition under
Article 8), Siemens-Elema will, and will cause the Shareholder Affiliates to,
subsequent to the Closing, cooperate with SJM and the SJM Affiliates in
attempting to obtain such consent or approval as promptly thereafter as
practicable. If such consent or approval cannot be obtained, Siemens-Elema shall
use and shall cause each Shareholder Affiliate to use its reasonable best
efforts to provide SJM or the respective SJM Affiliates with the rights and
benefits of the affected Commitment or Permit for the term of such Commitment or
Permit, and, if and to the extent that Siemens-Elema or a Shareholder Affiliate
provides the rights and benefits under any such Commitment or Permit, or any
other contract for which consent or approval cannot be obtained, SJM or the
respective SJM Affiliate shall assume the obligations and burdens thereunder to
such extent. After the Closing, Siemens-Elema shall cooperate with SJM in the
preparation of any financial statements required to be filed by SJM with respect
to the Business pursuant to U.S. federal securities laws.
6.2 CONDUCT OF BUSINESS. From the date hereof until the
Closing, Siemens-Elema shall cause the Business to be conducted in the ordinary
course consistent with past practice. Prior to the Closing, without the prior
written consent of SJM or unless otherwise contemplated or permitted by this
Agreement, none of Siemens-Elema or any Shareholder Affiliate in respect of the
Business will:
(a) merge or consolidate with any person, acquire any stock or
other ownership interest in any Person or substantially all of the assets of any
business as an entity or liquidate, dissolve or otherwise reorganize or seek
protection from creditors;
(b) except as set forth in Schedule 6.2, enter into any other
agreements, commitments or contracts (including without limitation joint venture
agreements or material license agreements) which are material to the Business,
except agreements, commitments or contracts entered into in the ordinary course
for the purchase, sale or lease of goods or services, consistent with past
practice; or
(c) make any investment of a capital nature either by purchase
of stock or securities, contributions to capital, property transfers or
otherwise, or by the purchase of any property or assets of any other individual,
firm or corporation.
6.3 [RESERVED]
6.4 ACCESS.
6.4.1 From the date of this Agreement to and including the
Closing Date, Siemens-Elema shall provide, and shall cause each of the
Shareholder Affiliates to provide, SJM, its counsel, financial advisors,
auditors and other authorized representatives, with such information pertaining
to the Business as SJM from time to time reasonably may request with respect to
Siemens-Elema, the Shareholder Affiliates, the Assets and the Business, and
shall permit, and shall cause each of the Shareholder Affiliates to permit, SJM
and its representatives reasonable access, during regular business hours and
upon reasonable notice, to the offices, properties, books and records of
Siemens-Elema, the Shareholder Affiliates and the Business, as SJM from time to
time reasonably may request, and will instruct the employees, counsel and
financial advisors of Siemens-Elema and the Shareholder Affiliates to cooperate
with the investigation of the Business; provided that no investigation shall
affect any warranties or representations given by Siemens-Elema to SJM in this
Agreement and provided further, however, that any such investigation shall be
conducted in such a manner so as not to interfere with the operations of the
Business consistent with past practice. This will include, without limitation,
access promptly following execution of this Agreement to information, books,
records, and personnel regarding product pricing, supplier costs, specifications
for products in development and patent applications. In addition, to the extent
not previously delivered or made available to SJM, Siemens-Elema shall cause to
be delivered or made available to SJM all internal or third party environmental
and health and safety studies and reports with respect to the Business, in each
case after January 1, 1992.
6.4.2 In order to facilitate the resolution of any claims made
by or against Siemens-Elema or any Shareholder Affiliate with respect to third
parties prior to or after the Closing, upon reasonable notice, SJM shall and
shall cause its Affiliates to, after the Closing: (i) afford the officers,
employees and authorized agents and representatives of Siemens-Elema reasonable
access, during regular business hours, to the offices, properties, books and
records of SJM International (and any successor thereto) and its Affiliates
relating to the Business, (ii) furnish to the officers, employees and authorized
agents and representatives of Siemens-Elema such additional financial and other
information regarding the Business as Siemens-Elema may from time to time
reasonably request and (iii) make available to Siemens-Elema, the employees of
SJM International (and any successor thereto) and its Affiliates whose
assistance, testimony or presence is necessary to assist Siemens-Elema in
evaluating any such claims and in defending such claims, including the presence
of such persons as witnesses in hearings or trials for such purposes; provided,
however, that such investigation shall not unreasonably interfere with the
businesses or operations of SJM, SJM International or any of their Affiliates;
provided further, however, that neither SJM nor any of its Affiliates shall be
obligated to disclose any information which it holds under a legally binding
obligation of confidentiality or which is protected by any privilege.
6.4.3 In order to facilitate the resolution of any claims made
by or against SJM or any of its Affiliates with respect to third parties after
the Closing, upon reasonable notice, Siemens-Elema shall, and shall cause each
Shareholder Affiliate to, after the Closing: (i) afford the officers, employees
and authorized agents and representatives of SJM reasonable access, during
regular business hours, to the offices, properties, books and records of
Siemens-Elema and the Shareholder Affiliates with respect to Siemens-Elema and
the Shareholder Affiliates and the Business, (ii) furnish to the officers,
employees and authorized agents and representatives of SJM such additional
financial and other information regarding the Business for the period prior to
the Closing as SJM may from time to time reasonably request and (iii) make
available to SJM, the employees of Siemens-Elema and the Shareholder Affiliates
whose assistance, testimony or presence is necessary to assist SJM in evaluating
any such claims and in defending such claims, including the presence of such
persons as witnesses in hearings or trials for such purposes; provided, however,
that such investigation shall not unreasonably interfere with the business or
operations of SiemensElema or its Affiliates; provided further, however, that
neither Siemens-Elema nor any of its Affiliates shall be obligated to disclose
any information which they hold under a legally binding obligation of
confidentiality or which is protected by any privilege.
6.5 NON-DISCLOSURE AGREEMENT. The terms of the Bilateral
NonDisclosure Agreement (the "Non-Disclosure Agreement"), dated as of October
27, 1993, between Siemens-Pacesetter, Inc. and SJM are hereby incorporated by
reference, except that Section 10 thereof shall be deemed amended to provide
that Swiss law shall govern the NonDisclosure Agreement and that any disputes
relating thereto shall be settled by arbitration in the manner provided in
Section 12.8 of this Agreement. Each of the parties hereto agrees to be bound by
the terms of the Non-Disclosure Agreement incorporated herein by reference. The
Non-Disclosure Agreement shall remain in full force and effect until the
Closing.
6.6 ANTITRUST, COMPETITION LAW FILINGS. As promptly as
practicable after the execution of this Agreement, each party to this Agreement
shall file or cause its Affiliates to file any reports or notifications that may
be required to be filed under such competition, investment, foreign exchange,
tax or other laws of such jurisdictions as may be necessary to effect the
transactions contemplated by this Agreement; provided, however, that SJM shall
be responsible (with the cooperation of Siemens-Elema and its Affiliates) for
all filings of reports or notifications under all applicable antitrust laws.
6.7 SUMMARY OF TANGIBLE PERSONAL PROPERTY AND ASSETS.
SiemensElema shall, upon request by SJM, furnish or make available to SJM a
summary of tangible personal property, owned or leased by, in the possession of,
or used by Siemens-Elema or the Shareholder Affiliates in connection with the
Business.
6.8 CLAIMS HISTORY. Siemens-Elema shall promptly make available
and furnish access to SJM a products claims history with respect to
Siemens-Elema and the Shareholder Affiliates in connection with the Business.
6.9 FDA RECERTIFICATION. Siemens-Elema shall as regards the
Business promptly furnish or make available such information as SJM may
reasonably request regarding compliance by Siemens-Elema (Pacemaker Division)
with the applicable terms of the Consent Decree of Permanent Injunction
(captioned U.S. v. Siemens Medical Systems, Inc. and dated March 23, 1994) (the
"Consent Decree").
6.10 GRANT OF LICENSE. SJM, SJM International and each of their
Affiliates designated pursuant to Section 1.1 hereby grants to Siemens
Aktiengesellschaft ("Siemens AG"), effective at the Closing, a worldwide,
irrevocable, non-exclusive, perpetual, royalty free, paid up right and license
to use the patents, copyrights, trade secrets, designs, drawings, software,
know-how, technology and other intellectual property and proprietary matters
assigned or transferred to SJM or one of its Affiliates, to make, have made,
sell, have sold, use, lease, license, or otherwise dispose of products intended
for use in or as products, other than Cardiac Stimulation Devices (including,
without limitation, the right and license to make, have made, sell, have sold,
use, lease, license or otherwise dispose of Cardiac Stimulation Devices or
parts, components, modules, subsystems or subassemblies thereof, in or as parts,
components, modules, subsystems or subassemblies of or for, products intended
for use other than as Cardiac Stimulation Devices), and to render services with
respect to any such products used or intended for use or uses other than as
Cardiac Stimulation Devices. The rights and licenses granted under this Section
6.13 may be freely sublicensed, assigned, transferred or disposed of, in whole
or in part, without the prior written consent of SJM, any of its Affiliates or
any of the successors in interest of any of the foregoing; any license,
assignment, transfer or other disposition by SJM, any of its Affiliates, and any
of the successors in interest of any of the foregoing shall be subject to such
rights and licenses granted to Siemens AG.
6.11 OTHER FINANCIAL STATEMENTS.
On or before the earlier of (i) the date which is 30 days from
the date hereof and (ii) the Closing Date, Siemens-Elema shall deliver to SJM an
audited combined balance sheet for the Business as of September 30, 1992, as
well as an audited combined income statement and combined cash flow statement
for the fiscal year then ended together with the related notes and schedules
thereto in each case prepared from the books and records of the Business in
accordance with U.S. GAAP on a consistent basis. Upon the delivery by
Siemens-Elema to SJM of the Closing Balance Sheet, Siemens-Elema shall also
deliver to SJM an audited combined income statement and combined cash flow
statement for the Business for the period beginning October 1, 1993 and ending
on the Closing Date together with related notes and schedules thereto. Within 30
calendar days after the end of June, 1994, and each calendar month thereafter,
Siemens-Elema shall deliver to SJM unaudited profit and loss information for the
Business based on financial information normally prepared by Siemens-Elema for
delivery to Siemens AG.
To the extent necessary to permit SJM to comply with the rules
and regulations of the United States Securities and Exchange Commission,
Siemens-Elema shall provide to SJM financial information prepared in accordance
with U.S. GAAP consisting of an unaudited interim balance sheet, dated as of the
last day of, and an income statement and statement of cash flow, for the period
beginning January 1, 1994 and ending on the last day of such calendar quarter as
required by the applicable rules and regulations of the Securities and Exchange
Commission. If the last day of such calendar quarter is after the Closing Date,
Siemens-Elema shall cooperate in the preparation of such interim unaudited
financial statements.
6.12 AMENDMENTS TO SCHEDULES.
(a) No later than July 31, 1994, Siemens-Elema shall deliver to
SJM any Schedules referenced in Article 4 but not attached hereto as of the date
hereof, as well as any updates to or corrections of Schedules attached hereto,
which Schedules shall be corrected to delete any reference to "knowledge". If at
any time thereafter and prior to the Closing Date Siemens-Elema learns that any
representation contained in Article 4 is or has become untrue or incorrect in
any material respect, Siemens-Elema shall promptly notify SJM of (i) the
relevant facts and circumstances and (ii) the amendments to the Schedules hereto
which Siemens-Elema believes in good faith would be necessary to make the
representations contained in Article 4 true and correct in all material respects
in light of such facts and circumstances. Each of such new or additional
Schedules which Siemens-Elema is obligated to deliver no later than July 31,
1994, as well as any subsequent proposed amendment is herein referred to as an
"Amendment".
(b) If the facts and circumstances underlying any Amendment
would have an adverse effect which is material, Siemens-Elema and SJM shall
negotiate in good faith appropriate adjustments, if any, in the price to be paid
by SJM under Section 2.1 and in the amount of liability or liabilities to be
assumed by SJM or the SJM Affiliates under Section 1.2(b).
ARTICLE 7
ADDITIONAL COVENANTS
7.1 LIABILITY FOR EMPLOYEES AND EMPLOYEE BENEFIT PLANS.
7.1.1 IN GENERAL. Except as provided on Schedule 4.11, as of
the Closing Date, SJM and an SJM Affiliate shall employ (where employment
continues by operation of law) or, where employment does not continue by
operation of law, shall offer employment to, each Employee listed on Schedule
4.11 employed on terms which are not less favorable to such Employee, taken as a
whole, as the terms in effect immediately prior to the Closing Date. Each such
Employee who continues in employment by operation of law or who accepts an offer
of employment pursuant to this Section 7.1.1 is hereafter referred to as a
"Transferred Employee." Siemens-Elema shall indemnify and hold harmless SJM, and
any SJM Affiliate for any Losses as a result of any severance, termination
indemnity, compensation, or other benefit or amount under any Employee Benefit
Plan with respect to:
(a) any Employee who is not a Transferred Employee;
(b) any Employee who would otherwise be a Transferred Employee,
but who withholds his individual consent or objects to the transfer
under local labor law and thus refuses to become an employee of SJM or
an SJM Affiliate, as the case may be; and
(c) any former Employee who terminated employment for any
reason prior to or on the Closing Date.
7.1.2 LIABILITY FOR EMPLOYEE BENEFIT PLANS. As of the Closing
Date, SJM or the appropriate SJM Affiliate shall assume the Employee Benefit
Plans listed on Schedule 7.1.2 which they are required under the laws of the
applicable jurisdictions to assume or which they, with the consent of
Siemens-Elema and the Shareholder Affiliates, as appropriate, have agreed to
assume (the "Assumed Employee Benefit Plans"). SiemensElema and the Shareholder
Affiliates agree to do all things reasonably necessary to accomplish the
assumption of the Assumed Employee Benefit Plans, including, with respect to
private plans, the transfer to SJM or the designated SJM Affiliate of insurance
contracts and other assets to fully fund the Benefit Obligations of the Sellers
under such plans as of the Closing Date, and shall not withhold their consent if
such Employee Benefit Plans are capable, under the laws of the applicable
jurisdictions, of being assumed.
7.1.3 Nothing herein expressed or implied is intended or shall
be construed to confer upon or give to any person, firm or corporation, other
than the parties hereto and their respective permitted successors and assigns,
any rights or remedies under or by reason of this Agreement.
7.1.4 Siemens-Elema shall, or shall cause a Shareholder
Affiliate to, indemnify, save and hold harmless SJM and the SJM Affiliates and
the Affiliates of any of them from and against any and all Losses arising under:
(a) any Employee Benefit Plan maintained or contributed to by
SiemensElema or the Shareholder Affiliates, other than any Employee
Benefit Plan and obligations assumed by SJM and the SJM Affiliates
pursuant to Section 7.1.2 above, regardless of whether the Losses
relate to or arise out of conditions, events or transactions which
exist or occur prior to, on or after the Closing Date; and
(b) any Employee Benefit Plan and obligations assumed by SJM or
the SJM Affiliates pursuant to Section 7.1.2 above, to the extent such
Losses relate to or arise out of conditions, events or transactions
which exist or occur on or prior to the Closing Date. SJM shall, or
shall cause a SJM Affiliate to, indemnify, save and hold harmless
Siemens-Elema and the Shareholder Affiliates from and against any and
all Losses related to Employee Benefit Plans and obligations assumed by
SJM and the SJM Affiliates pursuant to Section 7.1.2 above, to the
extent such Losses relate to or arise out of conditions, events or
transactions which exist or occur following the Closing Date.
7.2 SALES AND OTHER TAXES.
Each of Sellers and SJM and the SJM Affiliates will be
responsible for the payment of, and Siemens-Elema and SJM shall indemnify and
hold the other party and its Affiliates harmless against, 50% of all transfer,
documentary, recording, notarial, sales, use, registration, stamp and other
similar taxes, fees and expenses (including, but not limited to, all applicable
stock transfer or real estate transfer taxes and including any penalties,
interest and additions to such tax), incurred in connection with this Agreement
or any Ancillary Agreement and the transactions contemplated hereby or thereby.
Sellers and SJM and the SJM Affiliates shall cooperate in timely making and
filing all Tax Returns as may be required to comply with the provisions of laws
relating to such taxes. SJM or an SJM Affiliate will bear 100% of any value
added tax (VAT) imposed with respect to its purchase of the Assets; provided,
however, that the relevant SJM Affiliate will be entitled to a credit for such
VAT against such SJM Affiliate's VAT obligation and provided further that where
allowed by local law, SJM or the relevant SJM Affiliate will be permitted to
satisfy its obligation to pay VAT by assigning its claim for a refund of such
VAT to the applicable Seller.
7.3 NON-COMPETITION.
7.3.1 During the period from the date of this Agreement to and
including the fourth anniversary of the date hereof (or, if not enforceable for
such period in any country, for such shorter period as shall be enforceable in
such country), Siemens-Elema shall not, nor shall it permit any of its
Affiliates to, directly or indirectly, engage in the development, marketing,
production, sale or distribution anywhere in the world of Competitive Products
(as defined below).
7.3.2 As used in Section 7.3.1 hereof, the phrase "directly or
indirectly, engage in" includes any direct or indirect ownership, profit
participation or other interest by Siemens-Elema or its Affiliates, whether as
owner, stockholder, partner, joint venturer, beneficiary or otherwise, in any
Person; provided, however, that the foregoing provisions shall not prevent
Siemens-Elema or any of its Affiliates from (a) investing in businesses that
compete with the Competitive Products where such investments are incidental
investments in public companies and constitute, in the aggregate, less than 5%
of the outstanding securities or voting interest of each of such companies, (b)
acquiring businesses an incidental portion (such portion being deemed to be
incidental if the assets, revenues or income relating to the business which
competes with the Competitive Products is less than 5% of the assets, revenues
or income, respectively, of the business being acquired) of the business of
which competes with the Competitive Products (unless the excess over 5% of the
competing portion of such business is divested within six months from the date
of such acquisition) or (c) investing in investment funds or investment
partnerships which in turn invest in companies or entities which may be engaged
in the production, sale or distribution of Competitive Products so long as
neither Siemens-Elema nor any of its Affiliates exercise control over such
investment decisions.
7.3.3 As used in this Section 7.3, (i) "Competitive Products"
means "Cardiac Stimulation Devices" (as defined in Section 13.1) and other
devices performing the same purpose or function as, or that are competitive
with, Cardiac Stimulation Devices, and shall include products intended for use
in or as products that are Cardiac Stimulation Devices (including, without
limitation, parts, components, modules, subsystems or subassemblies thereof, or
parts, components, modules, subsystems or subassemblies of and for, products
intended for use as or products that are Cardiac Stimulation Devices) except to
the extent that they are intended for use in or as products other than Cardiac
Stimulation Devices and (ii) "Affiliate" does not include any Person once it is
no longer an Affiliate of Siemens AG.
7.4 NON-SOLICITATION. For thirty-six months from the Closing
Date, neither Siemens-Elema nor any Shareholder Affiliate, on the one hand, nor
SJM nor any of its Affiliates, on the other hand, shall specifically solicit to
hire any current employees of the other party without the prior written consent
of such latter party, provided that nothing herein shall restrict or preclude
the rights of either party to make generalized searches for employees by use of
advertisements in the media (including without limitation, trade media) or by
engaging search firms to engage in searches which are not targeted or focused on
the employees of the other party.
7.5 SIEMENS NAME. Immediately after the Closing, except as
otherwise permitted under the License Agreement referred to in Section 3.2.3,
SJM will take, and will cause each SJM Affiliate to take, all action necessary
to cease the use of the name "Siemens" (or any variant thereof) and related
trademarks, corporate names, and trade names incorporating the name "Siemens",
and any "Siemens" logos and trade dress, in each case in connection with the
conduct of the Business. Effective upon the Closing, Siemens-Elema shall cause
the Shareholder Affiliate in France and its shareholders to take all necessary
action to change its name to exclude the word "Pacesetter."
7.6 CONFIDENTIALITY. Except as otherwise provided in this
Agreement, after the Closing Sellers and their Affiliates shall not use or
disclose to third parties any information disclosed to and transferred and
assigned, licensed or otherwise made available to SJM or its Affiliates in
connection with the Business and transfer of Assets hereunder. Without
limitation, this obligation of confidentiality shall apply to information
related to the Products, business plans, strategies, technologies, and future
business relationships of the Business. This obligation of confidentiality shall
not apply to the extent any such information (a) is or becomes part of the
public domain through no fault of Sellers (but only after and only to the extent
that it is published or otherwise becomes part of the public domain); (b) after
the Closing comes into the possession of Sellers from a third party who was not,
to Sellers' knowledge, under a continuing obligation of confidence to the
disclosing party; or (c) is disclosed by Sellers pursuant to judicial
compulsion, provided that disclosing party is notified at the time such judicial
action is initiated. Disclosures relating to the Products, business plan,s
strategies and future business relationships of SJM or the Sellers shall not be
deemed to be in the public domain or in the possession of the receiving party
merely because they are embraced (but not disclosed) by general disclosures in
the public domain or the possession of the receiving party.
7.7 ACCOUNTS RECEIVABLE. Regarding accounts receivable sold as
part of the Assets sold hereunder, SJM may, by written notice given to
Siemens-Elema at any time prior to one year after the Closing Date, sell back to
Siemens-Elema, and Siemens-Elema shall repurchase, at their face value any or
all such accounts receivable not collected because they were not at the Closing
Date documented by invoices and accompanying documentation as required to permit
and support collection in accordance with national, provincial and local law or
regulation. SJM shall deliver to Siemens-Elema an assignment of such accounts
receivable to be sold back to Siemens-Elema, and Siemens-Elema shall deliver to
SJM immediately available funds in the amount of such accounts receivable within
30 days after the date of SJM's written notice referred to above. Following such
assignment, SiemensElema shall be free to use any efforts to collect such
accounts receivable it has purchased as Siemens-Elema shall determine.
ARTICLE 8
CONDITIONS TO SJM'S OBLIGATIONS
The obligations of SJM to consummate the transactions contemplated by this
Agreement shall be subject to the satisfaction (or waiver by SJM in writing), on
or prior to the Closing Date, of all of the following conditions:
8.1 REPRESENTATIONS, WARRANTIES AND COVENANTS OF SIEMENS-ELEMA.
Siemens-Elema shall have in all material respects performed and complied with
all of its agreements and covenants contained herein to be performed at or prior
to the Closing Date and the representations and warranties of Siemens-Elema
contained herein shall be true on and as of Closing Date in all material
respects.
8.2 NO PROHIBITION. No statute, rule or regulation or order of
any court or administrative agency shall be in effect which prohibits
consummation of the transactions contemplated hereby.
8.3 DELIVERIES. Siemens-Elema shall have made or caused to be
made delivery to SJM of the items set forth in Section 3.2 hereof.
8.4 NO MATERIAL ADVERSE EFFECT. No occurrences or events which,
individually or in the aggregate, have a Material Adverse Effect shall have
occurred after September 30, 1993 and be continuing; and Siemens-Elema and SJM
shall not have failed to agree on the consequences to an Amendment as
contemplated in Section 6.12(b).
8.5 GOVERNMENTAL AND OTHER APPROVALS. All governmental filings,
authorizations and approvals which are identified on Schedules 4.9 and 5.2 that
are required for the consummation of the transactions contemplated hereby or to
permit SJM and the SJM Affiliates, after consummation of the transactions
contemplated hereby, to carry on the Business in the manner now conducted, and
each of the consents and approvals identified on Schedule 4.6, the absence of
which would have, individually or in the aggregate, a Material Adverse Effect,
and each of those consents listed on Schedule 8.5, will have been made or
obtained.
8.6 U.S. ASSET PURCHASE AGREEMENT. The closing of the purchase
and sale under the U.S. Asset Purchase Agreement (as defined in Section 13.1)
shall have occurred.
ARTICLE 9
CONDITIONS TO SIEMENS-ELEMA'S OBLIGATIONS
The obligations of Siemens-Elema to consummate the transactions contemplated by
this Agreement shall be subject to the satisfaction (or waiver by Siemens-Elema
in writing), on or prior to the Closing Date, of all of the following
conditions:
9.1 REPRESENTATIONS, WARRANTIES AND COVENANTS OF SJM. SJM and
SJM International each shall have in all material respects performed and
complied with all of their agreements and covenants contained herein to be
performed at or prior to the Closing Date, and all of the representations of SJM
contained herein shall be true on and as of the Closing Date in all material
respects.
9.2 NO PROHIBITION. No statute, rule or regulation or order of
any court or administrative agency shall be in effect which prohibits
consummation of the transactions contemplated hereby.
9.3 DELIVERIES. SJM shall have made or caused to be made
delivery to Siemens-Elema of the items set forth in Section 3.3 hereof.
9.4 GOVERNMENTAL APPROVALS. All governmental filings,
authorizations and approvals that are required for the consummation of the
transactions contemplated hereby or to permit SJM and the SJM Affiliates, after
consummation of the transactions contemplated hereby, will have been made or
obtained.
9.5 U.S. ASSET PURCHASE AGREEMENT. The closing of the purchase
and sale under the U.S. Asset Purchase Agreement shall have occurred.
ARTICLE 10
INDEMNIFICATION AND RELATED MATTERS
10.1 SURVIVAL. Subject to the limitations and other provisions
of this Agreement, the representations and warranties of SJM and Siemens-Elema
contained herein shall survive the Closing and shall remain in full force and
effect, regardless of any investigation made by or on behalf of SJM or
Siemens-Elema, as the case may be, Siemens-Elema, for a period of one year after
the Closing Date; provided, however, that (A) the representations and warranties
in Sections 4.1.1, 4.1.2, 4.1.3, 4.3.1, 4.14 and 4.17 shall survive for a period
of two years after the Closing Date, (B) the representations and warranties in
Sections 4.2, 4.3.15 and 4.3.16 shall only survive until the adjustment to the
Cash Consideration has been resolved pursuant to Section 2.2, and (C) the
representations and warranties in Sections 4.7 and 4.18 shall not survive the
Closing.
10.2 INDEMNIFICATION BY SIEMENS-ELEMA. Subject to the terms and
conditions of this Article 10, Siemens-Elema agrees to indemnify and hold SJM
and its Affiliates, including, in each case, any of their respective directors,
officers, employees and representatives, harmless from and against:
10.2.1 any and all Losses resulting from any breach of any
representation or warranty as of the Closing Date, or any knowing, negligent or
wilfull act or omission in breach of any covenant or other agreement of
Siemens-Elema contained in this Agreement (other than Sections 7.1 and 7.2, it
being understood that the sole remedy for breach thereof shall be pursuant to
Sections 7.1 and 7.2, as the case may be); and
10.2.2 any and all Losses resulting from Excluded Liabilities.
10.3 INDEMNIFICATION BY SJM. Subject to the terms and
conditions of this Article 10, SJM agrees to indemnify and hold Siemens-Elema
and its Affiliates, including, in each case, any of its or their respective
directors, officers, employees and representatives, harmless from and against:
10.3.1 any and all Losses resulting from any breach of any
representation or warranty as of the Closing Date, or any knowing, negligent or
wilfull act or omission in breach of any covenant or agreement of SJM contained
in this Agreement (other than Sections 7.1 and 7.2, it being understood that the
sole remedy for breach thereof shall be pursuant to Sections 7.1 and 7.2, as the
case may be); and
10.3.2 any and all Losses resulting from Assumed Liabilities.
10.4 LIMITATION ON INDEMNIFICATION LIABILITIES. The
indemnification obligations of Siemens-Elema contained in Section 10.2 hereof
shall not be effective until the aggregate dollar amount of all Losses which
would otherwise be indemnifiable under Section 10.2 exceeds US$2,000,000 (the
"Threshold Amount"), and then only to the extent such aggregate amount exceeds
the Threshold Amount. The indemnification obligations of Siemens-Elema under
Section 10.2 shall be effective only until the dollar amount paid in respect of
the Losses indemnified against under such Section aggregates to an amount equal
to US$30,000,000 (the "Liability Cap"). The Threshold Amount and the Liability
Cap contained in this Section 10.4 shall not apply to any obligations arising
under Section 2.2.4 regarding fees and expenses, Sections 6.1, 6.4.1, 6.5, 6.6,
6.11, Article 7 or Article 12 or to any Losses arising from Excluded
Liabilities.
10.5 NOTICE OF INDEMNIFICATION. In the event any legal
proceeding shall be threatened or instituted or any claim or demand shall be
asserted by any person in respect of which payment may be sought by one party
hereto from the other party under the provisions of this Agreement, the party
seeking indemnification (the "Indemnitee") shall promptly cause written notice
of the assertion of any such claim of which it has knowledge which is covered by
this indemnity to be forwarded to the other party (the "Indemnitor") which
notice, in the case of a claim arising under Section 7.1, 7.2, 10.2 or 10.3,
must be received by the Indemnitor before the expiration of the relevant
survival period set forth in Section 10.1. Any notice of a claim by reason of
any of the representations, warranties, covenants or agreements contained in
this Agreement shall state specifically the representation, warranty, covenant
or agreement with respect to which the claim is made, the facts giving rise to
an alleged basis for the claim, and the amount of the liability asserted against
the Indemnitor by reason of the claim.
10.6 INDEMNIFICATION PROCEDURE FOR THIRD-PARTY CLAIMS. In the
event that an Indemnitee receives written notice of the commencement of any
action or proceeding, the assertion of any claim by a third party or the
imposition of any penalty or assessment for which indemnity may be sought
pursuant to this Article 10 (a "Third-Party Claim"), and such Indemnitee intends
to seek indemnity pursuant to this Article 10, the Indemnitee shall promptly
provide the Indemnitor with notice of such action, proceeding, claim, penalty or
assessment, and the Indemnitor shall, upon receipt of such notice, be entitled
to participate in or, at the Indemnitor's option, assume the defense, appeal or
settlement of such action, proceeding, claim, penalty or assessment with respect
to which such indemnity has been invoked with counsel of its own choosing, and
the Indemnitee will cooperate fully with the Indemnitor in connection therewith.
In the event that the Indemnitor fails to assume the defense, appeal or
settlement of such action, proceeding, claim, penalty or assessment within 30
days after receipt of notice thereof from the Indemnitee, the Indemnitee shall
have the right to undertake the appeal of such action, proceeding, claim,
penalty or assessment at the Indemnitor's expense, subject to the rights of the
Indemnitor in the immediately succeeding sentence. If the Indemnitee assumes
such defense and proposes to settle or compromise any such action, proceeding,
claim, penalty or assessment then the Indemnitee shall give written notice
thereof and the Indemnitor shall have the right to participate in the settlement
or assume or reassume the defense of such action, proceeding, claim, penalty or
assessment.
10.7 WAIVERS OF CERTAIN RESTRICTIONS. Siemens-Elema on behalf
of itself and the Shareholder Affiliates hereby waives, and neither SJM nor any
of its Affiliates shall be obligated to comply with, any applicable statutory
provision requiring SJM or any of its Affiliates to examine the Business or any
of the Assets after receipt and to notify Sellers without delay of any defect
discovered. The parties hereby agree that any claims hereunder may be made at
any time during the applicable survival period.
10.8 RIGHT TO CURE. Any party that is obligated to indemnify,
defend and/or hold harmless any Person pursuant to any provision of this Article
10 shall have the right to cure, within a reasonable time and in a manner
reasonably satisfactory to such Person, any matter giving rise to such
obligation; provided, however, that any such cure shall not relieve or reduce
any such obligation to the extent that such cure is inadequate.
ARTICLE 11
TERMINATION PRIOR TO CLOSING
11.1 TERMINATION. This Agreement may be terminated at any time
prior to the Closing:
11.1.1 by the mutual written consent of the parties; or
11.1.2 by either Siemens-Elema, on the one hand, or SJM and SJM
International, on the other hand, if there has been a breach of a material
representation or breach of a material covenant on the part of the other party
in the representations, warranties and covenants contained herein, unless such
breach is cured within 30 days of receipt of notice of such breach; or
11.1.3 by either Siemens-Elema, on the one hand, or SJM and SJM
International, on the other hand, if the Closing has not occurred by October 31,
1994; provided that no party may terminate this Agreement pursuant to this
clause if such party's failure to fulfill any of its obligations under this
Agreement shall have been the reason that the Closing Date shall not have
occurred on or before said date; and provided further that such date shall be
extended until December 31, 1994, if the Closing did not occur by such date
because of the failure of SJM, Siemens-Elema or one of their respective
Affiliates to receive one of the governmental approvals or authorizations
contemplated by this Agreement because of the failure of any applicable waiting
period to expire; or
11.1.4 by either Siemens-Elema, on the one hand, or SJM and SJM
International, on the other hand, if there shall be any law or regulation that
makes consummation of the Acquisition or any other material component of the
transactions contemplated hereby illegal or otherwise prohibited or if any
judgment, injunction, order or decree enjoining SJM, Siemens-Elema or one of
their respective Affiliates from consummating the transactions contemplated
hereby is entered and such judgment, injunction, order or decree shall become
final and nonappealable.
11.2 EFFECT OF TERMINATION. If this Agreement is terminated
pursuant to Section 11.1, this Agreement shall become void and of no effect with
no liability on the part of any party hereto, except (i) as set forth in
Sections 6.5 and 12.6 and (ii) that nothing shall relieve any party hereto for
liability for any breach of this Agreement.
ARTICLE 12
MISCELLANEOUS
12.1 ENTIRE AGREEMENT. This Agreement (including the exhibits
hereto, the Schedules and the documents referred to herein and the other
documents executed on the date hereof) and the Non-Disclosure Agreement contain
the entire understanding of the parties hereto in respect of the subject matter
contained herein and supersede all prior agreements and understandings between
the parties with respect to such subject matter. There are no restrictions,
promises, representations, warranties, covenants, or undertakings, other than
those expressly set forth or referred to herein or therein.
12.2 AMENDMENT; WAIVER. No waiver and no modification or
amendment of any provision of this Agreement shall be effective unless
specifically made in writing and duly signed by the parties to be bound thereby.
Waiver by a party of any breach of or failure to comply with any of the
provisions of this Agreement by any other party shall not be construed as, or
constitute, a continuing waiver of, or a waiver of any other breach of, or
failure to comply with, any other provision of this Agreement.
12.3 ASSIGNMENT. This Agreement and all of the provisions
hereof shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and permitted assigns, but neither this Agreement
nor any of the rights, interests or obligations hereunder shall be assigned by
any of the parties hereto without the prior written consent of the other
parties; provided, however, that SJM may assign this Agreement and its rights,
interests and obligations hereunder in whole or in part to one or more directly
or indirectly wholly owned subsidiaries of SJM without the consent of
Siemens-Elema; provided, however, that such assignment shall not relieve SJM of
any of its obligations hereunder.
12.4 HEADINGS; USAGE. The paragraph headings contained herein
are for the purposes of convenience only and are not intended to define or limit
the contents of said paragraphs. The meanings of any terms defined herein are
equally applicable to both the singular and plural forms of the terms defined.
12.5 COOPERATION. Each party hereto shall cooperate, shall take
further action and shall execute and deliver such further documents as may be
reasonably requested by the other party in order to carry out the provisions and
purposes of this Agreement.
12.6 EXPENSES. Except as provided in Section 7.2, SJM shall
bear its and SJM International's, and Siemens-Elema shall bear its and the
Shareholder Affiliates' costs and expenses in connection with the negotiation,
preparation, performance and consummation of the transactions contemplated by
this Agreement, including all taxes of any type, the fees and disbursements of
all attorneys, accountants, appraisers, investment bankers and advisors retained
by or representing them in connection with the preparation and performance of
this Agreement; provided that Siemens-Elema and SJM shall each bear 50% of the
cost of all patent and trademark registrations contemplated hereby.
12.7 GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the substantive law of Switzerland other than the
UNCITRAL purchasing law and/or any law relating to conflict of law.
12.8 ARBITRATION.
12.8.1 All disputes arising out of or in connection with this
Agreement or any Ancillary Agreement, including any question regarding the
existence, validity or termination hereof or thereof, shall be finally settled
under Rules of Arbitration of the International Chamber of Commerce, Paris by
three arbitrators in accordance with the said Rules.
12.8.2 Each party shall nominate one arbitrator for
confirmation by the competent authority under the applicable Rules (Appointing
Authority). Both arbitrators shall agree on the third arbitrator within 30 days.
Should the two arbitrators fail within the above time-limit, to reach agreement
on the third arbitrator, he shall be appointed by the Appointing Authority. If
there are two or more defendants, any nomination of an arbitrator by or on
behalf of such defendants must be by joint agreement between them. If such
defendant fail, within the time-limit fixed by the Appointing Authority, to
agree on such joint nomination, the proceedings against each of them must be
separated.
12.8.3 The seat of arbitration shall be Berne, Switzerland. The
procedural law of this place shall apply where the Rules are silent.
12.8.4. The language to be used in the arbitration proceeding
shall be English.
12.8.5 The arbitrators appointed pursuant to this Section 12.8
shall have the power to grant temporary and permanent injunctive relief and
specific performance. The arbitrators shall not have the power to act as
"amiable compositeurs" with respect to any dispute submitted to such
arbitration, but rather shall make their decision based on their understanding
and interpretation of the applicable law and facts.
12.8.6 Either party to this Agreement may commence arbitration
proceedings in respect of which a notice has been timely given pursuant to
Section 10.5 at any time within one year from the date upon which such notice
was given to the other party.
12.9 SEVERABILITY. Whenever possible, each provision of this
Agreement will be interpreted in such manner as to be effective and valid under
the applicable law, but if any provision of this Agreement is held to be
prohibited by or invalid under applicable law, such provision will be
ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of such provision or the remaining provisions of this
Agreement.
12.10 COUNTERPART. This Agreement may be executed in one or
more counterparts, all of which taken together will constitute one and the same
instrument.
12.11 INTERPRETATION. This Agreement has been prepared and
executed in the English language. In case of any conflict or inconsistency
between the English language version and any translation hereof made for any
purpose, the English language shall govern the interpretation and construction
hereof, and for any and all other purposes, except as may be required by
applicable law.
12.12 NOTICES. All notices, requests and other communications
to any party hereunder shall be in writing and shall be given or made (and shall
be deemed to have been duly given or made upon receipt) by delivery in person,
by courier service, by cable, by facsimile transmission, by telegram or by
registered or certified mail (postage prepaid, return receipt requested) to the
respective parties at the following addresses (or at such other address for a
party as shall be specified in a notice given in accordance with this Section
12.12):
if to Siemens-Elema, to:
Siemens-Elema AB
Rontgenvagen 2
Solna, Sweden
Facsimile No.: 46-8-29 6974
Attention: Carl-Goran Myrin
with a copy to:
Siemens AG
Legal Department
Werner-von-Siemens-Strasse 50
D-91052 Erlangen
Facsimile No.: 49-9131-7-28667
Attention: Dr. Jurgen Biermann
if to SJM to:
St. Jude Medical, Inc.
One Lillehei Plaza
St. Paul, Minnesota 55117
Attention: Ronald A. Matricaria, President
and Chief Executive Officer
Attention: Diane M. Johson, Vice President
and General Counsel
with a copy to:
Lindquist & Vennum
4200 IDS Center
80 South Eighth Street
Minneapolis, MN 55402
Attention: Joel H. Green
and
Baker & McKenzie
One Prudential Plaza
130 East Randolph Drive
Chicago, Illinois 60601
Attention: John E. Morrow
12.13 PUBLICITY. Upon execution of this Agreement, the parties
shall jointly issue a press release, as agreed upon by them. Neither party
shall, without the prior written consent of the other, issue any statement or
communication to the public or to the press regarding this Agreement, or any of
the terms, conditions or other facts with respect to the Agreement, except as
required by law or the rules of any recognized stock exchange.
12.14 NO THIRD-PARTY BENEFICIARY. The provisions of this
Agreement are for the sole benefit of the parties to this Agreement and are not
for the benefit of any third party.
ARTICLE 13
DEFINITIONS
13.1 DEFINITIONS. For purposes of this Agreement, the following
terms have the meaning set forth below:
"Affiliate" means as to any Person controlling, controlled by,
or under common control with, such Person.
"Cash Consideration" shall have the meaning given to it in
Section 2.1.
"Ancillary Agreements" means the Assignments, the Business
Transfer Agreements, the Siemens Transitional Services Agreements and the SJM
Transitional Services Agreements.
"Assets" shall have the meaning given to it in Section 1.1(a).
"Assignments" shall have the meaning given to it in Section
3.2.5.
"Assumed Liabilities" shall have the meaning given to it in
Section 1.2(b).
"Benefit Obligations" shall have the meaning given to it in
Section 4.10.5(c).
"Business" means the research, development, manufacturing,
assembly, marketing, sales, maintenance and service of Cardiac Stimulation
Devices by Siemens-Elema and the Shareholder Affiliates or their Affiliates
(other than Siemens-Pacesetter, Inc., a Delaware corporation, its Subsidiaries
and Siemens Electric Limited, a Canadian corporation).
"Business Day" means any day that is not a Saturday, a Sunday
or a day on which banks are required or permitted to be closed in the State of
New York and the Kingdom of Sweden.
"Business Transfer Agreements" means the Business Transfer
Agreements to be executed by the Sellers on the Closing Date in a form to be
agreed upon by Siemens-Elema and SJM providing for the transfer of Assets to and
assumption of Assumed Liabilities by the respective SJM Affiliates.
"Cardiac Stimulation Devices" means devices for electrically
stimulating or shocking the heart and internal (but not external) holter
monitors which, in each case, are suitable for use by human patients, including,
without limitation: cardiac pacemakers, antitachycardia pacemakers,
cardioverters and defibrillator, including combinations thereof, whether
implantable or not; pulse generators and other waveform generators specially
designed for, and used with, such devices; leads, electrodes and sensors
specially designed for, and used with, such devices; mechanisms designed for
coupling such generators in a stimulating, shocking or sensing relationship to
the heart; data dispensing, processing and gathering systems designed for such
devices, including programmers, pacing system analyzers, defibrillation system
analyzers, testers, encoders, decoders, transmitters, receivers and computer
software-controlled systems (including the software) specially designed for use
with or as part of such devices. External defibrillator that shock the heart
from the surface of the body through the tissue are excluded.
"Closing" shall have the meaning given to it in Section 3.1.
"Closing Balance Sheet" shall have the meaning given to it in
Section 2.2.2.
"Closing Date" shall have the meaning given to it in Section
3.1.
"Commitments" shall have the meaning given to it in Section
4.6.
"Competitive Products" shall have the meaning given to it in
Section 7.3.3.
"Deal Balance Sheet" shall have the meaning given to it in
Section 4.2
"Designated Amount" shall have the meaning given to it in
Section 2.2.3.
"dollars" and the symbol "US$" means lawful currency of the
United States of America.
"Employee" shall have the meaning given to it in Section
4.10.5.
"Employee Benefit Plan" shall have the meaning given to it in
Section 4.10.5.
"Excluded Assets" shall have the meaning given to it in Section
1.1(b).
"Excluded Liabilities" shall have the meaning given to it in
Section 1.2(a).
"FDA" shall have the meaning given to it in Section 4.3.8.
"Financial Statements" shall have the meaning given to it in
Section 4.2.
"Liabilities" means any and all debts, liabilities and
obligations, whether accrued or fixed, absolute or contingent, matured or
unmatured.
"License Agreement" means the License Agreement, dated August
26, 1992, between Siemens AG and Medtronics, Inc.
"Lien" means any mortgage, claim, lien, pledge, charge,
usufruct, security interest, option, preemptive right, assessment, security
interest, restriction on transfer or encumbrance of any kind.
"Litigation" means any claim, action, suit or proceeding in any
court or before any arbitrator or governmental body, agency or official.
"Losses" means any and all Liabilities, obligations, duties,
demands, claims, actions, causes of action, assessments, losses, costs, damages,
deficiencies, taxes, fines or expenses, including, without limitation, interest,
penalties, reasonable attorneys' fees and all amounts paid in investigation,
defense or settlement of any of the foregoing; provided, however, that the
foregoing shall not include consequential damages.
"Material Adverse Effect" means any change in, or effect on,
the Business as currently conducted that is, or is reasonably likely to be,
materially adverse to the operations, results of operations, assets or financial
condition of the Business, taken as a whole, except for such changes or effects
that are the result of changes in general economic conditions or changes that
generally affect the industry in which the Business is operated.
"Medtronics Assignment" shall have the meaning given to it in
Section 3.2.2.
"Net Book Value" means the assets minus the liabilities
reflected on the applicable balance sheet, as adjusted.
"Non-Disclosure Agreement" shall have the meaning given to it
in Section 6.5.
"Permitted Liens" mean (i) Liens for inchoate mechanics' and
materialmen's liens for construction in progress and workmen's, repairmen's,
warehousemen's and carriers' liens arising in the ordinary course of the
Business which in the aggregate have a value of less than US$100,000, (ii) Liens
for Taxes not yet payable and for Taxes being contested in good faith, and (iii)
Liens and imperfections of title the existence of which would not materially
affect the use of the property subject to such lien, consistent with past
practice.
"Person" means any individual, sole proprietorship,
partnership, joint venture, trust, unincorporated association, corporation or
other such entity or government (whether domestic, foreign, Federal, state,
county, city or otherwise, including, without limitation, any instrumentality,
division, agency or department thereof).
"Post-Closing Litigation Losses" means all Losses resulting
from any Litigation against Siemens-Elema or any Shareholder Affiliate in
respect of the Business or the Business that are not Pre-Closing Litigation
Losses.
"Post-Closing Products Liability Losses" means any Losses
resulting from any product liability claims for Products implanted or otherwise
used with a patient on, before or after the Closing Date arising from a death,
injury, explant or other similar occurrence happening or alleged to have
happened after the Closing Date.
"Pre-Closing Litigation Losses" means any Losses resulting from
any Litigation pending or threatened against Siemens-Elema or any Shareholder
Affiliate at any time in respect of the conduct or condition of the Business or
the Assets on or before the Closing Date.
"Pre-Closing Products Liability Losses" means any Losses
resulting from any product liability claims for Products implanted or otherwise
used with a patient on or before the Closing Date arising from a death, injury,
explant or other similar occurrence happening or alleged to have happened on or
before the Closing Date.
"Products" shall have the meaning given to it in Section
4.13.1.
"Sellers" has the meaning given to it in Section 1.1.
"Settlement Agreement" means the Settlement Agreement dated
September 9, 1992 between Siemens AG and Medtronics, Inc.
"Shareholder Affiliate" shall have the meaning given to it in
Section 1.1(a).
"Siemens AG" has the meaning given to it in Section 6.9.
"Siemens Transitional Services Agreements" shall have the
meaning given to it in Section 1.4.1.
"SJM's Accountants" shall have the meaning given to it in
Section 2.2.4.
"SJM Affiliates" shall have the meaning given to it in Section
1.1(a).
"SJM Transitional Services Agreements" shall have the meaning
given to it in Section 1.4.2.
"Subsidiary" means in respect of any Person any corporation of
which the securities having a majority of the ordinary voting power in electing
the board of directors are, at the time as of which any determination is being
made, owned by such Person either directly or through one or more Subsidiaries.
"Tax" or "Taxes" means with respect to any Person any federal,
state, county, local or foreign income, gross receipts, profits, capital,
franchise, estimated, alternative minimum, add-on minimum, estimated, sales,
use, occupancy, transfer, registration, value added, ad valorem, excise, natural
resources, severance, stamp, occupation, premium, windfall profit,
environmental, customs, duties, levies, real property, personal property,
capital stock, mercantile, social security (or similar), unemployment,
disability, payroll, license, employment, employee or other withholding, or
other tax, governmental fee or like assessment or charge of any kind whatsoever,
including any interest, penalties or additions to tax or additional amounts in
respect of the foregoing, whether disputed or not and whether computed on a
separate, consolidated, unitary, combined or any other basis; the foregoing
shall include any transferee or secondary liability for a Tax and any liability
assumed by agreement or arising as a result of being (or ceasing to be) a member
of any Affiliated Group (or being included (or required to be included) in any
Tax Return relating thereto) or as a result of any spin-off, distribution or
other reorganization related to the disposition of any assets or business of
such Person or any other member of an Affiliated Group of which such Person is
or was a member.
"Tax Returns" means returns, amendments, statements, forms,
information, elections, declarations, reports, claims for refund, information
returns or other documents (including any related or supporting schedules,
statements or information) filed or required to be filed in connection with the
determination, assessment or collection of any Taxes of any party or the
administration of any laws, regulations or administrative requirements relating
to any Taxes.
"U.S. Asset Purchase Agreement" means the Asset Purchase
Agreement of even date herewith among Siemens-Pacesetter, Inc., a Delaware
corporation, SJM, SJM International, and Siemens Medical Systems, Inc., a
Delaware corporation.
"U.S. GAAP" shall have the meaning given to it in Section
2.2.2.
IN WITNESS WHEREOF, the parties hereto have executed this
Agreement as of the date first written above.
ST. JUDE MEDICAL, INC.
By______________________________________
Ronald A. Matricaria
President and Chief Executive Officer
ST. JUDE MEDICAL INTERNATIONAL, INC.
By______________________________________
Ronald A. Matricaria
President
SIEMENS-ELEMA AB
By_____________________________________
_____________________________________
[NON-U.S.]
ASSET PURCHASE AGREEMENT
AMONG
ST. JUDE MEDICAL, INC.,
ST. JUDE MEDICAL INTERNATIONAL, INC.
AND
SIEMENS-ELEMA AB
dated as of
June 26, 1994
TABLE OF CONTENTS
ARTICLE 1
TRANSFER OF ASSETS
1.1 Assets to Be Sold . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Assumption and Exclusion of Liabilities . . . . . . . . . . . 4
1.3 Transfer Documentation and Possession . . . . . . . . . . . . 5
1.4 Transitional Services . . . . . . . . . . . . . . . . . . . . 5
ARTICLE 2
CONSIDERATION AND MANNER OF PAYMENT
2.1 Consideration and Payment . . . . . . . . . . . . . . . . . . 6
2.2 Cash Consideration Adjustment . . . . . . . . . . . . . . . . 6
2.3 Allocation of Purchase Price . . . . . . . . . . . . . . . . 9
ARTICLE 3
CLOSING
3.1 The Closing . . . . . . . . . . . . . . . . . . . . . . . . . 9
3.2 Deliveries of Siemens-Elema . . . . . . . . . . . . . . . . . 9
3.3 Deliveries of SJM . . . . . . . . . . . . . . . . . . . . . . 10
3.4 Further Documents . . . . . . . . . . . . . . . . . . . . . . 11
ARTICLE 4
REPRESENTATIONS AND WARRANTIES OF SIEMENS-ELEMA
4.1 Authority, Organization, Capitalization and Qualification; Effect
of Agreement . . . . . . . . . . . . . . . . . . . . . . . 11
4.2 Financial Statements. . . . . . . . . . . . . . . . . . . . . 13
4.3 Absence of Certain Developments. . . . . . . . . . . . . . . 13
4.4 Title to Personal Property and Assets . . . . . . . . . . . . 15
4.5 Patents, Trademarks and Copyrights . . . . . . . . . . . . . 15
4.6 Commitments . . . . . . . . . . . . . . . . . . . . . . . . . 16
4.7 Litigation. . . . . . . . . . . . . . . . . . . . . . . . . . 17
4.8 Permits . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
4.9 Governmental Consents . . . . . . . . . . . . . . . . . . . . 18
4.10 Employee Benefit Plans. . . . . . . . . . . . . . . . . . . . 18
4.11 Employees . . . . . . . . . . . . . . . . . . . . . . . . . . 21
4.12 [Reserved]. . . . . . . . . . . . . . . . . . . . . . . . . . 21
4.13 Company Products; Regulation . . . . . . . . . . . . . . . . 21
4.14 Tax Matters . . . . . . . . . . . . . . . . . . . . . . . . . 22
4.15 [Reserved]. . . . . . . . . . . . . . . . . . . . . . . . . . 22
4.16 Brokerage . . . . . . . . . . . . . . . . . . . . . . . . . . 22
4.17 Affiliated Transactions . . . . . . . . . . . . . . . . . . . 23
4.18 Insurance . . . . . . . . . . . . . . . . . . . . . . . . . . 23
4.19 [Reserved] . . . . . . . . . . . . . . . . . . . . . . . . . 23
4.20 Inventory . . . . . . . . . . . . . . . . . . . . . . . . . . 23
4.21 Accounts and Notes Receivable . . . . . . . . . . . . . . . . 23
ARTICLE 5
REPRESENTATIONS AND WARRANTIES OF SJM
5.1 Corporate Power and Authority; Effect of Agreement . . . . . 24
5.2 Consents . . . . . . . . . . . . . . . . . . . . . . . . . . 25
5.3 Availability of Funds . . . . . . . . . . . . . . . . . . . . 25
5.4 Litigation . . . . . . . . . . . . . . . . . . . . . . . . . 25
5.5 Brokerage . . . . . . . . . . . . . . . . . . . . . . . . . . 25
5.6 Certain Ownership Interests . . . . . . . . . . . . . . . . . 26
ARTICLE 6
COVENANTS
6.1 Cooperation . . . . . . . . . . . . . . . . . . . . . . . . . 26
6.2 Conduct of Business . . . . . . . . . . . . . . . . . . . . . 27
6.3 [Reserved] . . . . . . . . . . . . . . . . . . . . . . . . . 27
6.4 Access . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
6.5 Non-Disclosure Agreement . . . . . . . . . . . . . . . . . . 29
6.6 Antitrust, Competition Law Filings . . . . . . . . . . . . . 29
6.7 Summary of Tangible Personal Property and Assets . . . . . . 29
6.8 Claims History . . . . . . . . . . . . . . . . . . . . . . . 29
6.9 FDA Recertification. . . . . . . . . . . . . . . . . . . . . 29
6.10 Grant of License. . . . . . . . . . . . . . . . . . . . . . . 29
6.11 Other Financial Statements . . . . . . . . . . . . . . . . . 30
6.12 Amendments to Schedules . . . . . . . . . . . . . . . . . . . 30
ARTICLE 7
ADDITIONAL COVENANTS
7.1 Liability for Employees and Employee Benefit Plans . . . . . 31
7.2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
7.3 Non-Competition . . . . . . . . . . . . . . . . . . . . . . . 33
7.4 Non-Solicitation . . . . . . . . . . . . . . . . . . . . . . 34
7.5 Siemens Name . . . . . . . . . . . . . . . . . . . . . . . . 34
7.6 Confidentiality . . . . . . . . . . . . . . . . . . . . . . . 34
7.7 Accounts Receivable . . . . . . . . . . . . . . . . . . . . . 34
ARTICLE 8
CONDITIONS TO SJM'S OBLIGATIONS
8.1 Representations, Warranties and Covenants of Siemens-Elema . 35
8.2 No Prohibition . . . . . . . . . . . . . . . . . . . . . . . 35
8.3 Deliveries . . . . . . . . . . . . . . . . . . . . . . . . . 35
8.4 No Material Adverse Effect . . . . . . . . . . . . . . . . . 35
8.5 Governmental and Other Approvals . . . . . . . . . . . . . . 35
8.6 U.S. Asset Purchase Agreement . . . . . . . . . . . . . . . . 36
ARTICLE 9
CONDITIONS TO SIEMENS-ELEMA'S OBLIGATIONS
9.1 Representations, Warranties and Covenants of SJM . . . . . . 36
9.2 No Prohibition . . . . . . . . . . . . . . . . . . . . . . . 36
9.3 Deliveries . . . . . . . . . . . . . . . . . . . . . . . . . 36
9.4 Governmental Approvals . . . . . . . . . . . . . . . . . . . 36
9.5 U.S. Asset Purchase Agreement . . . . . . . . . . . . . . . . 36
ARTICLE 10
INDEMNIFICATION AND RELATED MATTERS
10.1 Survival . . . . . . . . . . . . . . . . . . . . . . . . . . 37
10.2 Indemnification by Siemens-Elema . . . . . . . . . . . . . . 37
10.3 Indemnification by SJM . . . . . . . . . . . . . . . . . . . 37
10.4 Limitation on Indemnification Liabilities . . . . . . . . . . 37
10.5 Notice of Indemnification . . . . . . . . . . . . . . . . . . 38
10.6 Indemnification Procedure for Third-Party Claims . . . . . . 38
10.7 Waivers of Certain Restrictions. . . . . . . . . . . . . . . 39
10.8 Right to Cure . . . . . . . . . . . . . . . . . . . . . . . . 39
ARTICLE 11
TERMINATION PRIOR TO CLOSING
11.1 Termination . . . . . . . . . . . . . . . . . . . . . . . . . 39
11.2 Effect of Termination . . . . . . . . . . . . . . . . . . . . 40
ARTICLE 12
MISCELLANEOUS
12.1 Entire Agreement . . . . . . . . . . . . . . . . . . . . . . 40
12.2 Amendment; Waiver . . . . . . . . . . . . . . . . . . . . . . 40
12.3 Assignment . . . . . . . . . . . . . . . . . . . . . . . . . 40
12.4 Headings; Usage . . . . . . . . . . . . . . . . . . . . . . . 40
12.5 Cooperation . . . . . . . . . . . . . . . . . . . . . . . . . 41
12.6 Expenses . . . . . . . . . . . . . . . . . . . . . . . . . . 41
12.7 Governing Law . . . . . . . . . . . . . . . . . . . . . . . . 41
12.8 Arbitration . . . . . . . . . . . . . . . . . . . . . . . . . 41
12.9 Severability. . . . . . . . . . . . . . . . . . . . . . . . . 42
12.10 Counterpart. . . . . . . . . . . . . . . . . . . . . . . . . 42
12.11 Interpretation . . . . . . . . . . . . . . . . . . . . . . . 42
12.12 Notices . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
12.13 Publicity . . . . . . . . . . . . . . . . . . . . . . . . . . 44
12.14 No Third-Party Beneficiary . . . . . . . . . . . . . . . . . 44
ARTICLE 13
DEFINITIONS
13.1 Definitions . . . . . . . . . . . . . . . . . . . . . . . . . 44
EXHIBITS
NUMBER NAME OF EXHIBIT
1.4.1 Form of Siemens Transitional Services Agreement
3.2.2 Form of Medtronics Assignment and Assumption Agreement
SCHEDULES
NUMBER NAME OF SCHEDULE
1.1(a) Shareholder Affiliates
1.1(a)(i) Furniture, Fixtures, Equipment, Machinery and Other
Tangible Personal Property
1.1(a)(ii) Vehicles
1.1(a)(iii) Inventories
1.1(a)(iv) Accounts Receivable
1.1(a)(viii)Contracts, Licenses, etc.
1.1(a)(ix) Intellectual Property
1.1(a)(xiii)Advances, Deposits, Prepaid Invoices and Other Prepaid
Expenses
1.1(a)(xv) Interests in Real Property Leases
2.2.2 Adjustments
2.2.2.1 Intercompany Eliminations
4.1.4 Consents
4.1.5 Defaults
4.2 Financial Statements
4.3 Certain Developments
4.4(a) Title to Personal Property
4.4(b) Condition of Equipment and Fixed Assets
4.5(a) Patents, Trademarks, Service Marks, Trade Names,
Copyrights; Registrations; Applications for
Registration
4.5(b) License Agreements
4.5(c) Claims and Disputes Regarding Intellectual Property
4.5(d) Outstanding Orders, Judgments and Decrees Restricting
Use of Intellectual Property
4.5(e) Liens on Intellectual Property
4.6(a) Commitments
4.6(b) Commitments Requiring Consent
4.7 Litigation
4.8 Missing Permits; Consents
4.9 Governmental Consents
4.10.1 Material Employee Benefit Plans
4.10.3 Consequences Resulting from Consummation of
Transactions; No Change in Control Provisions
4.10.4 Statements By Authorized Representatives
4.11(a) Employees
4.11(b) Works Councils, Unions, Other Labor Organizations and
Collective Bargaining Agreements
[4.11(c) Material Compliance with Laws
4.11(d) Complaints, Demand Letters, Charges]
4.13.1(a) Governmental Notices, Citations and Decisions Regarding
Products
4.13.1(b) Field Notifications, etc.
[4.14.1 U.S. Real Property]
4.14.2 Permanent Establishments
4.17 Affiliated Transactions
4.18 Insurance
5.2 Consents
6.2 Conduct of Business; Agreements, etc.
7.1.2 Assumed Employee Benefit Plans
8.5 Certain Consents
